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1 – Introduction: 
 
 
1.1 – FKBPs: big family with huge functional diversity 
 
The FK506 binding proteins (FKBPs) are members of the family of immunophilin proteins 
and display peptidyl prolyl cis-trans isomerase activity (PPIase)[1, 2]. This enzymatic action 
plays a role in the folding of numerous proteins as the interconversion of peptide bonds (like 
Xaa-proline) often is a rate-limiting step [3] (see figure 1.1). The process is accelerated by 
binding of the target sequence at the active site of the FKBP and stabilization of the transition 
state by hydrogen bonds during isomerization [4]. Generally, the effectiveness of PPIases 
tends to be low, demanding high concentrations of these proteins. The same is true for the 
PPIase-independent chaperone function of some FKBPs that includes binding of non-native 
proteins, inhibition of unwanted inter- and intramolecular interactions and separation of 
productive and non-productive folding steps [5]. 
 
                                 
 
Figure 1.1: FKBPs possess peptidyl-prolyl-cis-trans-isomerase activity  
Schematic representation of cis-trans isomerization of the peptide bond between proline and the adjacent residue. 
Blue: Nitrogen; red: carbonyl oxygen of peptide bond. 
 
Apart from their role in protein maturation, the diverse members of the FKBP protein family 
also act as receptors of the natural compounds FK506 and rapamycin: by formation of the 
FKBP12*FK506 complex, not only the PPIase activity of FKBP but also the phosphatase 
activity of the secondary target calcineurin is inhibited [6, 7]. A blockage of calcineurin 
causes reduced activation of the transcription factor NF-AT that stimulates IL-2 expression 
and thereby promotes activation of T-cells [8]. In contrast, the complex of FKBP12 and 
rapamycin inhibits the action of the kinase mTOR that results in general reduction of protein 
biosynthesis and cell growth [9-11]. Interestingly, FKBP12 is more abundant in nerve tissue 
than in the immune cells [12], and its expression is especially strong after nerve injury [13]. 
trans cis 
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Thus, a neuro-protective or even neurotrophic effect of FKBP12 is supposed [14] as 
rapamycin enhances neurite outgrowth in certain neurons [15].  
FKBP proteins with higher molecular weight contain several domains, including ones with 
PPIase and FK506 binding capability (FKBD), domains for interaction with Hsp90 
(TPR/tetratricopeptide domain) [16, 17] and domains for putative interaction with calmodulin 
(calmodulin-binding domain (CBD)). Figure 1.2 provides an overview of important FKBPs 
and their domain structure.  
 
 
Figure 1.2: Larger FKBPs contain several domains  
Simplified scheme of the domain structures of human FKBPs.  
N-Terminus: left; C-Terminus: right.  
 
 
1.1.1 – FKBP12: the archetype of the family 
 
The prototypic member of the FKBP family, FKBP12, consists of a single FKBD domain     
[18] and is almost ubiquitously expressed in all human tissues [19]. The protein binds FK506 
and rapamycin with very high affinity (Kd: 0.2 and 0.4 nM) [20], is stabilized by formation of 
the complex and inhibits the target protein within the ternary complex with calcineurin or 
FK506 binding domain 1 
FK506 binding domain 2 
Tetratricopeptide domain 
Calmodulin binding domain 
Helix-loop-helix domain 
ER retention signal 
Transmembrane domain 
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mTOR [6, 21]. Structurally, the FKBD domains are dominated by an amphipathic, five-
stranded ß-sheet that has a right-handed twist and turns around a central alpha-helix. In most 
cases, a hydrophobic pocket forms the binding pocket for FK506 and rapamycin [18, 22, 23].  
Other cellular proteins are influenced by FKBP12 as well: an interaction between FKBP12 
and the ryanodine receptor [24, 25], one of the main calcium influx channels of the 
endoplasmatic reticulum, results in a better performance of the channel [26]. The 
phosphorylation status of inositol-1,4,5-triphosphate receptor (IP3R) is also regulated by the 
phosphatase calcineurin that in turn is recruited to the receptor via FKBP12 [27]. FKBP12 
represents a natural ligand of the TGF-ß receptor 1 [28] and stabilizes its inactive 
conformation [29, 30]. Altogether, the protein plays an important role either by interacting 
with target proteins itself or by mediating protein-protein interactions, resulting in altered 
regulation of the binding partner. 
Another finding supports this model of FKBP action: in brain-restricted FKBP12 knockout 
mice, interactions between Raptor and mTOR seem to be stronger than in wild type mice, 
resulting in increased basal mTOR and S6Kinase phosphorylation. On a behavioural level, the 
mice show better contextual fear memory and display abnormal repetition [31]. 
In a cell culture model of Parkinson’s disease, the reduction of FKBP12 resulted in reduced 
aggregation of alpha-synuclein and protected cells from cell death [32], thus providing an 
explanation for neuroregenerative and neuroprotective properties of FKBP proteins. On the 
other hand, researchers had shown before that FKBP12 mRNA cannot be detected in human 
neuroblastoma cells; nevertheless, a protective effect of FK506 and a non-immunosuppressive 
analogue could be observed which must be at least partially FKBP12-independent [33]. 
 
 
1.1.2 – FKBP51 and FKBP52: the multi-domain members 
 
FKBP51 was initially isolated from murine T-cells [34] and murine adipocytes [35] where its 
expression is specifically induced during final steps of differentiation. Further characterization 
revealed that the protein contains PPIase activity, binds to FK506 and rapamycin, but does not 
inhibit calcineurin activity [36]. This large FKBP12 homologue is expressed in a multitude of 
human tissues, often even in molar excess compared to FKBP12 [19]. FKBP51 is a multi-
domain protein: the TPR domain plays an important role in mediating interactions with 
Hsp70/90 [37, 38], while only one of the two FKBD (FK506/Rapamycin binding) domains 
displays PPIase activity [16]. 
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One of the best-studied functions of FKBP51 is its ability to reduce hormone binding affinity 
of the glucocorticoid receptor. In accordance with this finding some monkey species are 
hyposensitive to cortisol, and FKBP51 is overexpressed in some of their tissues [39, 40]. The 
monkey version of the protein displays stronger inhibitory effects on hormone binding of the 
receptor compared to human FKBP51 [41]. In spite of structure determination so far no exact 
mechanism could be determined that explains the different effects of FKBP51 variants [42]. 
The expression of FKBP51 can be strongly increased by corticosteroids [43, 44]. Therefore a 
feedback mechanism for adjusting the glucocorticoid susceptibility is created by the fact that 
FKBP51 reduces the activity of the glucocorticoid receptor [45],[46]. This neuroendocrine 
circuit is part of the HPA (hypothalamic – pituitary – adrenal) axis which can be considered 
as one main regulator of the stress response. 
At the MPI of Psychiatry it has been found that polymorphisms within the FKBP51-encoding 
gene (FKBP5) seem to increase the risk of relapse into depressive episodes and attenuate 
patients’ response to antidepressive treatment [47, 48]. Additionally, FKBP5 gene mutations 
seem to influence the response of healthy subjects upon psychosocial stress [49]. In african-
american patients, a correlation between single nucleotide polymorphisms in the FKBP5 gene 
and abuse-induced suicide was established [50]. Another study revealed that genetic 
variability in FKBP5 might increase the number of depressive episodes in bipolar subjects 
[51]. Altogether these results implicate an important role of FKBP51 in HPA axis 
dysregulation and suggest that targeting the protein might be beneficial for treatment of 
depressed patients.  
FKBP51 expression is influenced by other steroid hormones as well, suggesting an 
importance of the protein in the regulation of glucocorticoid, progesterone and androgen 
receptors [52]. Concerning the latter, an especially interesting role of FKBP51 has been 
identified in prostate cancer cells, as the co-chaperone seems to promote androgen receptor 
complex formation and increases its activity [53, 54]. 
Furthermore, decreased FKBP51 expression in old age seems to contribute to memory 
impairment in mice [55]. Similarly, the co-chaperone is involved in stabilization of the Tau 
protein, causing its hyperphosphorylation and aggregation. As a consequence, senile plaques, 
a hallmark of Alzheimer’s disease, are stabilized [56]. 
Very recently, FKBP51 has been proposed as a negative regulator of the Akt signaling 
pathway: it functions as a scaffolding protein to recruit the phosphatase PHLPP to Akt, 
resulting in decreased survival signaling. Thus, certain cell lines are more susceptible to 
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chemotherapeuticals. Interestingly, FKBP51 is downregulated in a number of cancer cell lines 
[57]. A possible role as a tumour suppressor protein still has to be established. 
 
The large immunophilin FKBP52 (or synonymously Hsp56) was originally characterized in 
1992 as a protein with four clearly distinguishable domains that are arranged like in FKBP51 
[58-60]. Again, the first PPIase domain exhibits enzymatic activity and binds FK506 and 
rapamycin, while FKBD2 shows extremely low activity and does not bind the natural 
compounds. There can be also found a putative ATP/GTP binding site whose function is not 
yet well characterized [61].    
Additionally, FKBP52 contains a phosphorylation site that can be modified by casein kinase 
II and changes the Hsp90 binding ability [62]. Furthermore the protein represents the cellular 
factor that binds a single-stranded region of the genome of the adeno-associated virus (AAV) 
and inhibits DNA synthesis [63]. This inhibitory effect can be modified by dephosphorylation 
of specific Ser/Thr/Tyr residues in FKBP52 [64]. The cellular expression of FKBP52 can be 
induced by heat-shock, and the promoter region of the corresponding gene contains a 
consensus sequence for binding of the heat-shock transcription factor in rabbits [65]. 
 
Figure 1.3: Exchange of FKBP51/52 occurs during maturation of the glucocorticoid receptor 
FKBP51 and FKBP52 play different roles during the assembly cycle of the glucocorticoid receptor (GR): while 
FKBP51 (51) reduces hormone binding, FKBP52 (52) is involved in recruiting dynein to the complex and 
allowing  nuclear translocation. 
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Just like FKBP51, FKBP52 is part of the glucocorticoid receptor complex and plays a role 
during functional maturation of the receptor: it interacts with Hsp90 and Hsp70; these 
proteins themselves recruit and displace co-chaperons (FKBP51, FKBP52, Hip, Hop, Chip) 
[66]. In a yeast model system it could be demonstrated that by expression of human FKBP52 
the hormone-dependent transcriptional activity of the glucocorticoid receptor could be 
increased significantly [67]. For this effect, the TPR and PPIase domains of FKBP must be 
present [68]. FKBP52 also binds via its PPIase domain to the motor protein dynein which is 
connected to microtubuli and accelerates the translocation of protein from the cytoplasm into 
the nucleus [69, 70]. Importantly, a crucial step during receptor activation seems to be the 
exchange of bound FKBP51 with FKBP52 (“switching”; see figure 1.3) [71].  
Recently, FKBP52 was found to bind to the hyperphosphorylated form of tau protein and 
inhibits its function and accumulation. This “anti-tau activity” may play a role in protecting 
neurons against degenerative diseases [72]. 
 
 
1.1.3 – FKBP12.6, FKBP13 and FKBP25: the less popular ones 
 
The immunophilin FKBP12.6 is very similar to its close relative FKBP12: the sequence 
identity is 85%, and the inhibition of calcineurin activity in vitro is similarly effective as the 
one of FKBP12 [73, 74].  The proteins exhibit highly overlapping functions in vivo as they 
both bind ryanodine receptors with high affinity. FKBP12.6 interacts preferentially with the 
ryanodine receptor in heart muscle cells [75]. Binding of the FKBP to the receptor stabilizes 
its closed conformation and influences cooperative interactions between receptor subunits. 
Mutagenesis experiments revealed that PPIase activity is not involved in this function of 
FKBPs [76]. 
Knockout of the FKBP12.6 gene resulted in a cardiac hypertrophy in male mice; the organs of 
females were normal. Obviously oestrogen seems to have protective influences on this issue. 
Nevertheless, both genders similarly display dysfunction of calcium release in myocardial 
cells [77]. 
 
The immunophilin FKBP13 has strong homology to FKBP12; within the active centre of the 
PPIase domain it is even completely conserved [78]. The protein carries an N-terminal 
retention sequence which keeps the protein in the lumen of the endoplasmatic reticulum. 
Therefore a role of FKBP13 in the folding of newly synthesized proteins is proposed [79]. In 
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yeast a homologous protein is known [80]: its expression is increased by an unfolded-protein-
response (UPR) element in the 5’ region of the gene in presence of denatured proteins in the 
ER [81, 82].  
As first physiological binding partner the homologue of the erythrocyte membrane 
cytoskeletal protein 4.1 was identified [83]. The interaction occurs via a histidyl-prolyl moiety 
in the membrane protein. As FKBP13 interacts with a homologue as well, it is discussed 
whether the protein is a general component of membrane scaffolds. 
  
The immunophilin FKBP25 is different from other FKBPs with respect to its ligand binding 
characteristics: it binds rapamycin (Kd = 0.9 nM) with much higher affinity than FK506       
(Kd = 160 nM) [84-86]. This preference can be explained structurally by differences in the 
50S loop region, by the flexibility of an insertion within the 40S loop and the substitution of a 
residue within the ligand binding pocket [87]. 
Moreover, in contrast to other FKBPs, FKBP25 displays a highly hydrophilic N-terminal 
domain that has no identity to other known proteins. This domain consists of a helix-loop-
helix motif with a high proportion of charged amino acids. A nuclear localization signal is 
located in that area as well as different residues that can be phosphorylated by casein kinase 
II; as FKBP25 forms a stable complex with the kinase, it can be found mainly in the nucleus 
[88]. 
The biological relevancy of the protein is still largely unknown. It is well understood that 
expression of FKBP25 is negatively regulated by the tumour suppressor protein p53 [89]. 
There are reports about FKBP25 interacting with the N-Terminus of histone deacetylases 
(HDAC1 and HDAC2) and the transcription factor YY1, modifying its DNA binding 
capability [90]. Furthermore, the “High Mobility Group” protein HMG II and the GTP 
binding protein Rab5 were identified as potential binding partners [91]; the latter binds to the 
phosphorylated isoform of FKBP25. Whether the PPIase activity plays a crucial role in this 
process or whether other mechanisms are more meaningful could not yet be resolved.  
Likewise, there are no findings at all about which genes could be regulated differentially by 
the influence of FKBP25. 
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1.2 – Rapamycin and the Target of Rapamycin (TOR): inextricably linked 
 
The macrolidic small molecule rapamycin (also: Sirolimus) was originally isolated from the 
bacterial species Streptomyces hygroscopicus in the 1970s and was named after the location, 
the Easter Island (Rapa Nui) [92-94]. The fungicidal action of the natural compound was 
discovered first [95], while its effects against transplanted tumours [96] and its immune-
suppressive action [97] were observed later. The latter was confirmed in organ transplantation 
experiments with animals [98] which demonstrated that rapamycin reduces allograft rejection. 
In the 1990s, the natural compound proved its effectiveness in clinical trials after kidney 
transplantations in humans [99]. In 1997 rapamycin was finally approved by the FDA as trade 
brand “Rapamune” for human application. Furthermore, rapamycin-coated stents are widely 
used in patients suffering from vascular obliteration as the anti-proliferative effect of the 
natural compound can prevent restenosis effectively [100-102]. 
Structural similarities of rapamycin and the compound FK506 as well as their shared 
immunosuppressive effect gave rise to the suggestion that both natural compounds make use 
of related mechanisms of action: it could be demonstrated that rapamycin and FK506 bind to 
the co-chaperones of the FKBP family with high affinity [18, 103]. Surprisingly, two different 
signaling pathways in T-lymphocytes are affected by rapamycin and FK506, respectively 
[20]: while the complex of FKBP12 and FK506 binds and inhibits the protein phosphatase 
calcineurin [6], a yeast gene was discovered that causes a resistance against rapamycin when 
mutated. Therefore the gene was named “Target of Rapamycin” (TOR) [104, 105]. Further 
analysis of the gene product identified the protein as a member of the family of PI3K-like 
kinases [105] which are involved in regulation of cell cycle progression [106]. Later on, a 
homologous mTOR complex was identified in mammalian cells [107] which activates protein 
biosynthesis by phosphorylation of the translational regulators 4E-BP1 and S6Kinase in a 
mitogen-dependent manner [10, 108, 109]. The physiological relevancy of the protein is 
stressed by the fact that a homozygous knockout of mTOR is lethal in an early stage of mouse 
embryonic development [110]. 
The crystal structure of FKBP12 in complex with rapamycin and the rapamycin-binding 
domain of mTOR (FRB domain) was solved in order to further assess the allosteric 
mechanism of rapamycin action (see figure 1.4). It turned out that there is a direct blockage of 
the FRB domain of mTOR by FKBP12 that might influence interactions with actual 
substrates [23, 111]. Interestingly, direct protein-protein interactions play a subordinate role 
within this complex; rapamycin itself forms mostly hydrophobic contacts to amino acids of 
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FRB on one side of the macrolide, and interactions to residues in FKBP12 on the other side. 
For the latter contacts, defined loop structures of FKBP12 are especially important, harboring 
numerous H-bonds that strengthen the interaction.     
The molecular mechanisms of kinase inhibition are not yet known: whether complex 
formation with FKBP12 blocks substrate binding sites or whether FKBP12*rapamycin 
directly interacts with the kinase domain still must be determined. Recent discoveries suggest 
that FKBP12*rapamycin interferes with oligomerization of mTOR, resulting in abolished 
activity of the obligatorily dimeric kinase [112].  
 
 
Figure 1.4: Rapamycin binds to FKBP12 and complexes the FRB domain of mTOR  
Cartoon representation of the crystal structure “2fap” [111]: 
ternary complex of FRB (green)*rapamycin (green, sticks; oxygen atoms red)*FKBP12 (red) 
 
This dogma of FKBP12 being the only relevant rapamycin-dependent mTOR regulator was 
not challenged until recently: Bai and colleagues demonstrated that mTORC1 regulation via 
Rheb is mainly mediated by FKBP protein 38 [113]. They claim that FKBP38 represents an 
intrinsic inhibitor of mTOR kinase activity and binds to FRB domain in a similar way as the 
FKBP12*rapamycin complex. This binding seems to take place in absence of rapamycin as 
well. Mechanistically, the GTP-bound form of Rheb interacts with FKBP38 and reduces its 
inhibitory action on mTOR. Wang and Fonseca refuted those findings: they were unable to 
observe any inhibition of mTOR signaling by FKBP38 [114]. Furthermore, Uhlenbrock and 
FRB of 
mTOR 
FKBP 12 
rapamycin 
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colleagues could not detect any interaction of Rheb with FKBP38 [115]. Thus, the hypothesis 
of FKBP38 contributing crucially to mTORC1 regulation cannot be sustained. 
Recently, a novel mTOR inhibitor, a small molecule named “torin1”, has been developed: 
Torin1 is a highly potent and selective ATP-competitive inhibitor that directly targets the 
active site of mTOR kinase [116]. It affects cell growth and proliferation with higher 
efficiency than rapamycin and acts on both mTOR complexes similarly. Importantly, the use 
of torin1 in mTORC1 inhibition revealed rapamycin-insensitive functions of the complex, 
mainly involving phosphorylation of the mTOR substrate 4E-BP1 [117]. With Ku-0063794, 
another compound has been discovered that inhibits mTOR kinase activity [118]. Finally, the 
small molecule inhibitors PP242 and PP30 (“TORKinibs”) exhibit low-nanomolar mTOR 
affinity and affect mTOR to a further extent than rapamycin does [119]. Generally, these 
active-site inhibitors exert more direct effects than the allosteric inhibitor rapamycin whose 
inhibitory effect might be dependent on further factors like FKBP availability and binding 
competition. 
 
1.3 – mTOR complexes: composition defines substrates 
 
The Ser/Thr kinase mTOR is a large protein that has a molecular weight of around 290 kDa 
and consists of several domains (see scheme in figure 1.5) [120]. A PI3K-related domain is 
located at the C-terminus and is highly conserved among eukaryotes [121]. This domain plays 
a crucial role because it contributes the kinase activity to mTOR [109, 122]. In immediate 
vicinity the small FRB domain (FKBP12-rapamycin-binding) can be found [21] which 
comprises 11 kDa and provides the capability of rapamycin binding by its 4-helix-bundle 
structure [23, 123]. N-terminally, 20 HEAT repeats are located that contain each two 
interacting alpha helices and a variable spacer region [120]. These repeats provide binding 
sites for different cofactors (Raptor, Rictor) and substrates (4E-BP1, S6Kinase) [124]. Finally, 
mTOR contains two domains named FAT and FATC; the latter might play a role in sensing 
the intracellular redox potential and in adjusting mTOR structure by formation of a disulfide 
bond [125].   
 
Figure 1.5:  The PI3K-like kinase mTOR is a multi-domain protein 
Schematic representation of the domain structure of mTOR; left side: N-Terminus; right side: C-terminus 
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Just like in yeast, the protein mTOR can be found in two distinct complexes: in mTORC1 and 
mTORC2 [104, 126]. mTORC1 is mainly involved in sensing energy and nutrition in 
dependence of cellular signals and in adjusting protein biosynthesis and cell growth 
accordingly [127]. This first complex consists of mTOR, mLST8 (GßL) and Raptor [128]. 
Although it does not contain enzymatic activity, Raptor (“regulatory associated protein of 
TOR”) is an essential component of mTORC1. It rather functions as a scaffold and supports 
mTOR in recruitment of substrates [129]: insulin stimulates binding of 4E-BP1 to the 
complex. Raptor includes three HEAT repeats and seven WD40 units for interaction with 
binding partners. Nevertheless, its association with mTOR is very dynamic: under conditions 
of nutrient deficiency, the binding of Raptor to mTOR gets stronger [130] while rapamycin 
treatment reduces this interaction [131]. Detergents can also interfere with the binding. 
Another important part of mTOR complex is the protein mLST8 which consists of WD40 
units almost completely. By utilizing these units, it interacts with the kinase domain of 
mTOR. Initially it was assumed that LST8 exerts regulatory effects on mTOR [128]; but 
knockout experiments revealed that the protein is not essential for proper function [132]. 
mTORC1 enhances cell growth by phosphorylation of proteins that are involved in regulation 
of protein translation, gene expression and autophagy. The most important substrates of 
mTOR are regulators of protein translation, namely the eIF4E-binding protein (4E-BP1) [108] 
and the ribosomal p70 S6Kinase (S6K) [10]. Both proteins occupy key positions within the 
cap-dependent protein biosynthesis machinery and are regulated reciprocally: S6K, a positive 
regulator of translation, is activated by phosphorylation, while the translational inhibitor 4E-
BP1 is inactivated by mTORC1.   
4E-BP1 binds to the initiation factor eIF4E and thereby inhibits the formation of a complex 
that allows initiation of translation by unwinding the 5’ ends of mRNA [133]. A 
phosphorylation by mTOR inactivates 4E-BP1, causing release of eIF4E and increase of 
mRNA translation at the ribosomes [134]. Active S6Kinase phosphorylates different proteins 
within the ribosomal subunits, mainly initiation factors and elongation factors. These events 
trigger the assembly of the translation machinery [135]. Both mTORC1 substrates contain a 
conserved 5 amino acid sequence, a so-called “TOR-signaling motif” (TOS motif)  that
mediates the interaction with Raptor [136].  
By cryo-electron microscopy, the three-dimensional structure of mTORC1 complexes has 
been revealed at low resolution [112]: it turns out that mTORC1 forms dimers with a central 
cavity. The interface areas are stabilized by mTOR-Raptor interactions. Other components, 
like mLST8 and PRAS40, are bound to the outside portion of the complex. When rapamycin 
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is added in presence of FKBP12, the complex binds to one mTORC1 dimer, resulting in 
conformational changes that weaken the interaction between mTOR and Raptor. As 
phosphorylation of 4E-BP1 is abolished in presence of rapamycin, it is assumed that it 
demands the presence of one mTORC1 dimer. Maybe, 4E-BP1 is bound to one monomer, 
while the phosphorylation is performed by the adjacent monomer. 
 
Within the mTORC2 complex, mTOR can be found together with mLST8, Rictor and Sin1 
[137, 138] while the latter two are exclusive components of this complex. The kinase activity 
of TORC2 cannot be reduced by acute application of rapamycin, and binding of 
FKBP12*rapamycin does not occur [126]. Presumably the components of mTORC2 complex 
block binding of FKBP12*rapamycin to the FRB domain of mTOR. Under conditions of 
prolonged rapamycin treatment, reduced formation of TORC2 might occur as newly 
synthesized TOR protein is sequestered [139]. 
Rictor, the rapamycin-insensitive companion of mTOR, is a large protein of 190 kDa. Its 
function within the mTORC2 complex is still widely unknown. Obviously the protein is 
comparable to Raptor in TORC1: it represents a scaffold for assembly of the different 
components and may be involved in substrate binding [140]. A heterozygous knockout of 
Rictor causes lethality of mice in the tenth week of embryonic development [132]. This 
implicates physiological importance of the protein. 
mTORC2 complex exerts an important regulatory influence on Akt kinase: it phosphorylates 
Akt together with PDK1 kinase within a hydrophobic motif and allows its complete activation 
[141]. Is it not clear whether the two activating kinases can work independently. Anyway, Akt 
kinase is most active when it is phosphorylated twice [142]. This phosphorylation state is also 
used as a measure for mTORC2 activity. 
Some functions of the mTORC2 complex are not yet understood completely. Clearly, the 
complex has regulatory effects on actin accumulation and therefore on cytoskeleton dynamics 
[143]. This effect might be mediated by proteins of the Rho family of small GTPases and 
protein kinase C (PKC). Regulatory pathways which act upstream of mTORC2 and contribute 
to its activation or inhibition are not yet well characterized.  
Recently, it has been reported that mTORC2 associates with ribosomes, and that this 
interaction is necessary for activation of the complex [144].  Thus, mTORC2 activation can 
be reduced in static cells, because the number of ribosomes in a cell is proportional to its 
growth activity. 
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1.4 – PI3K/Akt/mTOR signaling pathway: integrator of multiple signals 
  
One important function of the mTORC1 complex consists of initiating cell growth in presence 
of growth factors or insulin. During this process, signaling pathways are triggered which 
include the kinases Akt (protein kinase B, PKB) and mTOR as major effectors. These proteins 
crucially co-determine survival of a cell and thus regulate processes like growth, proliferation 
and apoptosis [145]. 
After activation of the insulin receptor by hormone binding, this growth factor triggers an 
important growth-mediating signaling pathway, namely the PI3K/Akt kinase pathway. During 
this process, activation of phosphatidyl inositol 3 kinase (PI3K) occurs that in turn produces 
the second messengers PIP3 (phosphatidyl-inositol-3,4,5-triphosphate) and PIP2 
(phosphatidyl-inositol-3,4-diphosphate) [146]. They stimulate recruitment of the kinase Akt 
by its PH (Pleckstrin Homology) domain and induce membrane localization of the protein 
[147]. There, Akt is phosphorylated by the kinases PDK1 and PDK2 at the regulatory amino 
acid residues T308 and S473; this activates Akt completely. Recently PDK2 (3-
phosphoinositid-dependent protein kinase 2) was identified as the rapamycin-independently 
regulated mTOR complex mTORC2 [141]. 
Akt kinase phosphorylates the tumour suppressor proteins TSC1/2 at several positions and 
thereby causes a reduction of inhibitory effects on mTOR [148]. This event actually increases 
the activity of mTORC1 complex and stimulates protein biosynthesis via its substrates 4E-
BP1 and S6Kinase. The complete signaling pathway is referred to as Insulin-PI3K-Akt-TSC-
mTORC1-S6K1/4E-BP1 (see figure 1.6). 
The important role of the tumour suppressor proteins TSC1 and TSC2 (Tuberous Sclerosis 
Protein 1 und 2) can be clarified by the fact that inactivating mutations cause development of 
tuberous sclerosis [149]. The proteins TSC1 and TSC2 form a functional complex in which 
TSC1 mainly exerts stabilizing action while TSC2 acts as GTPase activating protein (GAP) 
on subordinate targets. A crucial role of the complex is the inhibition of mTORC1: if the 
activity of the TSC proteins is lost, hyperactivation of mTOR complex 1 is induced which 
results in excessive cell growth and tumour formation.  
Target of the GTPase activating action of TSC1/TSC2 complex is the small regulatory 
GTPase Rheb (Ras-homolog enriched in brain). TSC2 activates Rheb’s intrinsic GTPase and 
converts it to its inactive, GDP-bound state [150, 151]. In turn Rheb acts as positive regulator 
of mTORC1, activating its kinase function [152]. This can be verified by overexpressing 
Rheb which leads to increased phosphorylation of 4E-BP1 and S6Kinase.  
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PRAS40 (proline-rich Akt substrate 40 kDa, [153]) represents another important regulator of 
mTORC1 activity and transfers mitogen-dependent signals directly to mTOR without a detour 
via the TSC complex [154]. In its hypophosphorylated form, PRAS40 acts as a direct 
inhibitor of mTOR kinase activity; when it becomes phosphorylated by Akt kinase, its 
inhibitory action decreases [155]. Normally, PRAS40 interacts with mTOR via Raptor [156] 
and thereby competes with other substrates for binding to the kinase [157].  
As increased mTOR activity leads to higher biosynthesis of ribosomes and protein translation 
rates, and as these processes entail significant energy consumption, mTOR must have a 
mechanism to detect the current energy level of the cell. The AMP-activated protein kinase 
AMPK serves as such a sensor of cellular ATP concentration and detects the AMP/ATP ratio. 
At high AMP concentrations the kinase is activated by direct AMP binding and 
phosphorylates TSC2 which in turn reduces mTORC1 activity via Rheb [158, 159].  
 
                    
 
Figure 1.6: mTOR senses different stimuli by integrating several upstream components  
Simplified representation of the PI3 kinase-Akt-mTOR signaling pathway.  
 
 
AMPK 
PRAS40 
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After successful activation of S6Kinase by mTORC1 the Akt signaling pathway is dampened 
by S6K1-dependent negative feedback inhibition [160]: S6Kinase directly phosphorylates 
IRS-1 (insulin receptor substrate 1) and thereby hinders its bridging function between the 
insulin receptor and PI3Kinase, also by promoting its degradation [161]. This auto-regulatory 
connection within the complex PI3K/Akt/mTORC1 signaling pathway serves as a tool for 
fine-tuning of insulin sensitivity.  
Recently, DEPTOR has been identified as a novel interaction partner of mTOR that inhibits 
kinase activity. Its expression is directly regulated and suppressed by mTORC1 and mTORC2 
[162, 163]. DEPTOR expression levels are relatively low in different human cancer cell lines. 
In some types of myeloma cells, the protein seems to be overexpressed, leading to Akt 
activation and maintenance of survival. 
 
The influence of amino acids on mTORC1 regulation is well characterized, but the underlying 
mechanisms were enigmatic for a long time. Recently, Sancak [164] and Li [165] discovered 
that mTORC1 interacts with members of the family of GTP-binding Rag proteins: these 
proteins form heterodimers, and amino acid supplementation converts them into a GTP-bound 
state. Once activated, RagB interacts directly with the mTORC1 component Raptor [164]. 
Another protein complex, called Ragulator, binds to Rag and triggers its translocation to 
lysosomes. As a consequence, mTORC1 is recruited to this compartment, where it is enabled 
to interact with membrane-bound Rheb, resulting in mTOR activation. Altogether, activated 
Rag mediates the interaction of mTORC1 and its activator at the surface of lysosomes [166].  
 
During the process of autophagy, cellular proteins and whole organelles are degraded in order 
to provide basic building blocks for cellular metabolism and regeneration, especially in times 
of starvation. Autophagy is essential for cell survival as it prevents cell death or damage 
[167]. Under conditions of amino acid abundance, mTORC1 also plays an important role in 
suppressing autophagy: via Raptor, it recruits the kinase ULK1, phosphorylates it and hereby 
inhibits its autophagy-inducing function [168]. When amino acids are missing and the cell is 
starving, mTORC1 is inactive, and the hypophosphorylated ULK1 complex translocates to 
the autophagosome in order to initiate the process [169].  
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1.5 – mTOR carries on signals by phosphorylating three main substrates 
 
1.5.1 – 4E-BP1: many phosphorylation sites, one kinase? 
 
Protein synthesis, a process tightly controlled in eukaryotes, is triggered mainly by mitogens, 
like insulin, amino acids and growth factors [170]. As a first crucial step, the 40S subunit of 
the ribosome must be recruited to mRNA which is done by the assembly of a “translation 
initiation complex” at the 5’ 7-methyl guanosine cap structure [171, 172]. One key component 
of this complex is the initiation factor eIF4E whose availability is regulated by sequestration 
of its binding protein 4E-BP1 (PHAS-I) [173, 174]. In its hypophosphorylated form, 4E-BP1 
is active and binds to eIF4E [175]. After sequential phosphorylation of its multiple 
phosphorylation sites, 4E-BP1 is inactivated and releases eIF4E which in turn initiates cap-
dependent translation [134].  
 
         
Figure 1.7: 4E-BP1 is inactivated by sequential phosphorylation events 
Schematic representation of 4E-BP1 phosphorylation sites; order of phosphorylation events by mTORC1 is 
indicated. Under in vivo conditions, phosphorylation of S65 and T70 is rapamycin-sensitive. 
 
Four phosphorylation sites seem to be crucial for regulation of 4E-BP1 (T37, T46, S65, T70) 
because they are regulated via growth signals (especially insulin) [176]. Furthermore, these 
sites are conserved evolutionarily and within the family of 4E-binding proteins [177]. As    
4E-BP1 contains a C-terminal TOS motif, it is a substrate of mTORC1 [178] and is 
phosphorylated by the kinase in a strictly hierarchical manner: first, the residues T37 and T46 
are modified by mTORC1, creating the basis for phosphorylation of T70 [179]. Lastly, Ser65 
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is phosphorylated, resulting in total loss of eIF4E binding [180] (see figure 1.7). The pairs of 
phospho-residues seem to modulate 4E-BP1 activity in a cooperative way: the first two 
residues are not sufficient for inactivation, while pS65 and pT70 alone cannot inhibit binding 
of 4E-BP1 to eIF4 completely [181]. 
Interestingly, only S65 and T70 phosphorylation can be reduced by rapamycin treatment in 
vivo; T37 and T46 do hardly respond to mTORC1 inhibition by the small molecule and do not 
depend on the TOS motif [182, 183]. Under in vitro conditions, mTORC1 phosphorylates 
T37/T46, while it has little effect on the phosphorylation state of S65/T70 [184]. Thus, 
speculations about mTORC1 not being the only kinase that regulates the different 
phosphorylation sites in 4E-BP1 cannot be maintained. It rather must be assumed that some of 
the mTORC1 functions cannot be affected by rapamycin. 
Rapamycin inhibition of mTOR activity has different effects on the substrates 4E-BP1 and 
S6Kinase in some cell types (e.g. HEK293 and HeLa cells). While T389 phosphorylation of 
S6Kinase is abolished reliably after short or long-term rapamycin treatment, regulation 
appears much more complicated for 4E-BP1. Here, phosphorylation of the critical residues 
S37/S46 is reduced during the first six hours of rapamycin treatment. Afterwards, the 
phosphorylation recovers, resulting in hyperphosphorylated 4E-BP1 at 12 hours of treatment, 
accompanied by high levels of cap-dependent protein translation in absence of active 
S6Kinase [185, 186]. As the TOS motif of 4E-BP1 and mTORC1 are necessary to induce this 
hyperphosphorylation, it is speculated whether some functions of mTORC1 are rapamycin-
insensitive. Some mechanisms have been proposed that might explain these differences, 
involving binding or release of regulatory proteins like PRAS40 to mTORC1 [157], changes 
in phosphorylation state of Raptor [187, 188] or post-translational modifications of mTOR 
itself.   
 
 
1.5.2 – p70 S6Kinase: more than just a regulator of translation  
 
p70 S6Kinase1 is a member of the AGC family of serine/threonine protein kinases and is 
present in mammalian cells as two isoforms. These isoforms are produced from the same 
transcript by differential translation and are regulated similarly [189]. The larger protein 
S6K1L (p85 S6K) carries an N-terminal extension that contains signals for nuclear 
localization, while the small isoform S6K1S (p70 S6K) is mainly present in the cytoplasm 
[190]. A second S6Kinase, named S6K2, is highly identical to S6K1 especially within the 
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catalytic and the autoinhibitory domain [191]. Both S6K1 and S6K2 are present ubiquitously 
in mammalian tissues. The amino acid sequence of S6K1 is totally conserved within 
mammals, while S6K2 displays alterations [192].  
 
                     
Figure 1.8: S6Kinase is activated by two phosphorylation steps 
Schematic representation of S6Kinase phosphorylation sites and involved kinases (adapted from Pearce et al. 
[193]). 
 
The activity of S6K is mainly regulated by the canonical IR-PI3K-Akt-TSC-mTOR signaling 
pathway in response to stimuli like growth factors, mitogens and nutrients. During activation, 
the kinase is phosphorylated in a complex manner at multiple serine and threonine residues 
within the C-terminal regulatory domain and the kinase domain (see figure 1.8): first, T389 is 
phosphorylated by mTOR in a TOS-motif dependent way [136]. This phospho-threonine 
serves as a binding site for the kinase PDK1, whose action leads to phosphorylation of T229 
within the catalytic activation loop [194]. Additionally, the nucleocytoplasmatic shuttling of 
the isoforms seems to be regulated by phosphorylation events [195]. S6K1 regulates a lot of 
effector proteins by direct phosphorylation, among them ribosomal proteins (S6, IF-4B and 
the eEF2 kinase [196, 197]), transcription factors (CREM) and proteins involved in cell 
survival (Bad1, PDCD4) [198]. IRS (insulin receptor substrate) phosphorylation serves as a 
mechanism of negative feedback and causes inhibition of the whole pathway [160, 199]. 
The termination of S6K signaling is mainly mediated by three mechanisms: first, association 
with the protein phosphatases PP2A and PP1 leads to dephosphorylation of specific sites and 
renders the kinase inactive [200]. Secondly, recent studies suggest that the cellular S6K 
protein levels might be regulated by ubiquitin-dependent degradation in an unknown manner 
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[201]. Lastly, the activation of the tumour suppressors PTEN and TSC1/2 inhibit mTOR 
activity which in turn reduces S6K activation [202]. 
The kinase passes on an anabolic signal in order to influence cell size and growth by affecting 
protein translation and cellular energy levels. Insulin and insulin-like growth factor 1 
signaling (IIS) pathway and the mTOR pathway play a role in regulation of life span in lower 
organisms and in mice [203]. In flies, variant forms of S6K seem to influence fat metabolism, 
immune response and longevity [204]. Recently it has been demonstrated that S6K1-knockout 
mice show an increased life span and are less prone to age-related disease. These effects are 
caused by gene expression patterns that are similar to the ones seen during caloric restriction 
and are connected to activity of AMP-activated protein kinase (AMPK) [205]. Furthermore, 
in a transgenic mouse model of Alzheimer’s Disease, mTOR inhibition by rapamycin and 
resulting S6Kinase inactivation decelerated Aß protein accumulation and disease progression. 
These effects are mainly caused by increased autophagy of affected cells [206]. 
Recently, an interaction of the prolyl isomerase Pin1 with S6K in hepatocarcinoma cells has 
been described. Overexpression of Pin1 increases insulin-dependent S6K phosphorylation, 
resulting in enhanced cell transformation and tumorigenesis [207]. 
 
 
1.5.3 – Akt/PKB: connecting the mTOR complexes 
 
The Akt protein kinases (alternatively: Protein Kinases B) are involved in regulation of a 
variety of cellular processes, including survival, growth and metabolism. This is mainly 
achieved by three different, but nevertheless highly homologous isoforms (Akt1, 2 and 3) 
[208] which share a common mechanism of activation but act on different downstream 
substrates. The Akt proteins are integrated in the insulin-PI3K signaling pathway which is 
activated upon reception of extra-cellular stimuli like growth factor or insulin [209]. As a 
consequence of PI3K activity, the concentration of PIP3 within the plasma membrane 
increases and allows recruitment of Akt to the membrane [210]. This re-localization triggers 
phosphorylation of two residues of Akt (T308 within the catalytic domain and S473 within 
the C-terminal hydrophobic domain) by the kinases PDK1 [211] and mTORC2 [141], 
respectively (see figure 1.9). Once activated, Akt phosphorylates a lot of different substrates 
independently of the cellular localization. By phosphorylating the protein BAD [212], the 
transcription factor FOXO3 [213] and the pro-caspase9 [214], Akt inhibits proapoptotic 
processes and promotes cell survival. By alleviating the inhibitory action of the tumour 
suppressor protein TSC2 [215] and PRAS40 [155], Akt activates mTORC1 signaling and thus 
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promotes cell growth via promotion of ribosomal protein biosynthesis. Cell cycle progression 
can also be accelerated by Akt-mediated phosphorylation of the cyclin-dependent kinase 
inhibitor p27Kip1 [216].  
                   
Figure 1.9: Akt kinase is activated by membrane recruitment and two phosphorylation steps 
Schematic representation of Akt kinase phosphorylation sites, involved kinases and cellular localization (adapted 
from Pearce et al. [193]). 
 
 
The importance of Akt kinase action on cellular processes has been demonstrated very clearly 
by knockout experiments in mice: animals missing Akt1 display impaired growth during all 
stages of development [217] and increased rates of apoptosis on a cellular level [218]. Akt2 
knockout results in a phenotype characterized by insulin resistance and subsequent 
hyperglycemia, accompanied by the loss of pancreatic ß-cells. In male mice, a severe form of 
diabetes occurs [219, 220]. Mice lacking Akt3 show impairment in brain development [221], 
but are otherwise healthy. Combined knockout experiments indicate that some functions 
overlap and thus can be compensated by other isoforms, especially by the indispensable Akt1 
[222]. Other tasks seem to be exclusive to certain Akt isoforms.   
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1.6 – Rapamycin in cancer treatment: promising in combination 
 
As PI3K/Akt/mTOR signaling is crucially involved in regulation of cell growth, proliferation 
and survival, hyperactivity of this pathway can be commonly found in a variety of human 
cancers (reviewed in [223]). Very often, mutations or silencing of the tumour-suppressor 
PTEN are responsible for excessive signaling; this can be observed in cancers including 
glioblastoma [224], melanoma [225], hepatocellular carcinoma [226] and cancers of lung, 
thyroid [227] and renal cells [228]. In some cases, there are additional factors, like PI3K 
mutations (especially deletions within the autoregulatory domain) that contribute to 
malignancy [229]. Although a single deregulated protein can be sufficient for cancer 
development, there are several different factors involved in hyperactivation of mTOR 
signaling in ovarian or breast cancer cells: here, aberrant Akt2 activation or overexpression 
are frequently found in addition to PTEN and PI3K mutations [230]. Interestingly, no 
malignant mutations of the kinase mTOR itself are reported. 
 
      
   Rapamycin (Sirolimus)                   Temsirolimus                                 Everolimus 
 
Figure 1.10: Rapalogues share the same core structure  
Structures of rapamycin and the two analogues temsirolimus and everolimus which carry different substitution at 
the cyclohexyl moiety. 
 
 
A general anti-proliferative effect of rapamycin has been reported for a panel of different 
cancer cells in mouse models [231]. To increase oral bio-availability and compound 
concentration in the target organs, several rapamycin analogues (“Rapalogues”) were 
developed (see figure 1.10). Some of these derivatives are metabolized to form rapamycin and 
therefore exhibit similar modes of action as the original compound concerning mTOR 
inhibition; others seem to exert additional FKBP-independent effects at high concentrations 
[232]. Preclinical studies, mainly using mouse models, verified the effectiveness of rapamycin 
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and its homologues: in mouse xenograft, the rapamycin-derivative everolimus was able to 
reduce growth of different human tumour transplants, mainly by affecting angiogenesis via 
VEGF signaling [233, 234]. In a mouse model of neuroendocrine tumours, rapamycin 
reduced tumour growth significantly and increased survival [235]. Interestingly, the effects of 
rapamycin can be further increased by co-administration of the PI3K inhibitor LY294002 
which reduces rapamycin-induced Akt hyperphosphorylation in human T-cell leukaemia 
[236], but not in melanoma cells [237]. Temsirolimus turned out to be a promising candidate 
in clinical trials with patients suffering from kidney carcinoma [238-240]. The compound was 
also successfully tested in model systems of human breast cancer, where it exerted anti-
proliferative effects mainly by reducing cyclin D and c-myc protein levels [241]. Similarly, 
everolimus is currently studied in several clinical trial targeting neuroendocrine tumours and 
renal cell carcinoma [242]. Unfortunately, the degree of rapamycin/rapalogue sensitivity 
varies greatly between different cell lines, rendering some of them totally resistant. As marker 
proteins for prediction of sensitivity, S6Kinase protein levels and activation state of Akt have 
been proposed for breast cancer cells [243].  
For temsirolimus and everolimus, clinical trials with cancer patients have been carried out, 
and promising results have been obtained [244]: treatment regimen could be adjusted in order 
to prevent side-effects (rash, mucositis, anorexia and fatigue), and survival rates could be 
increased especially with temsirolimus in patients suffering from renal cell carcinoma [245]. 
In mantle cell lymphoma, the compound worked in 38% of all patients and slightly delayed 
disease progression [246]. Nevertheless, in many cases a combinational therapy using both 
mTOR inhibitors and MAPK inhibitors (such as sorafenib) is preferable, as activation of 
MAPK signaling overrides mTOR inhibition in some types of cancers [247]. 
 
Due to complexity of PI3K/Akt/mTOR signaling, many mechanisms have been detected that 
generate resistance to rapamycin and rapalogues: first of all, mutations of FKBP12 
(predominantly D37G, [248-250]) reduce rapamycin binding affinity. This is also true for 
mutations in the FRB domain of mTOR (namely S2035I, [21]) which largely prevent 
FKBP12*rapamycin binding and thus abolish mTOR inhibition [251]. Secondly, the ratio of 
the initiation factor eIF4E and its inhibitor 4E-BP1 seems to be an indicator of tumour 
malignancy as either overexpression of eIF4E [252] or down-regulation of 4E-BP1 [253] 
increases the tendency of malign degeneration of cancer cells. Next, p53 status is known to 
influence the response of mouse embryonic fibroblast (MEF) cells after rapamycin treatment: 
if the tumour suppressor protein is mutated and not functional, rapamycin triggers a stress-
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induced apoptotic pathway, resulting in rapid cell death. Cells that express active p53 are 
protected against this effect of rapamycin [254]. ABC-transporters, like P-glycoprotein, are 
involved in generation of multi-drug-resistant phenotypes: rapamycin (as well as FK506 and 
cyclosporin A) has been reported to reverse drug-resistance by binding to the receptors and 
inhibiting their ATP hydrolyzing activity. Thus, the small molecules might also be substrates 
for transport [255, 256]. Another important mechanism of rapamycin resistance includes 
angiogenesis: as mTOR signaling regulates cap-dependent protein translation, concentration 
of HIF-1α (hypoxia inducible factor 1α) might be lowered after rapamycin treatment, 
resulting in reduced VEGF (vascular endothelial growth factor) release. As a result, growth of 
tumour xenografts in mouse models is inhibited significantly, although the original cells are 
resistant to rapamycin under cell culture conditions [231, 257, 258].  Finally, the application 
of growth factors (like insulin or IGF-I) suppresses rapamycin-mediated apoptosis. This 
happens mainly by triggering pathways involving Akt kinase which lead to inactivation of the 
protein Bad; Bad normally exerts pro-apoptotic effects [259]. 
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1.7 – Aim of the project: 
 
During the last two decades, the kinase mTOR turned out to be a central player in the 
regulation of cellular processes: it integrates mitogen-activated signaling pathways via 
PI3K/Akt kinase, energy-level dependent regulation via AMPKinase and allows inhibition via 
FKBP12*rapamycin. All these processes mediate modifications of mTOR activity and 
thereby induce fine-tuning of downstream processes like initiation of translation, ribosomal 
biogenesis, autophagy and actin organisation. 
The family of FK506-binding proteins comprises several functionally heterogeneous 
members that display high homology within their FK domains. This part of the protein is 
responsible for binding of the natural compound rapamycin, and it exerts PPIase activity. 
Thus, one could postulate that apart from FKBP12 other FKBPs might bind to the FRB 
domain of mTOR in presence of rapamycin and influence the kinase in a defined manner. 
 
Therefore this research project is dedicated to theses central questions: which members of the 
FKBP protein family bind to mTOR in a rapamycin-dependent manner? Does this interaction 
exert regulatory effects on mTOR kinase activity? 
 
A more profound characterization of the molecular mode of rapamycin action is crucial for a 
better understanding of its pharmacological effects in different tissues. This in turn could form 
the basis for the development of rapamycin-derivatives which are FKBP subtype-selective 
and therefore might allow mTOR inhibition in a cell type- or context-dependent manner. 
Eventually, this development might produce compounds that could allow mTOR inhibition 
without exerting the classical immunosuppressive action of rapamycin as a critical side effect. 
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2 – Materials:  
 
2.1 – Oligonucleotide primers: 
 
For amplification and cloning of FKBP nucleotide sequences the following oligonucleotide 
primers and cloning strategies were used together with the indicated vectors:  
 
Name Sequence (5’–3’) Amplificat  Cloning  strategy 
Eco-FKBP12-
Start 
AAAGAATTCATGGGAG
TGCAGGTGGAAACC 
Human FKBP12 
(Accession: 
NM_000801), 
324 bp 
With EcoRI and SalI in 
pPROEx-HTa and pYX424 
→ pProExHta-FKBP12, 
pYX424-FKBP12 
FKBP12-Stop-
Sal 
CCCGTCGACTCATTCCA
GTTTTAGAAGCTCC 
FKBP12.6-
EcoRI-forward 
CCGGAATTC 
ATGGGCGTGGAGATC
GAG 
Human 
FKBP12.6 
(NM_004116), 
360 bp 
With EcoRI and XhoI in 
pPROEx-HTa and pYX424  
→ pProExHta-FKBP12.6,  
pYX424-FKBP12.6 FKBP12.6-
XhoI-reverse 
GCTCGAGTCACTCTAA
GTTGAGCAGCTC 
FKBP13-EcoRI-
forward 
CCGGAATTCAAAAGG 
AAGCTGCAGATCGG 
Human FKBP13 
(NM_004470), aa 
27 – 142, 348 bp 
With EcoRI and XhoI in 
pPROEx-HTa and pYX424 
→ pProExHta-FKBP13, 
pYX424-FKBP13 
FKBP13-XhoI-
reverse 
GCTCGAGTTACAGCTC
AGTTCGTCGCTC 
FKBP25-EcoRI-
forward 
CCGGAATTCATGGCGG
CGGCCGTTCC 
Human FKBP25 
(NM_002013), 
675 bp 
 
With EcoRI and XhoI in 
pPROEx-HTa and pYX424 
→ pProExHta-FKBP25, 
pYX424-FKBP25 
FKBP25-XhoI-
forward 
GCTCGAGTCAATCAAT
ATCCACTAATTC 
FKBP51-NcoI-
forward 
GGCCATGGGGATGACA
CTGATGAAGG 
Human FKBP51 
(NM_004117), 
1374 bp 
With NcoI and XhoI in 
pProEx-HTa and pYX242 → 
pProExHta-FKBP51, 
pYX424-FKBP51 
FKBP51-XhoI-
reverse 
GCCTCGAGTCATACGT
GGCCCTCAGGTTTCTC 
FKBP52-NcoI-
forward 
GCGCCATGGGGATGAC
AGCCGAGGAG 
Human FKBP52 
(NM_002014), 
1380 bp 
 
With NcoI and XhoI in 
pProEx-HTa and pYX424 → 
pProExHta-FKBP52, 
pYX424-FKBP52 
FKBP52-XhoI-
reverse 
GCCTCGAGTCATGCTT
CTGTCGAACAAG 
FKBP51-FK1-
EcoRI-forward 
CGGAATTCATGACTAC
TGATGAAGGTGC 
Human FKBP51 
(NM_004117), 
fragment aa        
1-140, 420 bp 
With EcoRI and SalI in 
pPROEx-HTa and pXY424 
→ pProExHta-FKBP51 FK1, 
pYX424-FKBP51 FK1 
FKBP51-FK1-
SalI-reverse 
GCAGTCGACTCTCCTT
TGAAATCAAGGAGC – 
3’ 
FKBP52-FK1-
EcoRI-forward 
CCGAATTCATGACAGC
CGAGGAGATG 
Human 
FKBP52  
(NM_002014), 
Fragment aa       
1- 140, 420 bp 
With EcoRI and SalI in 
pPROEx-HTa and pYX424 
→ pProExHta-FKBP52 FK1, 
pYX424-FKBP52 FK1 
FKBP52-FK1-
SalI-reverse 
GTCGAC 
TCATTCTCCCTTAAAC
TCAAACAACTC 
 
Table 2.1:  Oligonucleotide primers and cloning strategies used for generation of FKBP plasmids 
The restriction sites are underlined, coding sequences are bold. 
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cDNA templates for human FKBP12, FKBP51 and FKBP52 were kindly provided by         
Dr. Theo Rein. Plasmids containing ORFs of FKBP12.6, FKBP13 and FKBP25 were a kind 
gift of Dr. Gunter Fischer. cDNA of human mTOR was provided by Prof. Jie Chen            
(see table 2.7).  
 
The following primers were used for generation of FRB constructs and FRB variants: 
 
Name Sequence Amplificat              Cloning  
            strategy 
His-FRB-forw-
EcoRI 
5’ - CGGAAT TCATGGAGA 
TGTGGCATGAAGG – 3’ 
 
 
Human FRAP1 
(TOR; 
NM_004958), 
aa 2025 - 2114 
 
With EcoRI and 
XhoI in pPROEx-Hta  
→ pProExHta-FRB His-FRB-rev-
XhoI 
 
5’ - GCTCGA GCCTTACTG 
CTTTGAGATTCG – 3’ 
GST-FRB-
forward-
BamHI 
5’ - 
GCGGATCCATGGAGATG
TGGCATGAA 
With BamHI and 
EcoRI in pGEX-4T2  
→ pGEX-4T2-FRB 
GST-FRB-rev-
EcoRI 
5’ – 
CGGAATTCTTACTGCTTT
GAGATTCGTCGG – 3’ 
 
Table 2.2: Oligonucleotide primers and cloning strategies used for generation of FRB plasmids 
 
 
The primers used for amplification of EGFP variants read as follows: 
 
Name Sequence Amplificat    Cloning   
    strategy 
EGFP-KasI-forw 5’ - GGCGCC ATG GTG AG 
C AAG GGC GAG GA – 3’ 
EGFP in vector 
pEGFP-N1 
(Accession 
Number 
U55762), 
bp 789 - 1395 
With KasI and 
NcoI in pPROEx-Hta 
→ 
pProExHta-EGFP 
EGFP-NcoI-rev 5’-CCATGG   
CCTTGTACAGCTCGTCC
ATGCCGAG – 3’ 
Table 2.3: Oligonucleotide primers and cloning strategies used for generation of EGFP plasmids 
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For generation of plasmids for FKBP expression in mammalian cells, the following primers 
were used: 
  
Name Sequence (5’–3’) Amplificat      Cloning     
    strategy 
12-FLAG-Eco-
forward 
CGGAATTCATGGACTAC 
AAGGACGATGACGATA
AG 
ATGGGAGTGCAGGTG
GAAACCATC  
Human 
FKBP12 
(Accession: 
NM_000801), 
324 bp 
With EcoRI and XhoI 
in pcDNA3  
→ pcDNA3-FLAG-
FKBP12 
12-XhoI-Stop-
reverse 
GG CTCGAG   
TCATTCCAGTTTTAGA
AGCTCCACA 
12.6-FLAG-
Eco-forward 
CGGAATTCATGGACTAC 
AAGGACGATGACGATA
AGATGGGCGTGGAGAT
CGAGACCATC 
Human 
FKBP12.6 
(NM_004116), 
360 bp 
With EcoRI and XhoI 
in pcDNA3  
→ pcDNA3-FLAG-
FKBP12.6 
12.6-XhoI-
Stop-reverse 
GGCTCGAGTCACTCTAA
GTTGAGCAGCTCC 
13ab26-FLAG-
Eco-forward 
CGGAATTCATGGACTAC 
AAGGACGATGACGAT 
AAGAAAAGGAAGCTGC
AG ATCGGGGTC 
Human 
FKBP13 
(NM_004470), 
aa 26 – 142, 
348 bp 
With EcoRI and XhoI 
in pcDNA3  
→ pcDNA3-FLAG-
FKBP13 
13-XhoI-Stop-
reverse 
GGCTCGAGTCACAGCT
CAGTTCGTCGCTC 
25-FLAG-Eco-
forward 
CGGAATTCATGGACTAC 
AAGGACGATGACGATA
AGATGGCGGCGGCCGT
TCCACAGCGG 
Human 
FKBP25 
(NM_002013), 
675 bp 
 
With EcoRI and XhoI 
in pcDNA3  
→ pcDNA3-FLAG-
FKBP25 
25-XhoI-Stop-
reverse 
GG CTCGAG   
TCAATCAATATCCACT
AATTCCACTT 
FKBP51 in 
pcDNA3 
TTTTGGTACCCCCACCA
TGGACTACAAGGACGAT
GACGATAAGACTAC 
TGATGAAGGTGCC 
Human 
FKBP51 
(NM_004117), 
1374 bp 
With XbaI and KpnI 
in pcDNA3  
→ pcDNA3-FLAG-
FKBP51 
3´FKBP51 in 
pGem 
GCGGTACCTCATACGTG
GCCCTCAGGTTTCTC 
FKBP52 in 
pcDNA3 
TTTTGGTACCATG 
GACTACAAGGACGATG
ACGATAAGACAGCCGA
GGAGAT 
Human 
FKBP52 
(NM_002014), 
1380 bp 
 
With XbaI and KpnI 
in pcDNA3 
→ pcDNA3-FLAG-
FKBP52 
3´FKBP52 in 
pGem4 
GCGGTACCTCATGCTTC
TGTCGAACAAG 
 
Table 2.4: Oligonucleotide primers and cloning strategies used for generation of  
                  FKBP expression plasmids 
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2.2 – Expression vectors: 
 
The following commercial vectors were used for protein expression in bacteria and yeast 
cultures: 
 
Name Size Usage Provides resistance / 
auxotrophy 
 
Manufacturer 
pProEx-Hta 4779 bp Expression of proteins 
with N-terminal 
hexahistidin tag in      
E. coli 
Ampicillin Invitrogen 
(Karlsruhe) 
pGex-4T2 4970 bp Expression of proteins 
as N-terminal GST-
Fusion in E. coli 
Ampicillin GE Healthcare 
(München) 
pYX223 7.6 kbp Inducible 
overexpression  of 
proteins in          
S. cerevisiae 
Ampicillin in E. coli; 
Histidine auxotrophy 
in S. cerevisiae 
Novagen/Merck 
(Darmstadt) 
 
Table 2.5: Vectors used for protein expression 
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The following commercially available protein expression plasmids were used for experiments 
in mammalian cell cultures: 
 
Name Vector Size Protein 
expression 
(from species) 
Order 
number 
Resistance in   
E. coli 
 
Manufacturer 
pRK5-
FLAG-
DEPTOR 
pRK5 7050 
bp 
Expression of 
FLAG-tagged 
DEPTOR 
 (H. sapiens) 
21334 Ampicillin Addgene 
(Cambridge, 
USA) 
pRK5-
myc-
Raptor 
pRK5 10754 
bp 
Expression of 
myc-tagged 
Raptor 
 (H. sapiens) 
1859 Ampicillin Addgene 
(Cambridge, 
USA) 
pRK5-
myc-
Rictor 
pRK5 10454 
bp 
Expression of 
myc-tagged 
Rictor 
 (H. sapiens) 
11367 Ampicillin  Addgene 
(Cambridge, 
USA) 
pRK7-
HA-S6K1-
WT 
pRK7 6200 
bp 
Expression of 
HA-tagged S6 
Kinase 1           
(R. norvegicus) 
8984 Ampicillin Addgene 
(Cambridge, 
USA) 
 
Table 2.6: Expression vectors used for protein expression in mammalian cells 
 
 
The plasmids for overexpression of FLAG-tagged human mTOR and the mutant S2035T 
were a kind gift of Prof. Jie Chen (UCLA, Riverside, USA): 
 
Name Vector Size Protein expression 
(from species) 
Resistance in E. coli 
 
pcDNA3-
FLAG-
mTOR 
pcDNA3 13225 
bp 
Expression of FLAG-
tagged mTOR 
 (H. sapiens) 
Ampicillin 
pcDNA3-
FLAG-
mTOR 
S2035T 
pcDNA3 13225 
bp 
Expression of FLAG-
tagged mTOR, 
mutant S2035T 
 (H. sapiens) 
Ampicillin 
 
Table 2.7: Expression vectors used for mTOR expression in mammalian cells 
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2.3 - Primary antibodies: 
 
For protein detection in immunoblotting experiments, the following primary antibodies were 
diluted in buffered protein solution (BSA or milk powder): 
 
Name Antigene 
sequence 
IgG subtype 
from species 
Dilution factor and 
used solution 
Manufacturer 
α-4E-BP1 
phospho S65 
Peptide around 
phospho S65 
IgG, monoclonal, 
from rabbit 
1:1000 in 5% (w/v) 
BSA in TBS 
Cell Signaling 
(Danvers, MA, USA) 
α-4E-BP1 
phospho 
T37/46 
Peptide around 
phospho T37/46 
IgG, monoclonal, 
from rabbit 
1:1000 in 5% (w/v) 
BSA in TBS 
Cell Signaling 
(Danvers, MA, USA) 
α-6xHis tag Hexahistidyl 
peptide 
IgG, polyclonal, 
from rabbit 
1:1000 in 5% (w/v) 
milk powder in TBS 
Abcam (Cambridge, 
UK) 
α-Actin Not known IgG, polyclonal, 
from rabbit 
1:5000 in 5% (w/v) 
milk powder in TBS 
Abcam (Cambridge, 
UK) 
α-Akt kinase 
(pan) 
C-terminal 
sequence of 
mouse Akt 
IgG, monoclonal, 
from rabbit 
1:1000 in 5% (w/v) 
milk powder in TBS 
Cell Signaling 
(Danvers, MA, USA) 
α-Akt 
phospho 
S473 
Peptide around 
phospho S473 
IgG, monoclonal, 
from rabbit 
1:1000 in 5% (w/v) 
BSA in TBS 
Cell Signaling 
(Danvers, MA, USA) 
α-FKBP12 Not known IgG, polyclonal, 
from rabbit 
1:1000 in 5% (w/v) 
milk powder in TBS 
Abcam (Cambridge, 
UK) 
α-FKBP12.6 Aa 1-81 
FKBP12.6 
IgG1, 
monoclonal, from 
mouse 
1:500 in 5% (w/v) milk 
powder in TBS 
Abcam (Cambridge, 
UK) 
α-FKBP13 Not known IgG, polyclonal, 
from rabbit 
1:1000 in 5% (w/v) 
milk powder in TBS 
Proteintech Group 
(Chicago, IL, USA) 
α-FKBP25 Peptide from 
aa1-100 
IgG, polyclonal, 
from rabbit 
1:1000 in 5% (w/v) 
milk powder in TBS 
Abcam (Cambridge, 
UK) 
α-FKBP38 Not known IgG, polyclonal, 
from rabbit 
1:1000 in 5% (w/v) 
milk powder in TBS 
Abcam (Cambridge, 
UK) 
α-FKBP51 Peptide from aa 
407-457 
IgG, polyclonal, 
from rabbit 
1:5000 in 5% (w/v) 
milk powder in TBS 
Bethyl Laboratories 
(Montgomery, TX, 
USA) 
α-FKBP52 Peptide from aa 
400-440 
IgG, polyclonal, 
from rabbit 
1:5000 in 5% (w/v) 
milk powder in TBS 
Bethyl Laboratories 
(Montgomery, TX, 
USA) 
α-FLAG DYKDDDDK IgG1, 
monoclonal, from 
mouse 
1:1000 in 5% (w/v) 
milk powder in TBS 
Sigma (Saint Louis, 
MS, USA) 
α-HA YPYDVPDYA IgG1, 
monoclonal, from 
mouse 
1:1000 in 5% (w/v) 
milk powder in TBS 
Roche Diagnostics 
(Mannheim) 
α-mTOR Not known IgG, polyclonal, 
from rabbit 
1:1000 in 5% (w/v) 
milk powder in TBS 
Cell Signaling 
(Danvers, MA, USA) 
α-MYC EQKLISEEDL IgG2a, 
monoclonal, from 
mouse 
1:1000 in 5% (w/v) 
milk powder in TBS 
Cell Signaling 
(Danvers, MA, USA) 
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α-p70 S6 
kinase 
C-terminus of 
human p70 S6 
kinase 
IgG, polyclonal, 
from rabbit 
1:1000 in 5% (w/v) 
milk powder in TBS 
Cell Signaling 
(Danvers, MA, USA) 
α-p70 S6K 
phospho 
T389 
Peptide around 
phospho T389 
IgG, polyclonal, 
from rabbit 
1:1000 in 5% (w/v) 
BSA in TBS 
Cell Signaling 
(Danvers, MA, USA) 
α-Raptor Not known IgG, polyclonal, 
from rabbit 
1:1000 in 5% (w/v) 
milk powder in TBS 
Cell Signaling 
(Danvers, MA, USA) 
α-Rictor Peptide around 
K1125 of 
human Rictor 
IgG, polyclonal, 
from rabbit 
1:1000 in 5% (w/v) 
milk powder in TBS 
Cell Signaling 
(Danvers, MA, USA) 
 
Table 2.8: Primary antibodies used in immunoblotting experiments and their properties  
 
2.4 – Secondary antibodies: 
 
The following secondary antibodies were used in immunoblotting experiments: 
 
Name Conjugation IgG subtype 
from species 
Dilution factor and 
used solution 
Manufacturer 
Mouse IgG Horseradish 
peroxidase 
Polyclonal, IgG, 
H&L,  from goat 
1:3500 in 5% (w/v) 
milk powder in TBS 
Abcam 
(Cambridge, UK) 
Rabbit IgG Horseradish 
peroxidase 
Polyclonal, IgG, 
H&L, from goat 
1:3500 in 5% (w/v) 
milk powder in TBS 
Abcam 
(Cambridge, UK) 
Goat IgG Horseradish 
peroxidase 
Polyclonal, IgG, 
H&L, from donkey 
1:3500 in 5% (w/v) 
milk powder in TBS 
Abcam 
(Cambridge, UK) 
 
Table 2.9: Secondary antibodies used in immunoblotting experiments 
 
2.5 – Bacterial strains: 
 
While Escherichia Coli strain DH5α was used especially for cloning of PCR products and for 
preparation of plasmid DNA, the strain BL21(DE3) is suitable for heterologous protein 
expression. The strains were purchased from Invitrogen (Karlsruhe) and display the following 
genotypes: 
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Strain Genotype 
DH5α F' Phi80dlacZ ΔM15 Δ(lacZYA-argF)U169 deoR recA1 endA1 
hsdR17(rK-mK+)phoA supE44 lambda- thi-1 
BL21(DE3)pLysS F–, ompT, hsdSB (rB–, mB–), dcm, gal, λ(DE3), pLysS, Cmr. 
 
Table 2.10: Bacterial strains used for cloning and expression experiments 
 
 
2.6 – Yeast strains: 
 
Saccharomyces cerevisiae wild type yeast cells and FKBP deletion mutants (provided by 
Euroscarf, Frankfurt) were used.  The genotypes are as follows: 
 
 Accession 
Number 
Name of 
the strain 
Mating 
type 
Genotype Deletion 
Wild 
type 
Y10000 BY4742 Mat a his3D1; leu2D0; 
lys2D0; ura3D0; 
/ 
Mutant Y12941 BY4742 Mat a his3D1; leu2D0; 
lys2D0; ura3D0; 
YNL135c::kanMX4 
YNL135c 
(=FPR1) 
 
Table 2.11: Yeast strains used for complementation assay 
 
 
2.7 – Mammalian cell lines: 
 
The following mammalian cell lines were used: 
 
Name Description Origin Provided by ATCC Number 
HeLa Cervix adenocarcinoma 
cells 
H. sapiens Dr. T. Rein CCL-2 
HEK293 Embryonic kidney cells H. sapiens Dr. T. Rein CRL-1573 
 
Table 2.12: Mammalian cell lines used for different experiments 
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2.8 – Media and additives for cell culture: 
 
The following media were used to maintain mammalian cell cultures: 
 
Name Contains Used for Manufacturer 
Dulbecco’s Modified 
Eagle Medium 
4.5 g/l glucose,               
L-glutamine 
HeLa, HEK,  Gibco-Invitrogen 
(Karlsruhe) 
Dulbecco’s Phosphate 
Buffered Saline 
 all cell lines Gibco-Invitrogen 
(Karlsruhe) 
Heat Inactivated Fetal 
Calf Serum (FCS) 
 all cell lines Gibco-Invitrogen 
(Karlsruhe) 
Pen Strep  5000 U/ml Penicillin, 
5000 U/ml streptomycin 
all cell lines Gibco-Invitrogen 
(Karlsruhe) 
0.25% Trypsin-EDTA  all cell lines Gibco-Invitrogen 
(Karlsruhe) 
 
Table 2.13: Media and additives used for cell culture experiments 
 
 
 
2.9 – siRNA: 
 
siRNA for RNAi experiments in HeLa cells was purchased from Thermo Fischer Scientific 
Dharmacon (Schwerte): 
 
Name Target Targeting sequence 
ON-TARGETplus 
Non-targeting Pool 
Control (non-targeting) unknown 
ON-TARGETplus siRNA 
J-009494-07-0005 
Human FKBP1A 
(=FKBP12; 
NM_0540145) 
GAGCCAAACUGACUAUAUC  
 
Table 2.14: siRNA used for knockdown experiments 
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2.10 - Chemicals: 
 
The chemicals used for this work are listed below and were purchased from the indicated 
companies: 
 
Acryl amid Roth (Karlsruhe)  
Adenosine 5´-Triphosphat  Roth (Karlsruhe) 
Adenine Roth (Karlsruhe) 
Agarose SeaKem  Biozym (Oldendorf) 
Agar-Agar Roth (Karlsruhe) 
Ammonium peroxodisulfate  Roth (Karlsruhe) 
Ammonium sulfate Roth (Karlsruhe) 
Ampicillin  Roth (Karlsruhe) 
Anti-FLAG M2 Affinity Gel Sigma (Steinheim) 
Anti-HA-Agarose Sigma (Steinheim) 
Bisacryl amid Roth (Karlsruhe) 
Boric acid  Calbiochem (San Diego, CA, USA) 
Bradford reagent Bio Rad (München) 
Brilliant Blue R250 Roth (Karlsruhe) 
Bromophenol Blue Merck (Darmstadt) 
Calciumchloride Roth (Karlsruhe) 
3-[(3-Cholamidopropyl)dimethylammonio]-1- 
       propanesulfonate (CHAPS) Roth (Karlsruhe) 
p-Coumaric acid Sigma-Aldrich (Steinheim)  
Desoxynucleotide mix NEB (Frankfurt am Main) 
DharmaFECT 2 transfection reagent Thermo Fischer Scientific (Schwerte) 
Dimethyl sulfoxide (DMSO)  Roth (Karlsruhe) 
1,4-Dithiotreitole  Roth (Karlsruhe) 
EDTA (Titriplex III) Merck (Darmstadt)  
Ethidium bromide  Roth (Karlsruhe) 
Everolimus Molcan (Toronto, Canada) 
EZview Red Anti-c-MYC Affinity Gel  Sigma (Steinheim) 
FK506  Fujisawa Pharmaceuticals (Osaka, Japan) 
FLAG peptide Sigma (Steinheim) 
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D-(+)-Galactose Roth (Karlsruhe) 
D-(+)-Glucose Roth (Karlsruhe) 
Glycerol (86-88% (v/v)) Roth (Karlsruhe) 
Glycerol phosphate Roth (Karlsruhe) 
Glycine Roth (Karlsruhe) 
GST ProCatch Sepharose Miltenyi Biotech (Bergisch Gladbach) 
HA peptide Sigma (Steinheim) 
Hepes Biomol (Hamburg) 
L-Histidine Roth (Karlsruhe) 
Imidazole Roth (Karlsruhe) 
Isopropyl-beta-D-thiogalactopyranoside (IPTG) Roth (Karlsruhe) 
LB medium (Luria/Miller) Roth (Karlsruhe) 
L-Leucine Roth (Karlsruhe) 
Lipofectamine 2000 Invitrogen (Karlsruhe) 
Lithium acetate (LiAc) Alfa Aesar (Karlsruhe) 
Lithium chloride Merck (Darmstadt) 
Luminol Roth (Karlsruhe) 
L-Lysine hydrochloride Roth (Karlsruhe) 
LY94002 NEB (Frankfurt am Main) 
Magnesium chloride Merck (Darmstadt) 
2-Mercaptoethanol Merck (Darmstadt) 
Milk powder Roth (Karlsruhe) 
MYC peptide Sigma (Steinheim) 
Ni-NTA agarose Qiagen (Hilden) 
Peptone from casein Roth (Karlsruhe) 
Phenylmethylsulfonyl fluoride (PMSF) Molekula (Vaterstetten) 
PI-103 Calbiochem (San Diego, CA, USA) 
Polyethylenglycole 4000 Roth (Karlsruhe) 
Ponceau S  Roth (Karlsruhe) 
Protease inhibitor cocktail  Sigma (Steinheim) 
Protein A resin GenScript (Piscataway, USA) 
Rapamycin (Lot #R020) Cfm (Marktredwitz) 
Saccharose Merck (Darmstadt) 
Salmon Sperm Carrier DNA Gibco-Invitrogen (Karlsruhe) 
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Sodium chloride (NaCl) Roth (Karlsruhe) 
Sodium dodecylsulfat (SDS)  Merck-Schuchardt (Hohenbrunn) 
Sodium orthovanadate Fluka Sigma-Aldrich (Steinheim) 
Sodium pyrophosphate dibasic Fluka Sigma-Aldrich (Steinheim) 
N,N,N',N'-Tetramethylethylenediamine (TEMED)  Roth (Karlsruhe) 
Torin1 provided by D. Sabatini 
Trichloro acetic acid Roth (Karlsruhe) 
Tris(hydroxymethyl)-aminomethane  Merck (Darmstadt) 
Triton X-100  Roth (Karlsruhe) 
Tween 20 Bio-Rad (München) 
L-Tryptophan Roth (Karlsruhe) 
Uracil Fluka Sigma-Aldrich (Steinheim) 
X-OMAT EX-II Developer  Kodak (Stuttgart) 
X-OMAT EX-II Fixer  Kodak (Stuttgart) 
Yeast extract  Roth (Karlsruhe) 
Yeast Nitrogen Base Fluka Sigma-Aldrich (Steinheim) 
Zotarolimus Molcan (Toronto, Canada) 
Zotarolimus isomer Molcan (Toronto, Canada) 
 
2.11 - Enzymes: 
 
The enzyms that were used for different assays are listed below:  
 
Akt1/PKBα (inactive) Millipore (Schwalbach) 
Antarctic Phosphatase  NEB (Frankfurt am Main) 
Immunoglobulin G (bovine) Thermo Fischer Scientific (Schwerte) 
Insulin solution, human Sigma-Aldrich (Steinheim) 
Lysozyme Roth (Karlsruhe) 
Phusion High Fidelity Taq Polymerase NEB (Frankfurt am Main)  
Restriction endonucleases  NEB (Frankfurt am Main)  
T4-DNA Ligase  NEB (Frankfurt am Main) 
Taq Polymerase NEB (Frankfurt am Main) 
TEV protease homemade;  
 plasmid provided by Dr. A. Bracher 
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2.12 - Kits: 
 
The following kits were used for DNA purification and FRET assays according to the 
manufacturer’s recommendations: 
 
CellTiter-Glo Luminescent Cell Viability Assay Promega (Mannheim) 
Genopure Plasmid Midi Kit    Roche (Mannheim) 
High Yield PCR Clean-up/Gel Extraction Kit SLG (Gauting) 
High Yield Plasmid Mini Kit    SLG (Gauting) 
HTRF Phospho Akt (Ser473)   Cis bio GmbH (Berlin) 
LanthaScreen TR-FRET Assay   Invitrogen (Karlsruhe) 
Nucleobond AX Mega Kit    Macherey-Nagel (Düren) 
 
 
2.13 - Markers: 
 
For size quantification of protein and DNA samples, the following standards were used:  
 
1 kb DNA Ladder NEB (Frankfurt am Main) 
Page Ruler Plus Prestained Protein Ladder   MBI Fermentas (St. Leon-Rot) 
Unstained Protein Molecular Weight Marker        MBI Fermentas (St. Leon-Rot) 
 
 
2.14 - Equipment: 
 
The following machines and lab items were utilized:   
 
Äkta Purifier chromatography system GE Healthcare (München) 
Centrifuge 6K15 Sigma (Osterode) 
Centrifuge Avanti J-25, Rotor JA-20  Beckman (Krefeld) 
Centrifuge Biofuge pico  Heraeus (Mannheim) 
Centrifuge Universal 30 F Hettich (Tuttlingen) 
CO2 incubator HeraCell Fischer Thermo Scientific (Schwerte) 
Developer machine 3M (Neuss) 
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Electrophoresis power supply Pharmacia/GE Healthcare (München) 
Flat bed scanner PrecisionScan HP GmbH (Böblingen) 
Gel Dryer 583  Bio Rad (München) 
Gel electrophoresis chambers  PeqLab GmbH (Erlangen) 
Gel electrophoresis system XCell Sure Lock Invitrogen (Karlsruhe)  
HiLoad 16/60 Superdex 75 pg GE Healthcare (München) 
Ice machine ZBE 150-MT      Ziegra (Isernhagen) 
Incubation shaker Innova 4000 NewBrunswick (Edison, NJ, USA) 
Incubator Polymax 1040 Heidolph Instruments  (Schwabach) 
Magnet stirer RCT basic  IKA Labortechnik (Staufen) 
Microscope DM IL Leica (Wetzlar) 
PCR cycler Gene Amp 9700 Applied Biosystems (Darmstadt) 
pH meter WTW 538  WTW (Weilheim) 
Pipettor Pipetus akku Hirschmann Laborgeräte (Eberstadt) 
Power Supply Power Pac 300 Bio Rad (München) 
Precision scales Master Pro LP4200S Sartorius (Göttingen) 
Reader Tecan GENios Pro Tecan (Crailsheim) 
Refrigerator Liebherr (Biberach) 
Shaking table SM25A Edmund Bühler (Hechingen) 
Thermomixer comfort  Eppendorf (Hamburg) 
Ultrapure water dispenser PureLab ultra  Elga Lab Water (Celle) 
Ultrasound Sonifier 450 Branson (Dietzenbach-Steinberg) 
UV transilluminator Faust (Meckenheim) 
UV/VIS spectrophotometer DU 530 Beckman (Krefeld) 
Vortexer Mini-Shaker MS2  IKA Labortechnik (Staufen) 
Water bath GfL 1002 GfL (Burgwedel) 
Work bench LaminAir HB2448     Heraeus (Mannheim) 
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2.15 - Consumables: 
 
384-well plates, low-binding surface   Corning (Kaiserslautern) 
96-well plates, low-binding surface   Corning (Kaiserslautern) 
96-well plates, transparent    Greiner Bio-One (Kremsmünster, AT) 
Cell scraper 25 cm     Sarstedt (Nümbrecht) 
Cellstar serological pipettes    Greiner Bio-One (Kremsmünster, AT) 
Centricon 10 kDa     Millipore (Schwalbach) 
Chromatography column 5 ml   Bio Rad (München) 
Falcon 6-well plates     BectonDickinson (Franklin Lakes,USA) 
Glass beads       Sigma (Steinheim) 
Medical X-Ray film Super RX   Fujifilm Corporation (Düsseldorf) 
Millex Stringe Filter 0.22 µm   Millipore (Schwalbach) 
Nunclon Surface cell culture dishes   Nunc A/S (Roskilde, DK) 
Protran BA 83 Nitrocellulose   Whatman (Dassel) 
Rotilabo Blotting paper    Carl Roth (Karlsruhe) 
SDS Mini gel cassettes    Invitrogen (Karlsruhe) 
SnakeSkin Dialysis Tubing 3,500 MWCO  Pierce/Fisher Thermo Scientific (Bonn) 
Test tubes      Sarstedt (Nümbrecht) 
 
 
2.16 – Software: 
 
For data collection and analysis, the following PC programs were used:  
 
COOT /CCP4      STFC 
Chimera      UCSF, Conrad Huang [261] 
Gimp 2.4.7      Spencer Kimball, Peter Mattis 
PyMol 0.99      DeLano Scientific  
SigmaPlot 10      Systat Software (Erkrath) 
Word, Excel 2000     Microsoft (München) 
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3 – Methods:  
 
3.1 – Standard cloning techniques: 
 
3.1.1 – Polymerase chain reaction (PCR): 
 
For a standard PCR reaction the following components were combined in a 0.2 ml PCR tube 
and a total volume of 50 µl: 
 
 400 µmol dNTP mix (stock: 20 mM) 
 100 nmol primer forward (Metabion, Planegg)  
 100 nmol primer reverse  
 100 ng  plasmid DNA template  
     1 U  Phusion “High Fidelity” Taq polymerase  
     5 µl        10x Phusion High-Fidelity buffer  
                
The polymerase chain reaction was performed in a thermo cycler following a defined time 
and temperature profile. Per 1 kb of polymerization, 1 minute elongation time was scheduled. 
Annealing temperature was chosen according to primer melting temperature. 
 
 step 1:   300 seconds  92°C  initial denaturation 
 step 2:   40 seconds  92°C  denaturation 
 step 3:   40 seconds  50-65°C annealing 
 step 4:   30-120 seconds 72°C  elongation 
                                                           30 repeats of steps 2-4 
 step 5: 300 seconds  72°C  final elongation 
 
3.1.2– Analysis and purification of PCR products: 
 
3.1.2.1 – Agarose gel electrophoresis: 
  
TBE buffer:                90 mM boric acid; 2.5mM EDTA; 90 mM Tris/HCl, pH 8.3 
DNA sample buffer:   40% (w/v) saccharose; 0.25% (w/v) bromophenol blue 
                                    20 mM EDTA, pH 8.0 
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To prepare an agarose gel, an appropriate amount of agarose (normally: 0.5 to 1.5 grams to 
yield 0.5 – 1.5% gels) was mixed with 100 ml TBE buffer and boiled in a microwave oven 
until it had dissolved completely. After the solution had cooled down to 60°C, 3 µl of 
ethidium bromide solution were added and mixed thoroughly. Then, the solution was poured 
into a gel tray. Air bubbles were removed, and the comb was put in place. After 30 minutes, 
the gel had solidified and was transferred to a gel chamber containing TBE buffer. The DNA 
samples (normally: 5 µl of a 100 ng/µl solution) were mixed with an equal amount of DNA 
sample buffer and were filled into the gel wells. Separation of DNA was performed by 
applying a current of 200 mA for 30 minutes (or until desired separation is achieved). 
 
3.1.2.2 – Isolation of DNA fragments: 
 
The PCR products were visualized as gel bands using an UV transilluminator and 
documented photographically, before the bands were excised with a scalpel. The „High Yield 
PCR and Gel Extraction Kit“ was used according to the manufacturer’s recommendations to 
isolate DNA from the gel slices. Usually concentrations of 30 – 50 µg DNA / ml were 
obtained (determined by standard UV measurement at 260 nm and 280 nm; 1 A260 = 50 ng/µl; 
optimal ratio A260/A280 between 1.8 and 2.0).  
 
3.1.3 – DNA restriction: 
 
For restriction of vector DNA and PCR products, the following components were combined:  
 
 1 µg  vector DNA (100 µg/ml)    
 10 U  restriction enzyme 1 (20 U/µl)  
 10 U restriction enzyme 2 (20 U/µl)  
 2 µl 10x restriction buffer                  
bidest. H2O                       ad 20 µl      
alternatively: 
1 µg   PCR product (50 µg/ml)    
 20 U  restriction enzyme 1 (20 U/µl)  
20 U  restriction enzyme 2 (20 U/µl)     
 4 µl 10x restriction buffer      
  bidest. H2O            ad 40 µl 
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For the enzyme combination EcoRI/XhoI, the buffer „EcoRI“ was used. For NcoI/XbaI and 
NcoI/SalI, NEB buffer II was utilized. The restriction mixtures of PCR products were 
incubated for 2 hours at 37°C, while the ones of the vectors were incubated at 37°C over 
night.  
To avoid re-ligation of single-cut vector, the vector restriction mixtures were supplemented 
with 1 µl of Antarctic Phosphatase (1 U/µl) and 2 µl of the corresponding 10x AP buffer. 
After 30 minutes of incubation at 37°C the samples were subjected to DNA purification using 
the „Gel Extraction Kit“. DNA concentrations of around 25 µg/ml were obtained; around 50% 
of the original amount of DNA were lost during the procedure. 
5 µl of the purified DNA samples were separated by gel electrophoresis (1.0% agarose gel) to 
check for contamination and yield.   
 
3.1.4 – DNA ligation: 
 
For ligation, vector DNA and PCR product were combined in a 1:3 ratio following the 
manufacturer’s recommendations. A typical ligation mixture contained the following 
components:  
 
1 µg   vector DNA (25 µg/ml)   
 3 µg  PCR product (25 µg/ml)   
10 U  T4 DNA ligase (20 U/µl)  
 1 µl 10x ligation buffer  
                        bidest. H2O                                                  ad 10 µl     
   
The mixture was incubated over night at 16°C. If an optimization of the reaction was 
necessary, a higher amount of PCR product was used. Alternatively, the concentration of 
ligase and/or the incubation time was increased. 
 
3.1.5 - Transformation into E. coli DH5α and BL21: 
 
3.1.5.1 – Preparation of competent cells: 
 
To prepare transformation-competent E. coli cells, 50 ml of sterile LB medium were 
inoculated with a small amount of glycerol stock and incubated over night at 37°C on a 
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shaking platform (200 rpm). 25 ml of this over-night culture were used to inoculate 500 ml of 
sterile LB medium. This culture was grown at 37°C until an OD600 of 0.3 was reached. 
Cells were harvested by 15 minutes of centrifugation at 5000 g and 4°C. The pellet was 
resuspended slowly and gently in 125 ml of cold, sterile 100 mM MgCl2 solution. After 
another centrifugation step (5000 g, 4°C, 15 minutes), the bacteria were resuspended in                   
25 ml of sterile 100 mM CaCl2 solution before another 200 ml 100 mM CaCl2 solution were 
added. The mixture was incubated on ice for 20 minutes. The cells were harvested again 
(4000 g, 4°C, 10 minutes) and resuspended in 10 ml of 100 mM CaCl2 solution with 10% 
glycerol (w/w). Finally, 100µl aliquots of the cell suspension were shock-frozen in liquid 
nitrogen and stored at -80°C until usage. 
 
3.1.5.2 – Transformation procedure: 
 
5 µl of the ligation reaction were added to 50 µl of thawed competent E. coli and mixed 
carefully. The cells were incubated for 30 minutes on ice and were exposed to a heat shock of 
42°C in a water bath for 60 seconds. After addition of 500 µl LB medium, the transformation 
mixture was grown at 37°C for 60 minutes on a shaking platform. Finally, the cells were 
harvested by short centrifugation, plated of LB agar plates containing antibiotics (100 µg/ml 
ampicillin or 50 µg/ml kanamycin) and incubated over night at 37°C. 
 
3.1.6 – PCR colony screening: 
 
To identify successfully transformed clones, single colonies on LB agar plates were picked 
and resuspended in 20 µl of sterile water. 2 µl of this suspension were used as DNA template 
in a standard PCR reaction. Thus, the PCR mixtures contained the following components: 
 
            400 µmol  dNTP mix (20 mM stock) 
 100 nmol vector-specific primer forward (Metabion, Planegg)  
 100 nmol vector-specific primer reverse  
     2 µl  clone suspension  
     1 U  Taq polymerase  
     2 µl         10x PCR buffer  
                             bidest. H2O                                                   ad 20 µl 
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The PCR mixtures were subjected to a standard temperature profile with reduced annealing 
temperature in a thermo cycler (300 s 92°C; 25 cycles of 40 s 92°C, 40 s 52°C, 90 s 72°C; 
300 s 72°C). 
Afterwards, the samples were analyzed on a 1.5% agarose gel. Short amplificats of around        
200 bp reflected the presence of empty vector, while DNA bands of higher molecular weight 
represented a successfully ligated insert. 
Positive clones were inoculated in 5 ml of antibiotic-supplemented sterile LB medium and 
incubated over night at 37°C with shaking (200 rpm). Plasmid preparation was performed 
using a MiniPrep Kit, following the manufacturer’s protocol. UV determination revealed a 
yield of around 100 µg plasmid DNA per ml solution. 
 
3.1.7 – Restriction control: 
 
To further verify successful cloning, plasmid DNA was subjected to enzymatic restriction. 
During this control assay the same restriction enzymes are used as for cloning; therefore the 
insert is cut out of the vector. 
The digestion mixtures contained the following components: 
 
  1 µg   plasmid DNA (100 µg/ml)   
 10 U  restriction enzyme 1 (20 U/µl)  
 10 U restriction enzyme 2 (20 U/µl)  
  2 µl 10x restriction buffer      
 bidest. H2O               ad 20 µl 
The restriction mixtures were incubated at 37°C for 60 minutes and analyzed on a 1.5% 
agarose gel. Preparations of plasmid DNA with insert were saved while plasmids without 
inserts were discarded.  
 
3.1.8 – DNA sequencing: 
 
For final approval of positive clones the plasmid DNA was sequenced using the chain 
termination sequencing technique and standard vector-specific primers. This service was 
provided by the “Microchemistry Core Facility” at the MPI of Biochemistry in Martinsried. 
The obtained sequences were compared to corresponding references in order to exclude base 
pair deletions and point mutations.  
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3.2 – Heterologous protein expression: 
 
3.2.1 – Expression of proteins with hexahistidin tag: 
 
3.2.1.1 – E. coli culture: 
 
Plasmid DNA encoding a specific hexahistidin tagged protein was transformed into the 
expression strain E. coli BL21. 3 l of sterile LB medium, supplemented with the appropriate 
antibiotics, were inoculated with an over night culture (maximal OD600: 0.1) and incubated at 
37°C on a shaking platform. As soon as an optical density of 0.5 was reached, protein 
expression was induced by addition of 1.8 ml 1 M IPTG (final concentration: 600 µM). After 
further 3 hours of incubation, the cells were harvested by centrifugation in a Sigma centrifuge 
at 4000 g and 4°C for 15 minutes.  
 
3.2.1.2 – Cell lysis: 
 
Lysis buffer:           50 mM Hepes; pH 8.0; 300 mM NaCl;  
                                  20 mM imidazole; 1 mM PMSF; 1 mg/ml lysozyme 
 
All further purification steps were carried out at 4°C or on ice. 
The cell pellet was resuspended in 50 ml lysis buffer and incubated on ice for 30 minutes. 
Treatment with an ultrasound sonifier was performed to complete cell lysis (8 cycles:                
15 seconds ultrasound in impulses, 15 seconds break; intensity: 5). To remove insoluble 
material, the lysate was centrifuged for 40 minutes at 4°C and 15000 g in a Beckman 
centrifuge.  
 
3.2.1.3 – Purification on nickel NTA sepharose: 
 
Washing buffer: 50 mM Hepes, pH 8.0; 30 mM NaCl; 50 mM imidazole; 
                           10% glycerol (v/v) 
Elution buffer:  50 mM Hepes, pH 8.0; 30 mM NaCl; 500 mM imidazole;  
                           10% glycerol (v/v) 
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5 ml nickel NTA resin were resuspended in 50 ml water and pelleted again by 5 minutes of 
centrifugation at 2500 g. Washing was repeated twice with each 50 ml lysis buffer. 
The cleared lysate was added to the resin and incubated for 3 hours with agitation at 4°C. 
Afterwards, the beads were pelleted by centrifugation (2500 g, 4°C), and the supernatant was 
discarded. The resin was resuspended in 50 ml washing buffer, incubated shortly and pelleted 
by centrifugation. This washing step was repeated twice. 
Next, the resin was resuspended in 5 ml washing buffer and transferred into a 5-ml 
chromatography column. As soon as the washing buffer had drained totally, 5 ml elution 
buffer were added. The eluate was collected in 0.5 ml fractions and checked for protein 
content by Bradford assay (see section 3.3.2). 
 
3.2.1.4 – Purification on anti-FLAG affinity resin: 
 
TBS:                          50 mM Tris; 150 mM NaCl; pH 7.5  
Elution buffer:             100 µg/ml FLAG peptide in TBS 
 
For FKBP51, analysis of elution fractions revealed an insufficient purity of the preparation. 
A second purification step had to be performed, taking advantage of the C-terminally fused 
FLAG peptide. This peptide (sequence: DYKDDDDK) binds to specific antibodies with high 
affinity and therefore allows binding of FLAG fusion proteins to immuno-affinity resin in 
which the antibodies are bound covalently to a sepharose matrix. 
1 ml of resuspended “ANTI-FLAG immuno-affinity resin” was transferred to a 5-ml plastic 
column and washed with 10 ml TBS. Then the pooled protein-containing fractions of the Ni-
NTA purification were loaded onto the column. After the flow through was completed, the 
resin material was washed with TBS until no protein could be detected any more in the 
washing buffer by Bradford assay. By addition of elution buffer the FKBP51-FLAG protein 
was released from the resin and collected in different fractions. Once again, protein content 
was quantified by Bradford assay, and protein-containing fractions were pooled.  
 
3.2.1.5 – Analysis of purified proteins by SDS gel electrophoresis: 
 
3.2.1.5.1 – Casting SDS gels: 
 
SDS running buffer:  25 mM Tris/HCl, pH 8.3; 250 mM glycine; 0.1% (w/v) SDS 
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SDS sample buffer 2x: 125 mM Tris/HCl; 10% (v/v) 2-mercaptoethanol; 
  “Lämmli buffer” [262] 4% (w/v) SDS; 0.004% (w/v) bromophenol Blue 
Resolving gel:     380 mM Tris/HCl, pH 8.8; 0.1% (w/v) sodium dodecylsulfate; 
                             10-16% (w/v) acryl amid; 0.2 – 0.3% (w/v) bisacryl amid; 
                                     0.12% (v/v) TEMED; 0.06% (w/v) ammonium peroxydisulfate 
Stacking gel: 375 mM Tris/HCl, pH 6.8; 0.1% (w/v) sodium dodeclysulfate 
                                    5% (w/v) acryl amid; 0.2 – 0.3% (w/v) bisacryl amid 
                                       0.2% (v/v) TEMED; 0,06% (w/v) ammonium peroxydisulfate (APS) 
Coomassie staining solution:      40% (v/v) ethanol, 10% (v/v) acetic acid  
                                         0.01% (w/v) coomassie brilliant blue  
Coomassie destaining solution:  40% (v/v) ethanol, 10% (v/v) acetic acid 
 
Acryl amid mix was prepared using 30% (w/v) acryl amid and 0.6% (w/v) bisacryl amid. For 
two mini gels of the indicated acryl amid concentration, following components were 
combined: 
 
final       
concentration 
acryl amid 
mix 
H2O 
bidest. 
TEMED 1 M Tris, 
pH 8.8 
10%  
(w/v) SDS 
10 % 
(w/v) APS 
10% 4.7 ml 3.9 ml 17 µl 5.4 ml 140 µl 85 µl 
12%  5.7 ml 3.0 ml 17 µl 5.4 ml 140 µl 85 µl 
16% 7.6 ml 1 ml 17 µl 5.4 ml 140 µl 85 µl 
 
Table 3.1: Components and necessary amounts for 2 “mini” SDS gels 
 
Ammonium peroxydisulfate and TEMED were added lastly because they induce radical 
formation and start the polymerization. The gel solution was filled into a commercially 
available mini gel cassette and was covered carefully with water. After the polymerization 
was completed, water was removed, and the gel cassettes were filled with stacking gel 
solution. Finally, 12 or 15-well combs were inserted. 
 
3.2.1.5.2 – Preparation of samples and gel run: 
 
Samples of the protein-containing fractions were diluted in SDS sample buffer and incubated 
at 95°C for 5 minutes to achieve denaturation. The samples were then loaded into the gel 
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wells and separated using a current of 30 mA in the “XCell SureLock Gel System” for 
approximately 60 minutes. Protein patterns were visualized by treatment with Coomassie 
staining solution for 30 minutes, followed by destaining in the destaining solution under mild 
agitation. The gel was put on a sheet of blotting paper and was conserved using a gel dryer. 
Finally, it was digitalized on a flatbed scanner. 
Alternatively, the gel was subjected to immunoblotting procedure (see section 3.7.3). 
 
3.2.2 – Proteins as GST fusion: 
 
PBS: 137 mM NaCl; 2.7 mM KCl;  
                                     4.3 mM Na2HPO4; 1.47 mM KH2PO4; pH 7.4 
Lysis buffer: PBS; 1 mM PMSF; 1 mg/ml lysozyme 
Elution buffer:              PBS; 10 mM glutathione; 10% glycerol 
 
Generally, the expression of GST fusion proteins was performed in the same way as for His-
tagged proteins; instead of Nickel NTA beads, GST ProCatch Sepharose was used as affinity 
resin together with the above mentioned lysis, washing and elution buffers as recommended by 
the manufacturer. 2 ml of resin were used for 50 ml of bacterial lysate.  
 
3.3 – Determination of protein concentration: 
 
3.3.1 – UV absorption: 
 
Because of the presence of aromatic amino acids (tyrosine, phenylalanine, tryptophan), protein 
solutions display absorption of ultra-violet light. The maximum of absorption is usually at   
280 nm. The Law of Lambert-Beer provides a connection between protein concentration and 
its UV absorption value: 
 
                        A =  ε  c  d,   being:  A: absorption at 280 nm 
                                                          ε: absorption coefficient  solution 
                                                          d: path length (depth of the cuvette) [cm] 
                                                          c: protein concentration [M]  
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The absorption coefficient of a protein can be deduced from its amino acid sequence as it 
depends mainly on the number of aromatic amino acids. The values for all expressed proteins 
can be found in appendix (see section 6.1). These values were computed using the ExPASy 
tools „ProtParam“ with the amino acid sequence as input. 
Determination of UV absorption was performed in a Beckman photometer. For calibration the 
quartz cuvette was filled with 100 µl of elution buffer, and a blank value was recorded. 
Afterwards, the protein samples were measured in the same manner. If necessary the samples 
were diluted in elution buffer to give A280 values between 0.1 and 1.0. Protein concentration 
can be calculated using the formula   c = A / (ε  d ), being d = 1 cm.                       
                                       
 
3.3.2 – Bradford assay [263]: 
 
In order to determine protein concentrations, a colorimetric assay according to Bradford is used 
routinely. This assay is based on an absorption shift of the dye “Coomassie Brilliant Blue” 
from red to blue after protein binding. Thus, the increase of absorption at 595 nm is directly 
proportional to the protein concentration of the sample. After determination of a reference 
array the concentration of every kind of protein sample can be determined. 
The assay was performed in transparent 96-well plates. Each well was filled with 100 µl of a 
20% (v/v) dilution of Bradford reagent in bidest. H2O. For a reference array 0, 1, 2, 3, 4 and    
5 µl of IgG (concentration: 1.4 mg/ml) were added and mixed thoroughly. The actual protein 
samples were diluted 1:10 in water if addition of 1 µl of undiluted sample resulted in excessive 
blue staining. 1 µl of the dilution was added to each well and mixed thoroughly. 
After 10 minutes of incubation all wells were read out in a Tecan “GENios Pro” reader with 
standard settings:  
 Measurement mode: Absorbance, endpoint;  
 Wavelength: 595 nm;  
 Number of reads: 10 reads;  
 3 s of orbital shaking before measurement.  
 
The optical density at 595 nm was plotted against the known protein concentration of the 
references, and a trend line was fitted. Using the linear equation of this trend line in Excel, the 
concentrations of the protein samples could be determined (after applying the corresponding 
dilution factors).  
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3.4 – Protein crystallization: 
 
3.4.1 – Tobacco etch virus (TEV) protease digestion: 
 
TEV cleavage buffer:             50 mM Tris/HCl, pH 8.0 
                                                0.5 mM EDTA 
                                                1 mM DTT 
                                          
All proteins that were purified using the expression vector pPRO-ExHta still carried an             
N-terminal hexahistidin tag which could influence the performance of proteins in downstream 
assays. In order to assure maximum wild type-like behavior, the purification tags of the 
proteins had to be removed. This is a standard procedure to prepare proteins for protein 
crystallization and structure determination.  
First, the Nickel-NTA-purified proteins were dialyzed twice against 2 l TBS for two hours. The 
exclusion size of the dialysis tubes was 3.5 kDa; thus the imidazole concentration of the 
protein samples was reduced efficiently. Protein concentrations were controlled by 
measurement of UV absorption at 280 nm. 
To start protease cleavage, the protein samples were mixed with Tobacco Etch Virus protease 
(recombinantly expressed as his-tagged protein in E. coli BL21 and purified using standard Ni-
NTA chromatography) in a molar ratio of 1:100. After addition of 10x cleavage buffer and 
DTT the mixtures were incubated over night at 4°C. A typical batch contained the following 
components: 
   
   100 nmol  FKBP51 FK1 (stock: 200 µM) 
     10 nmol  TEV protease (stock: 20 µM) 
       1:1000 1 M DTT 
  10x TEV buffer 
   
Progress of the cleavage reaction was checked by SDS gel analysis. If cleavage was 
incomplete, incubation time was extended by another 24 hours. 
To remove contaminating protease and cleaved his-tag, the samples were incubated with an 
appropriate amount of Nickel-NTA beads (normally: 1/10 of total volume) for one hour. After 
short centrifugation at 4000 g, the supernatant was transferred to another tube and extracted 
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once again with Nickel-NTA beads. After the beads were pelleted, the supernatant was cleared 
by passing it through a 0.22 µm syringe filter and analyzed on a SDS gel. 
 
3.4.2 – Reconstitution of ternary complexes: 
 
In order to create the respective ternary complexes of FRB and FK1 FKBP51/52 in vitro, 
rapamycin was added to an equimolar mixture of the two protein components. The macrolide 
was used in slight excess to ensure maximum yield of complex. 
A typical mixture contained the following compounds:  
 
         each 1 µmol  FK1 FKBP51/52 and FRB   
 1.2 µmol  rapamycin               
 
As the affinity of the FKBP*rapamycin complex to FRB is presumably very high, formation of 
ternary complexes occurs instantaneously; therefore incubation time was kept short                    
(5 minutes). 
 
3.4.3 – Gel filtration chromatography: 
 
As excessive rapamycin and unbound FKBP or FRB fractions had to be removed, the 
reconstitution mixture was submitted to another purification step. Since the proteins were all 
untagged, affinity chromatography could not be used; instead, gel filtration chromatography 
using a “HiLoad Superdex” column appeared suitable as this application permits the separation 
of a protein mixture based on the size of the single components.  
The column matrix consists of dextran which is bound covalently to cross-linked agarose. The 
average particle size is 34 µm. Therefore small proteins penetrate into the pores and are 
retained while the migration of large proteins and complexes is relatively undisturbed. Since 
the ternary complex is twice as large as the individual proteins, its separation was expected to 
be relatively simple: presumably, the ternary complex is eluted faster than its individual 
components. 
To start the purification procedure, the complex mixture was loaded via the injection valve into 
the super loop of the “Äkta Purifier” chromatography system. Afterwards, the solution was 
injected with a flow rate of 0.3 ml/min onto the “Superdex HiLoad 16/60” column which had 
been equilibrated with two column volumes of TBS before. 
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The running buffer TBS was pumped with a constant flow rate of 0.3 ml/min over the column, 
until all fractions were eluted completely at around 120 ml (corresponding to one column 
volume). By automatic recording of UV absorption at 280 nm by the Äkta system, the protein 
containing fractions could be determined. 
 
3.4.4 – Protein crystallization: 
 
The crystallization of the ternary complexes FRB*rapamycin*FK1 FKBP51 and 
FRB*rapamycin*FK1 FKBP52 was accomplished in co-operation with Dr. Andreas Bracher 
(MPI for biochemistry, Martinsried). 
To prepare initial screening for suitable crystallization conditions, the pooled Äkta fractions 
were concentrated in a Centricon tube (exclusion size: 10 kDa) by centrifugation at 15.000 g 
and 4°C until a protein concentration of 20 mg/ml was reached (determination after Bradford). 
In the department of structural cell biology (Elena Conti, MPI of Biochemistry, Martinsried) 
three “complex screens” of each 120 conditions including different buffers and precipitates 
were performed in nano-drop format. A “Phoenix Nanodispenser” robot performed all 
necessary pipetting steps in a completely automated manner. Digital imaging was also 
accomplished by an automated system; evaluation of the pictures occurred online. 
After 24 hours the first conditions were identified which allowed growth of single crystals. 
These conditions were further varied in a 24-well format and assayed in 2 µl drops on cover 
slips in siliconized wells. The plates were incubated at 20°C, and crystal growth was controlled 
microscopically. 
To harvest the crystals, they were transferred into a drop of precipitation buffer (supplemented 
with 10% (v/v) glycerol) using a fine manipulation loop. After 10 minutes of equilibration in 
the new buffer environment, the crystal was transferred into a drop of cryobuffer containing 
20% (v/v) glycerol. After another 10 minutes of incubation, the crystal was positioned as 
centrically and parallel to the loop as possible and quick-frozen in liquid nitrogen in a Dewar 
vessel. A magnetically sticking protective cap was put onto the mounting plate of the loop in 
order to prevent mechanical damage of the crystal. All manipulations of the crystal had to be 
accomplished strictly under liquid nitrogen since the crystal would have thawed immediately 
after exposition to air and thus would have become useless. 
The mounting plate with the crystal was kept in a sampler cassette in liquid nitrogen until it 
was needed for x-ray diffraction analysis at the synchrotron. Well-shaped, preferably big 
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crystals were used for X-ray exposure at beamline ID19 at the ESFR (European Synchrotron 
Radiation Facility) in Grenoble.  
For data processing and evaluation, the CCP4 software suite [264] was used: Data integration 
was done using Mosflm [265], data reduction was carried out by SCALA [266], and molecular 
replacement was performed using Arp Warp [267]; the crystal structure of the ternary complex 
FRB*C15-(R)-methylthienyl-Rapamycin*FKBP12 (PDB entry: 3fap) was used as an initial 
model. Graphical fitting and model building was done using COOT [268]. For intermediate 
refinement of the structures, Refmac [269] was executed  (5 cycles, 1.45 – 20 Å resolution 
range, weighting term 0.1, refine isotropic temperature factors). Finally, waters were added to 
the structure (peaks greater than 3sigma in the difference map).  
 
3.5 – Protein assays: 
 
3.5.1 – Fluorescence polarization assay: 
 
3.5.1.1 – Principle of the assay: 
 
Fluorescence polarization assays are used to determine binding interactions between a protein 
and a fluorescent ligand. Here, an important parameter is the decoupling between excited and 
emitted photon polarization which occurs when a molecule displays rotational diffusion. This 
diffusion (or tumbling) reaches its maximum when the fluorophor performs free rotation in a 
solution; it decreases when the fluorophor builds a complex with a protein as binding partner 
because the resulting complex is much larger and moves more slowly. Thus, the difference is 
biggest when the free molecule binds to a large protein partner [270].  
Practically, fluorescence polarization is determined by measurement of the intensity of parallel 
polarized light and perpendicularly polarized light. The following equation describes how        
P values are calculated mathematically: 
 
                     P = ( I parallel – I perpendicular) / ( I parallel + I perpendicular) 
 
     being:  P: fluorescence polarization 
                 I parallel: intensity of parallel polarized light emission 
                 I perpendicular: intensity of perpendicularly polarized light emission 
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To determinate protein activity or the portion of active protein in the mixture, an „active site 
titration” was performed: during this procedure the fluorescent FKBP ligands CK97 and 
CK182 (see figure 3.1) were titrated in different concentrations against FKBP protein. In 
accordance with the law of mass action the EC50 value should rise linearly with increasing 
ligand concentrations; this EC50 can be considered as the mean effective concentration, and it 
indicates at which ligand concentration half of the protein is bound. If the ligand concentration 
is plotted against the associated EC50 values, one obtains a straight line whose upward slope 
ideally is 0.5, and whose y axis intercept corresponds to the binding affinity of the protein that 
is independent of the ligand concentration (possibly: kd). 
 
[Protein] + [Ligand]   [Protein*Ligand] 
 
kd =  [Protein] * [Ligand] / [Protein*Ligand] 
 
3.5.1.2 – Experimental procedure: active site titration 
 
Assay buffer:      50 mM Hepes, pH 7.7; 30 mM NaCl; 0.01% (v/v) Tween20 
 
In a 96-well low-binding Corning plate, a serial dilution of FKBP protein was prepared. To this 
end, 23 wells in two rows were filled with each 50 µl of assay buffer. Another well contained 
100 µl of a 20 µM dilution of the respective FKBP protein in assay buffer. From this well,     
50 µl were transferred to the first well containing 50 µl of buffer and mixed well. Again, 50 µl 
were transferred to the next well. This transfer was repeated until the 1:1 dilution series of the 
protein was completed. The last well contained pure buffer. 
10 µl of these dilutions were pipetted into a 386-well low-binding plate before 10 µl of a CK97 
or CK182 dilution in assay buffer were added (double final concentration). For an active site 
titration, at least 5 different final concentrations of ligand were tested: 5, 50, 100, 150 and    
200 nM. Altogether, for every tested FKBP protein 5 dilution series with each 24 wells and 
each 5 different CK97 and CK182 concentrations were prepared. 
After 15 minutes of incubation at room temperature, a Tecan reader was used to determine 
fluorescence polarization values. The following settings were used:  
 Mode: Fluorescence Polarisation, end point 
 Wavelengths: Excitation: 485 nm; Emission: 535 nm 
 Number of reads: 10; Integration time: 100 µs 
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A plot of mP units against the protein concentration created a dose-response curve that could 
be analyzed by “Four-Parameter-logistic-curve” fitting in SigmaPlot. This analysis also 
revealed EC50 values that represent a protein concentration at which half of the protein is 
bound to ligand. The formula looks as follows: 
 
                                                       (top – bot)                        
                                                     1+(“x”/IC50)slope 
 
The calculated EC50 values were plotted against the corresponding CK97 or CK182 
concentration. This provided the opportunity to determine EC50 values by linear regression 
which are independent of the ligand concentration. They could be regarded as theoretical Kd 
values. The following equation gives the theoretical approach:  
 
                                      EC50 =  m   [CK97/182]  +  „Kd“ 
           
                          CK182                                                                    CK97 
Figure 3.1: Fluorescent tracers CK182 and CK97 were used for active site titration 
CK182 has been synthesized by coupling CK85 to a fluorescein derivative. CK97 contains a hexanoic acid 
spacer between the rapamycin moiety and the fluorescein (fluorophor in box). These two compounds were 
provided by C. Kress, RG Hausch, MPI of Psychiatry. 
y =  bot +    bot = minimum mP value top = maximum mP value 
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3.5.2 – FRET binding assay: 
 
FRET (Fluorescence Resonance Energy Transfer) is a quantum-mechanical phenomenon that 
involves energy transfer between two chromophores [271] and provides an elegant tool to 
characterize protein-protein interactions. Basically the concept describes the energy transfer 
between two partners that is possible just when they are located in close proximity with correct 
orientation. If such a system of interacting chromophores is excited with light energy of the 
absorption wavelength of the donor, it will transfer energy to the acceptor which thereby emits 
light on a wavelength different from the one of the donor. Thus, it is possible to determine the 
extent of energy transfer by measuring the intensity of light emission at acceptor wavelength 
and to deduce the intensity of the underlying protein-protein interaction. 
The time-resolved FRET assay that was used to investigate the interaction between FKBPs and 
FRB was originally developed by Invitrogen and is based on a Terbium-labelled anti-GST 
antibody and a GFP (green fluorescent protein) acceptor. As GST fusion protein, GST-FRB 
was used while all FKBPs were utilized as N-terminal EGFP-fusions (EnhancedGFP) in the 
assay. 
 
The assay was performed following the manufacturer’s recommendations: in a total volume of 
10 µl, 5 µl of rapamycin dilution (1:1 dilution in TR-FRET dilution buffer, starting at 4 µM) 
were combined with 5 µl of protein mixture in low-binding 384-well plates. The protein 
mixture contained variable amounts of the following components in dilution buffer: 
 
     5 nM  GST-FRB 
                        25 nM – 100 nM  EGFP-FKBP  
                           2.5 nM – 5 nM Tb-labelled anti-GST antibody 
 
After 15 minutes of incubation, the wells were read out using a Tecan “GENios Pro” reader 
with the following settings: 
 
 Measurement mode: Fluorescence Intensity, endpoint 
 FRET 1: Excitation: 340 nm; Emission: 495 nm 
 FRET 2: Excitation: 340 nm; Emission: 520 nm 
 Integration: 100 µs lag time; 200 µs integration time 
 Number of flashes: 10 
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The two emission intensities were plotted as ratio (520nm/495nm) against the rapamycin 
concentration. Then, an EC50 value was calculated by using the „Four-Parameter-Logistic-
Curve“-Fitting in SigmaPlot. This value corresponds to the rapamycin concentration at which 
the half-maximum concentration of the FRB*FKBP complex is present. 
 
3.5.3 – FRET mTOR kinase activity assay: 
 
The commercial “LanthaScreen mTOR Activity Assay“ was used to determine mTOR activity 
in presence of FKBP proteins and rapamycin. The assay was performed according to the 
manufacturer’s recommendations. Basically, the assay detects 4E-BP1 phosphorylation by a 
phospho-specific Terbium-labelled antibody. Energy transfer occurs between the antibody and 
the EGFP-N-Terminus of the mTOR substrate 4E-BP1. 
 
Assay buffer:   50 mM Hepes, pH 7.5; 0.01% (v/v) Tween 20;  
 1 mM EGTA; 10 mM MnCl2; 2 mM DTT. 
 
To prepare a rapamycin master dilution series, each 40 µl of DMSO were provided in 12 tubes. 
To the first tube 0.8 µl 10 mM rapamycin solution in DMSO were added to achieve a final 
concentration of 200 µM. 20 µl of this solution were transferred to tube number 2 and mixed 
well. If this procedure was repeated with the following tubes, a dilution series was obtained in 
which the rapamycin concentration decreased by 33% in consecutive tubes. 
To avoid issues concerning rapamycin solubility in water and to assure constant DMSO 
concentration in all assay wells, a 1:50 dilution was prepared by adding each 1 µl of the DMSO 
master dilution to 49 µl of assay buffer. The resulting dilution series ranged from 4 µM 
rapamycin to 0. 
In a total volume of 10 µl per well, 2.5 µl of rapamycin dilution (in assay buffer; starting at      
4 µM; 2% (v/v) DMSO), 5 µl kinase dilution and 2.5 µl substrate mix were combined. For this 
purpose, 384-well low-binding plates were used. After mixing the plate was incubated for      
60 minutes at room temperature. By addition of 10 µl antibody mix the reaction was stopped. 
Another incubation step of 30 minutes at room temperature was carried out. 
 
The following volumes and final concentrations were used for a test series with 12 wells: 
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                                         final concentration 
Kinase dilution: 0.7 µl 1:100 mTOR dilution  
 0.6 µl 10 µM FKBP                                    50 nM  
 ad 60 µl with assay buffer 
Substrate mix: 0.6 µl 2 mM ATP                                       10 µM 
 0.5 µl 90 µM EGFP-4E-BP1                    400 nM 
 ad 30 µl with assay buffer 
Antibody mix: 0.7 µl 0.33 µM Tb-Anti-P-antibody             1 nM 
 5 µl 500 mM EDTA                                   10 mM 
 ad 120 µl with assay buffer 
Reading of FRET intensities was performed using a Tecan reader as recommended by the 
manual. The reader settings were taken over from FRET binding assays (see section 3.5.2). 
Fluorescence intensities at 520 nm and 495 nm were recorded, and their ratio (A520/A495) was 
plotted against the corresponding rapamycin concentration. Once again the IC50 values of the 
test series was determined using „Four-Parameter-Logistic-Curve“-Fitting in SigmaPlot. 
 
3.5.4 – GST pulldown assay: 
 
GST pulldown assays are widely used to detect protein-protein interactions in vitro. For this 
procedure a tagged protein can be captured on resin material, forming a complex that allows 
simple fishing of interacting proteins. To do that, the resin is incubated with putative protein 
binding partners and washed thoroughly to reduce unspecific binding. By SDS-PAGE analysis 
all proteins that are bound to the resin can be resolved and identified.  
To determine FKBP binding to the FRB domain of mTOR, FRB was expressed as GST fusion 
and bound to glutathione sepharose resin. After addition of different FKBP proteins, successful 
formation of a ternary complex of FRB*rapamycin*FKBP was analyzed. 
1 µM GST-FRB and FKBP (0.5 - 1.5 µM) were combined in 100 µl PBS with 1 µM 
rapamycin and incubated for 30 minutes at room temperature.  50 µl of glutathione resin were 
added, mixed well and pelleted by centrifugation for 5 minutes at 1000 g. The resin was 
washed three times with each 500 µl PBS. Then, it was treated with     20 µl 1x SDS sample 
buffer and incubated at 95°C for 5 minutes in order to denature and release proteins from the 
resin. To pellet the resin, the samples were centrifuged for 1 minute at 1000 g. Finally, the 
supernatant was subjected to SDS gel electrophoresis and analyzed by Coomassie Brilliant 
Blue staining. 
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3.6 – Cell culture: 
 
3.6.1 – Cell lines and growth conditions: 
 
HeLa, HEK293 and MEF cells were generally kept at 37°C and 5% CO2 in a humidified 
incubator. Cell growth occurred as adherent culture in standard 125cm2 cell culture bottles. 
For HeLa, HEK293 and MEF cells, standard DMEM was supplemented with 10% fetal calf 
serum and 1% penicillin/streptomycin solution.  
 
3.6.2 – Maintenance of cells: 
 
When cell density at the ground of the cell culture bottles was too high for further cell 
division, the cell culture was split.  
During this procedure, DMEM medium was removed, and the cells were washed with 
approximately 10 ml of PBS under mild agitation. After the PBS was removed, 500 µl of 
trypsin/EDTA dilution was added and distributed evenly. Cells were incubated for 5 minutes 
at 37°C (or until all cells detached from the plastic surface), resuspended in 10 ml DMEM 
medium and singularized by pipetting up and down. To get rid of residual trypsin, the 
suspension was centrifuged for 5 minutes at 1000 g, and the cell pellet was resuspended in 
fresh DMEM/10% FCS. The cell suspension was then distributed into several bottles, culture 
dishes or 6-well plates. Finally, the original volume was re-established by filling up with 
DMEM/10% FCS. 
 
3.6.3 – Cell transfection: 
 
3.6.3.1 – Transfection with Lipofectamine 2000 reagent: 
 
To introduce expression plasmids into eukaryotic cells, lipofection is widely used as a 
convenient method. During the transfection procedure, plasmid DNA is packed into lipid 
vesicles which fuse with the phospholipid bilayer of cells and thus deliver the DNA into the 
interior. The transfection reagent Lipofectamine 2000 consists of polycationic lipids. 
Compared to other lipid-based transfection methods, very high transfection yields can be 
achieved. 
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Transfections were performed as recommended by the manufacturer. In detail, the following 
components were used for transfection of a 10 cm cell culture dish with cells                    
(80% confluency): 
 
 24 µg plasmid DNA (Midi-Prep)          in 1.5 ml DMEM medium 
 60 µl Lipofectamine 2000                    in 1.5 ml DMEM medium 
 
After 5 minutes of incubation at room temperature, the two components were combined and 
mixed thoroughly. During the following 20 minutes of incubation time, formation of DNA 
lipid vesicles occurred. 
The cells were prepared for transfection by washing them with PBS and supplying them with 
7 ml DMEM. 3 ml of the transfection mixture were added drop wise and carefully to the cells. 
The dishes were swayed mildly and incubated at 37°C and 5% CO2 in the incubator. After     
5 hours, 10 ml of DMEM with 20% FCS were added to improve cell growth. 40 hours later 
the cells were harvested or treated as indicated. 
 
3.6.3.2 – Transfection using calcium phosphate Ca3(PO4)2:  
 
2xHBS buffer:                0.1 M Hepes, 0.56 M NaCl, 3 mM Na2HPO4, pH 7.0 
 
Compared to commercial lipid-based reagents, this alternative transfection method is a bit less 
effective, but much cheaper. During the procedure, plasmid DNA is diluted in CaCl2 solution 
and mixed with Hepes buffered saline (HBS) [272]. This triggers the formation of a fine 
precipitate of positively charged calcium ions and negatively charged phosphate ions which 
bind the DNA on its surface. This complex formation facilitates introduction of DNA into 
cells. The exact mechanism of the process is not yet fully understood. As the yield of 
successfully transfected cells is variable, this method is used mainly when high transfection 
efficiency is not necessary. 
Cells were plated on 10 cm dishes to give 60-70% confluence on the day of transfection. 10 µg 
of DNA were diluted in 1.1 ml of sterile water, and 155 µl 2 M CaCl2 were added. While this 
solution was gently mixed, 1250 µl of 2xHBS were added drop wise. Immediately after, the 
whole mixture was given directly and drop wise to the cells. After an incubation of 24 hours at 
37°C and 5% CO2 in an incubator, the medium was removed. The cells were washed with 
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PBS, supplied with DMEM/10% FCS and incubated for another 24 hours. Then cells were 
harvested or used in other assays. 
 
3.6.3.3 – Transfection of siRNA: 
 
For FKBP12 knockdown experiments, we transfected HeLa cells as recommended by the 
manufacturer. Shortly, 0.5 µl 2 µM siRNA were diluted in 9.5 µl DMEM, and 0.5 µl of 
DharmaFECT 2 were diluted in 9.5 µl DMEM. After 5 minutes, the solutions were combined 
and mixed. 20 minutes later, the mixture was added to HeLa cells in a 96-well containing       
80 µl DMEM (final volume: 100 µl). After 48 h, cells were washed with PBS and lysed by 
addition of 50 µl 1x SDS sample buffer. Samples were boiled for 5 minutes and analyzed by 
SDS-PAGE /immunoblotting. 
  
 
3.6.4 – Starvation and stimulation of cells: 
 
In order to stimulate mTOR signaling and phosphorylation of downstream targets, transfected 
or untreated cells were starved: for this purpose, normal medium was removed, cells were 
washed once with PBS and fed with starvation medium (DMEM with 1% antibiotics). After at 
least 16 hours of serum starvation, amino acid starvation can be performed by replacing 
medium with PBS for 30 minutes. Afterwards, cells are kept in DMEM with 10% FCS and/or 
100 nM insulin. Simultaneously, rapamycin was added to the wells (range: 0 – 100 nM) to 
inhibit S6Kinase phosphorylation to different extents. After one hour of incubation at 37°C and 
5% CO2, the cells were washed twice with PBS and harvested. 
For stimulation of mTORC2 and subsequent Akt phosphorylation, addition of 100 nM insulin 
and incubation for 2 h is sufficient. 
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3.7 – Co-immunoprecipitation: 
 
3.7.1 – Lysis of eukaryotic cells: 
 
Lysis buffer:          40 mM Hepes, pH 7.5; 120 mM NaCl; 1 mM EDTA; 
 10 mM sodium pyrophosphate; 10 mM glycerol phosphate;  
                     0.5 mM sodium orthovanadate; 50 mM NaF; 0.3% (w/v) CHAPS; 
                     1% (v/v) protease inhibitor cocktail  
 
To harvest transfected cells in a 10 cm dish, the dishes were put on ice and washed three times 
with ice-cold PBS. All liquid was drained as thoroughly as possible before 500 µl of lysis 
buffer were added. The cells were removed from the surface using a cell scraper, and the 
suspension was transferred to a pre-cooled reaction tube. This lysis mixture was then 
incubated for 20 minutes at 4°C with vigorous shaking (1200 rpm) before it was cleared by   
20 minutes of centrifugation at 13 000 g and 4°C in a tabletop centrifuge. The supernatant 
was transferred to another tube and analyzed for total protein concentration by Bradford 
assay. 
 
 
3.7.2 – Immunoprecipitation: 
 
3.7.2.1 – IP with protein A resin and antibody: 
 
Cell lysate, containing 500 µg total protein, was treated with 1 µg anti-mTOR antibody and 
incubated over night at 4°C with mild agitation. To prepare the resin, 20 µl of Protein A/G- 
coupled sepharose beads were mixed thoroughly and washed twice with PBS and finally 
added to the lysate. The mixture was incubated for 4 hours at 4°C under agitation, before the 
resin was pelleted at 13.000 g and 4°C for 30 seconds in a tabletop centrifuge. The 
supernatant was removed immediately, and a sample was analyzed as “flow through” on an 
SDS gel. The pelleted beads were washed four times with each 1 ml lysis buffer. 
To elute bound protein, the resin was resuspended in 20 µl 2x SDS sample buffer and 
incubated for 5 minutes at 95°C. Finally, the suspension was centrifuged at 13 000 for          
60 seconds to pellet the resin. 10 µl of the supernatant were subjected to SDS gel 
electrophoresis.  
3 – Methods  
___________________________________________________________________________ 
64 
 
3.7.2.2 – IP with FLAG/HA/MYC affinity resin: 
 
IP elution buffer:  150 µg/ml FLAG peptide in TBS 
    100 µg/ml HA or MYC peptide in TBS 
 
Anti-FLAG/HA/MYC affinity resin contains the corresponding antibody covalently linked to 
the resin material. Like this, the material can simply be used to extract tagged proteins from 
lysates. As the binding does not depend on quality or quantity of a primary antibody, yields 
are optimized, and handling is much easier. The resin can be regenerated and re-used several 
times. 
To prepare the material for use, the affinity resin was washed three times with TBS. An 
amount of 1.5 mg total protein in cell lysate were combined with 50 µl of 50% resin 
suspension on ice and incubated for 2 hours at 4°C under agitation. After 2 minutes of 
centrifugation at 10 000 g and 4°C, the supernatant was removed; a sample was kept and 
analyzed as flow through on the SDS gel. The pelleted resin was washed 5 times with each    
1 ml lysis buffer. 
For elution of bound proteins, the resin was resuspended in 30 µl FLAG/HA/MYC elution 
buffer and incubated for 10 minutes at 4°C under agitation. The mixture was shortly 
centrifuged to pellet the beads. The supernatant was supplemented with an equal volume of  
2x SDS sample buffer and incubated at 95°C for 5 minutes. 15 µl of this mixture were 
separated on a SDS gel.  
 
3.7.3 – Immunoblotting: 
 
Blotting buffer:     20 mM Tris; 150 mM glycine; 0.02% (w/v) SDS; 20% (v/v) methanol  
Ponceau S:  0.5% (w/v) Ponceau S; 3% (v/v) acetic acid  
TBS-T:  TBS; 0.05% (v/v) Tween 20  
5% milk powder:  TBS-T; 5% (w/v) skimmed milk powder  
10% milk powder:  TBS-T; 10% (w/v) skimmed milk powder  
Primary antibody:  2 µg antibody in 2 ml 5% milk powder (1:1000) 
Secondary antibody:  1 µg antibody in 5 ml 10% milk powder (1:5000) 
ECL1:  100 mM Tris/HCl, pH 8.5;  440 mg/l Luminol,  
 150 mg/l P-Coumaric acid 
ECL2:  100 mM Tris/HCl, pH 8.5; 30% (v/v) H2O2  
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The immunoblotting procedure was performed according to recommendations of Invitrogen: 
After the SDS gel run was completed, the gel was put on a sheet of pre-soaked nitrocellulose 
membrane Protran BA 83 of the same size. A sheet of wet blotting paper was put on each side, 
and the pile was positioned with blotting sponges in the blotting chamber “XCell II Blot 
Module“. The chamber was filled with blotting buffer before protein transfer was started by 
applying a current of 400 mA for 70 minutes. 
Afterwards, the membrane was stained in Ponceau S solution for 2 minutes and then 
destained in water to an appropriate degree. Successful blotting was confirmed by complete 
transfer of all pre-stained molecular marker bands. Well positions were marked before the 
membrane was destained completely in distilled water. 
To block unspecific antibody binding sites, the blot was incubated in 5% skimmed milk 
powder solution for 60 minutes at room temperature. After a short washing step with TBS-T, 
the membrane was kept over night at 4°C with mild agitation in a dilution of the primary 
antibody. Superfluous and unspecifically bound antibody was removed by washing three 
times for 5 minutes with large volumes of TBS-T. Next, the membrane was incubated in a 
dilution of the secondary antibody for 60 minutes at room temperature. Antibody probing was 
completed by further three washing steps (each 5 minutes, large volumes of TBS-T).  
The luminescence reaction was started by combining 2 ml ECL1 and 2 ml ECL2, and adding 
the mixture immediately to the membrane. After 1 minute of incubation the blot was wrapped 
in cling foil, drained completely and put into an X-ray cassette. In the darkroom a sheet of 
medical X-ray film Super RX was put on the membrane under safelight conditions. The sheet 
was exposed to the blot for up to five minute in the closed cassette. The film was developed 
using a developer machine. Finally, the labels and markers were transferred to the film. 
 
3.8 – Yeast complementation assay: 
 
3.8.1 – Preparation of media: 
YPD medium:  1% (w/v) yeast extract; 2% (w/v) peptone; 2% (w/v) glucose  
SD medium:    0.5% (w/v) ammonium sulfate;  
 0.17% (w/v) yeast nitrogen base; 2% (w/v) glucose  
SG medium:            0.5% (w/v) ammonium sulfate; 0.17% (w/v) yeast nitrogen base;  
 2% (w/v) galactose 
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SD minimum medium was supplemented with amino acids to allow growth of auxotrophy 
mutants. For yeast transformed with the vector pYX242 lysine, leucine and uracil were added, 
while the vector pYX233 demands histidine, lysine and uracil. The following table gives an 
overview over the used amounts:  
 
Amino acid Final concentration 
(mg/l) 
Stock solution        
(per 100 ml ddH2O) 
ml stock solution per    
1 l SD-Medium 
Uracil 20 200 mg 10 ml 
L-Tryptophan 20 1 g 2 ml 
L-Histidine/HCl 20 1 g 2 ml 
L-Lysine/HCl 50 1 g 5 ml 
L-Leucine 60 1 g 6 ml 
 
Table 3.2: Amino acid supplementation in yeast growth media 
 
The amino acid stock solutions were autoclaved and stored at 4°C. The uracil solution was 
checked for precipitation before use and warmed in a water bath if necessary. 
 
3.8.2 – Yeast cultures: 
 
The yeast strains were plated on SD plates and incubated for several days at 30°C. As soon as 
enough cell material was available, the yeast cells were collected with a sterile inoculating loop 
and resuspended in 15% (v/v) glycerol. The glycerol stocks were stored at –80°C and served as 
backup. 
Both strains were also grown as liquid cultures. For this purpose, a single colony was 
transferred from an agar plate to 50 ml SD medium in a sterile flask. After some days the cell 
density (OD600) increased, and the cells were ready for further treatment. 
 
3.8.3 – Yeast transformation: 
 
To generate a preparatory culture, 20 ml YPD medium were inoculated with the desired yeast 
strain and incubated over night at 30°C and 200 rpm on an orbital shaker. 5 ml of this culture 
were added to 50 ml YPD medium and shaken at 30°C until an optical density of 0.6 was 
reached. The yeast cells were then pelleted for 5 minutes in a sterile 50 ml tube at 2000 g and 
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resuspended in 25 ml of sterile water. After repetition of the previous centrifugation step, the 
water was removed, and the cells were resuspended in 1 ml of 100 mM lithium acetate 
(LiAc). The mixture was centrifuged at maximum speed for 15 seconds to pellet the cells. 
After the supernatant was discarded, the pellets were resuspended in 400 µl 100 mM LiAc 
and aliquoted à 50 µl. Once again the cells were pelleted, and the supernatant was removed. 
The transformation mix contained the following components which were added to the cells in 
the indicated order: 
 
            240 µl     50% (w/v) PEG  
              36 µl     1 M LiAc 
              25 µg    SS DNA (salmon sperm carrier DNA, denatured at 95°C for 5 minutes) 
                5 µg    plasmid DNA, diluted in 70 µl of sterile water  
 
The samples were mixed thoroughly until the cell pellets were dissolved completely. Next, the 
cells were incubated for 30 minutes at 30°C on a rocking platform. A heat shock was applied 
by rising the temperature to 42°C for 20 minutes. The cells were then pelleted by                  
15 seconds of centrifugation at 7000 g before the supernatant was discarded, and the pellet 
was resuspended carefully in 30 µl of sterile water. The cell suspension was spread on agar 
plates with the appropriate selective medium and incubated for several days.  
 
3.8.4 – Yeast colony PCR: 
 
Yeast colony screen was done as described in section 3.1.6 for E. coli cells. Instead of 
bacteria colonies, a small amount of resuspended yeast colony was used as DNA template for 
PCR, together with appropriate vector-specific primers. 
 
3.8.5 – Lysis of yeast cells: 
 
Using a saturated starter culture, yeast cells were incubated in 50 ml of SD medium and 
grown at 30°C on a shaking platform until an OD600 of 1.0 was reached. The cells were 
harvested by centrifugation for 10 minutes at 2000 g and 4°C, resuspended in 1 ml 10 mM 
sodium azide and incubated on ice. By centrifugation of 1 minute at 14000 g, the cells were 
pelleted again. The supernatant was discarded, and the pellet was resuspended in 200 µl       
1x SDS sample buffer. The mixture was incubated on a heating block at 96°C for 10 minutes, 
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before 200 µl of washed glass beads were added. To allow effective disruption of the yeast 
cells, the samples were vortexed vigorously for 2 minutes. Using a 21 gauge needle, a hole 
was poked into the bottom of the sample tubes, and the tubes were placed into fresh tubes. By 
centrifugation at 2000 g for 10 seconds, the liquid was expelled into the bottom tube. While 
the beads could be discarded, the liquid fraction was centrifuged at 14000 g for 2 minutes to 
pellet any insoluble material. A defined volume of the supernatant was loaded into SDS gels 
and subjected to SDS-PAGE and immunoblotting as described before. 
 
3.8.6 – Complementation assay procedure: 
 
Successfully transformed deletion mutants were distributed on glucose-containing SD plates 
and on galactose-containing SG plates, supplemented with 5 µM rapamycin. Hereby, the 
glucose plates served as control, while the galactose plates induced expression of FKBP and 
thus potentially influenced rapamycin susceptibility. The plates were each separated into eight 
segments (one clone per segment) and incubated at 30°C for several days. The colonies were 
documented photographically, and growth behavior of the yeast clones was directly 
compared. 
 
3.8.7 – Yeast growth curves: 
 
In order to evaluate growth of the individual yeast transformants more exactly, optical density 
of yeast suspension culture was recorded over 48 hours. To do that, the respective clone was 
inoculated in 150 µl SD medium (with an appropriate amino acid supplementation) on a 
transparent 96 well plate and incubated in a Tecan reader at 30°C. The initial OD was not 
higher than 0.1 in any of the wells. 
By using an appropriate reader program, the absorption at 595 nm was determined every       
180 minutes. After 15 measurements the upper plateau of the hyperbolic growth curve was 
reached in most cases, and the experiment was stopped. 
 
Reader settings: Absorbance, endpoint 
 Wavelength: 595 nm 
     Number of reads: 10; time between move & read: 1 ms 
 
3 – Methods  
___________________________________________________________________________ 
69 
 
The growth curve was obtained by plotting the OD values against time (in minutes) in an 
Excel worksheet.  
 
3.9 – In vitro kinase assay: 
 
Procedure for immunoprecipitation of mTOR complex 1: 
 
For mTORC1 preparation, HEK293 or HeLa cells were plated in 10 cm dishes and were 
transfected using Ca3(PO4)2 with 30 µg of myc-Raptor plasmid. The following day, cells were 
starved by changing medium to simple DMEM without serum. After another 16-24 h, amino 
acid starvation was performed by incubating cells in TBS for 30 minutes. Finally, cells were 
stimulated by addition of DMEM with serum/insulin/amino acids for 60 minutes. 
Cells were washed twice with TBS and lysed in 500 µl of CHAPS-containing lysis buffer (see 
section 3.7.1). Lysates were shaken for 30 minutes at 4°C, then centrifuged for 15 minutes at 
full speed and 4°C. While the pellets were discarded, 100 µl of “EZview Red Anti-c-Myc 
Affinity Gel” were added to the supernatant; then, the samples were rotated at 4°C for 2 h. 
The beads were collected by centrifugation (8000 rpm, 1 minute), washed six times with each  
1 ml of lysis buffer (without protease inhibitor mix). The immunoprecipitates were eluted by 
addition of 100 µl elution buffer (TBS with 100 µg/ml MYC peptide) and gentle shaking at 
4°C for 10 minutes. 
 
 
Procedure for immunoprecipitation of HA-S6K: 
 
Lysis buffer:          40 mM Hepes, pH 7.5; 120 mM NaCl; 1 mM EDTA; 
 10 mM sodium pyrophosphate; 10 mM glycerol phosphate;  
                     0.5 mM sodium orthovanadate; 50 mM NaF; 1% (v/v) Triton X-100 
                             1% (v/v) protease inhibitor cocktail 
 
 
HEK293 cells in 10 cm dishes were transfected using Ca3(PO4)2 with 30 µg of HA-S6Kinase 
plasmid. After 24 h, cells were starved with simple DMEM without serum. The following 
day, cells were incubated in TBS for 60 minutes. Addition of rapamycin (final concentration: 
100 nM) ensures total dephosphorylation of S6Kinase. 
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Cells were washed twice with TBS and lysed in 500 µl of lysis buffer. After 30 minutes of 
shaking at 4°C, the lysates were centrifuged for 15 minutes at full speed and 4°C. 100 µl of 
monoclonal Anti-HA agarose were added to the supernatant before the samples were rotated 
at 4°C for 2 h. 
The beads were spun down and washed excessively with each 1 ml of Triton buffer. Elution 
was performed by addition of 100 µl TBS with 200 µg/ml HA peptide and gentle shaking at 
4°C for 10 minutes. 
 
 
In vitro kinase assay: 
 
Kinase buffer:  20 mM Tris/HCl, pH 7.4 
   10 mM MgCl2 
0.2 mM ATP 
 
Generally, the assay conditions are identical for the mTOR substrates 4E-BP1, S6Kinase and 
Akt kinase. Recombinant 4E-BP1 and pulled-down S6Kinase were combined with mTORC1 
eluate. 
 
In a total volume of 40 µl, the following components were mixed: 
 
a. 8 µl 5x kinase buffer 
b. 20 ng recombinant EGFP-4E-BP1                                                                      
or 5 µl HA-S6K IP eluate 
c. 2-5 µl of mTORC1 IP eluate  
d. bidest. H2O ad 40 µl 
e. 0.5 µl 4 µM rapamycin / torin1 (final concentration: 50 nM) 
f. 1 µl 2 µM recombinant FKBP (final concentration: 50 nM) 
 
The reaction was incubated at 37°C for 30 minutes and stopped by addition of 15 µl             
4x SDS sample buffer and boiling for 5 minutes at 95°C. 
The samples were resolved by SDS-PAGE on a 12% gel and analyzed by Western blotting 
using the appropriate anti-phospho antibody. 
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4 – Results:   
 
4.1 – Recombinantly expressed FKBPs are functional: 
 
4 .1.1 – FKBPs can be expressed successfully in E. coli: 
 
For different in vitro activity and binding experiments, some members of the FKBP protein 
family were expressed in E. coli and purified using standard methods of affinity 
chromatography as previously described [60, 84, 273]. The integrity and purity of the His-
tagged FKBP proteins were verified by performing gel runs on 16% SDS gels. Around       
100 pmol of protein were loaded per lane to achieve satisfactory signal intensity.  
Representative gel pictures are shown in figure 4.1.1A. It can be observed that the small 
FKBPs 12, 12.6 and 13 as well as the FK1 domains of FKBP51 and FKBP52 are relatively 
pure: the gel does not display any contaminating bands here. For the FKBPs of higher 
molecular weight (FKBP25, FKBP51, FKBP52), degradation bands and unspecific signals are 
more frequent, implying a higher degree of contamination. As the protein band of the correct 
size represents the main species in every case, it could be expected that the protein 
preparations exhibit reasonable activity in downstream assays. This was also further approved 
in active-site titrations (see section 4.1.2). 
 
 
                     
 
 
 
Figure 4.1.1: Recombinantly expressed FKBPs are sufficiently pure 
Representation of SDS protein gels stained with Coomassie Brilliant Blue. 
(A) SDS gel of different FKBPs  
(B) SDS gel demonstrating TEV cleavage of His-tags 
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For protein crystallization, FKBPs were treated with TEV protease to cleave off His-tags. The 
progress of this procedure was checked, too. The resulting gel picture shows the proteins 
before and after TEV treatment (see figure 4.1.1B). Notably, the excessive extraction 
procedure after cleavage increases purity of the proteins significantly. 
 
For FRET binding assays, EGFP fusions proteins of several FKBPs were generated and 
expressed. Again, SDS gel analysis was performed in order to control their quality. As figure 
4.1.2 reveals, the protein preparations contain contaminations: for the full-length FKBP51 and 
52 fusion proteins (lane 7 and 8), at least one second species is present. The fusion proteins of 
the smaller FKBPs appear to be of higher purity. But as many of the protein assays to be 
performed allow big variations of protein concentration, the concentration of main product 
can be considered as sufficient for usage in downstream assays.  
  
             
Figure 4.1.2: Recombinantly expressed EGFP fusion proteins are larger and less pure 
Representation of an SDS gel stained with Coomassie Brilliant Blue. 50 pmol of each protein was analyzed.  
St: standard protein ladder. 
 
 
4.1.2 – Recombinant FKBPs display high ligand-binding activity: 
 
As the purification procedure can affect integrity and activity of expressed proteins in a 
negative way, these parameters must be checked before further use. For this purpose, “active 
site titration” with the synthetic fluorescein-labeled FKBP ligands CK97 and CK182 
(“tracers”) was performed [274]. This experiment enables us to verify whether the 
concentration of purified proteins (determined by UV measurement) really corresponds to the 
concentration of active protein. 
During the experiment, the FKBP is titrated against a fixed concentration of labeled ligand. 
This results in a classical binding curve with characteristic s-shape in a half-logarithmic plot 
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(see figure 4.1.3A). When the experiment is repeated with tracer concentrations higher than 
the Kd, the transition point of the curve shifts towards the right side for these high-affinity 
tracers and therefore towards higher FKBP concentrations. For each curve, EC50 values were 
determined by curve-fitting, and these values were plotted against the actual tracer 
concentrations. A line can be fit into the individual data points, and the intersection with the y 
axis can be determined by linear regression. The resulting EC50 value in absence of tracer can 
theoretically be considered as a Kd-like constant (see figure 4.1.3.B; FKBP13 and FKBP25 in 
section 6.2 of appendix). 
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Figure 4.1.3: Tracers bind to FKBPs with high affinity 
(A) Binding curves of titration of FKBP12 against 10-200 nM CK97; half-logarithmic plot 
(B) Plot of calculated EC50 values against the actual tracer concentration; linear equation is shown, 
intersection with y-axis is printed in bold. 
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B 
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Altogether, the slope values of FKBP51 and FKBP52 are above the ideally expected value of 
0.5. The other FKBPs display slope values below 0.5. Thus, the protein concentration 
determined by UV measurement must be corrected; the correction factor can be calculated by 
forming the quotient of 0.5 and the slope value. If the concentration value determined by UV 
measurement is multiplied with this factor, the corrected value can be obtained. This value is 
used to calculate protein amount that is utilized in all downstream protein assays. 
 
The following table gives an overview of all determined values: 
 
Protein Slope Correction 
factor 
Kd Protein 
concentration, UV-
determined (µM) 
Protein 
concentration, 
corrected (µM) 
FKBP12 0.29 1.7 1.1 200 345 
FKBP12.6 0.39 1.3 9.4 700 897 
FKBP13 0.22 2.3 0.6 60 136 
FKBP25 0.34 1.5 13 20 29 
FK1 FKBP51 0.16 3.1 0.7 240 744 
FKBP51 0.71 0.7 3.1 20 14 
FK1 FKBP52 0.15 3.3 2.0 280 924 
FKBP52 0.57 0.9 4.9 30 26 
 
Table 4.1.1: Protein concentrations must be corrected corresponding to results of active-site-titration 
Protein concentrations after UV determination and after correction for all tested FKBP proteins 
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4.1.3 – Competition assays reveal high-affinity binding of natural ligands: 
 
After activity and actual protein concentration of purified FKBPs were verified, further 
fluorescence polarization assays with different ligands were performed. By titrating the 
proteins against a constant amount of fluorescent tracer (CK97, CK182), a binding curve was 
generated (see figure 4.1.4), and Kd values for the binding were calculated. The ideal tracer 
concentration for CK97 and CK182 was determined as 0.5 nM in previous experiments.   
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Figure 4.1.4: Fluorescein-labeled rapamycin and FK506 analogs bind to FKBPs with different affinities 
Binding curves (half-logarithmic plot of protein concentration against fluorescence polarization anisotropy (mP)) 
for     (A)    0.5 nM CK97       (B)     0.5 nM CK182 
By fitting of the individual curves using “Kd fit” the dissociation constants of the binding were determined. 
A 
B 
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As expected, binding of the rapamycin derivative CK97 turned out to be highly affine for all 
tested FKBPs: Kd values cluster below 15 nM and even reach sub-nanomolar affinity for 
FKBP12 (see table 4.1.2). In contrast, the FK506/rapamycin analogue CK182 displayed low 
nanomolar binding only for FKBP12 and FKBP12.6; binding to FKBP13 was 10fold weaker, 
and the affinity to FKBP25 was in the µM range. This finding is in line with previous 
observations that showed a clear selectivity of FKBP25 for rapamycin compared to FK506. 
 
Protein Kd for binding to CK97 (nM) Kd for binding to CK182 (nM) 
FKBP12 0.2 ± 0.06 1.0 ± 0.09 
FKBP12.6 1.3 ± 0.19 7.2 ± 0.49 
FKBP13 2.9 ± 0.2 160 ± 9.2 
FKBP25 13 ± 2 >2500 
FKBP51 2.5 ± 0.4 n.d. 
FKBP52 4.9 ± 0.6 n.d. 
 
Table 4.1.2: Affinities of CK97 and CK182 are highly different for the tested FKBPs  
Comparison of Kd values for CK97 and CK182 (in nM); medium deviation is indicated; n.d.: not determined. 
 
In direct comparison to the Kd values determined by active-site titration (see table 4.1.1), Kd 
values for FKBP12, 13, 25, 51 and 52 are highly consistent. Only for FKBP12.6, a slight 
deviation could be detected (1.3 nM vs. 9.6 nM).  
As the compounds CK97 and CK182 are modified by addition of a fluorescein moiety, their 
binding characteristics might differ from the ones of the natural products rapamycin and 
FK506: although fluorescein is not attached at sites involved in FKBP binding, it cannot be 
excluded that sterical hindrance alters accessibility of certain regions of the molecule. 
To overcome this problem, competition assays were performed to evaluate Ki values for the 
unmodified ligands rapamycin, FK506 and CK85: during these experiments, protein and 
tracer concentrations are constant while a ligand (rapamycin, FK506 or CK85) is titrated to 
the mixture. With increasing ligand concentrations the tracer which is bound to the FKBP 
protein is replaced successively. The ligand concentration that displaces 50% of the tracer is 
referred to as “the IC50” of the binding. The resulting binding curves are presented in figure 
4.1.5. The detection limit of CK97 precluded a dilution of this tracer below its Kd. To account 
for this situation, the formula for curve fitting has been adjusted to conditions of FKBP 
concentration not being much smaller than Kd [274] (whole formula see appendix section 6.3).  
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Figure 4.1.5: Competition assays reveal high affinity of natural ligands to FKBPs 
Binding curves (half-logarithmic plot of ligand concentration against fluorescence polarization anisotropy (mP)) 
(A) 0.5 nM CK97 as tracer and rapamycin  
(B) 0.5 nM CK97 as tracer and FK506 
(C) 0.5 nM CK182 as tracer and CK85      
By fitting of the individual curves by “Kd fit” (see appendix section 6.8 for exact formula) the dissociation 
constants of the binding were determined.   
A 
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In table 4.1.3 the results of the series of experiments are shown: for FKBP12, affinity for both 
rapamycin and FK506 was highest, displaying values in the picomolar range. Similarly, 
FKBP12.6 was an excellent binder of both compounds. The larger FKBP12 homologues also 
show highly affine binding to rapamycin, ranging below 10 nM. For FK506, the values vary 
quite a lot: FKBP52 binds best with around 23 nM while the affinity of FKBP13 is 5fold less. 
FKBP25 could not be bound to FK506 at all. CK85, a simplified analogue of the FKBP 
binding moiety of rapamycin and FK506, bound to FKBP12 and FKBP12.6 with high 
affinity.  
 
 
Protein Ki Rapamycin 
(CK97) (nM) 
Ki CK85 
(CK182) (nM) 
Ki FK506 
(CK97) (nM) 
FKBP12 0.6 
±0.17 
12. 4 
±3.1 
0.2 
±0.01 
FKBP12.6 0.4 
±0.06 
24.4 
±2.8 
4.4 
±1.04 
FKBP13 7.2 
±0.7 
318 
±101 
166 
±29.7 
FKBP25 
 
5.9 
±1.76 
n.d. 
 
n.d. 
 
FKBP51 3.7 
± 0.9 
n.d. 104 
± 14 
FKBP52 4.2 
± 0.7 
n.d. 23 
± 3 
 
Table 4.1.3: Binding constants for unlabeled compounds rapamycin, CK85 and FK506 
Comparison of Kd values for rapamycin, CK85 and FK506; in brackets: used tracer. 
Median deviation is indicated; n.d.: not determined. 
 
 
When the binding affinities of the labelled compound CK97 are compared to the natural 
product rapamycin (see tables 4.1.2 and 4.1.3), it turns out that the values are quite consistent: 
for FKBP12, the deviation is smallest (0.4 nM), while it is biggest for FKBP13 (4.3 nM) and 
FKBP25 (7.1 nM). FKBP51 and FKBP52 lie in-between with deviations of 1.2 nM and       
0.7 nM. Altogether it can be stated that the fluorescein-modified compound reflects binding 
characteristics of the natural compound very well. 
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4.2 – Rapamycin induces binding of different FKBPs to FRB/mTOR in vitro: 
 
4.2.1 – In GST pulldown assays, FRB/mTOR recruits FKBP*rapamycin complexes: 
 
GST pulldown assays were performed in order to examine direct interaction of mTOR and 
FKBP51/52 under in vitro conditions; this has been demonstrated for FKBP12 before [275]. 
As full-length mTOR protein is quite large (around 290 kDa) and unstable in insolated form, 
it cannot be obtained easily. So we decided to perform the experiment with the FRB (FK506-
rapamycin-binding domain) of mTOR which can be expressed as a GST-fusion protein with 
high yields [23]. As FKBP binding partners, we used recombinantly expressed FK1 domains 
of FKBP51 and FKBP52. The pulldown batches were separated by SDS PAGE and subjected 
to Coomassie staining.  
On the gel image (see figure 4.2.1), pulldown eluates can be seen in lanes 2-6 and 8-12, while 
the load is present in lane 1. The latter represents the amount of protein that has been loaded 
onto the beads and thus can be eluted again. As there is less FRB protein detectable in the 
eluates than in the load, it can be concluded that there was loss of protein during the pulldown 
procedure, mainly caused by washing and insufficient elution. Importantly, the pulldown 
yields of FRB do not differ much and allow a comparison of the samples. 
 
                         Load                                                                                             FK1 FKBP51/52 
                                      -       +      +      +     +             -      +       +      +      +     GST-FRB 
                                      +       -      +      +     +            +       -       +      +      +      rapamycin 
 
    lane                        1         2        3         4       5       6       7        8       9      10      11      12 
 
Figure 4.2.1: FK1 domains of FKBP51 and 52 bind to FRB in presence of rapamycin 
For the GST pulldown assay, 0.5, 1.0 and 1.5 µM FK1 domains of FKBP51 and FKBP52 were incubated with 
1 µM GST-FRB on GST beads in absence and presence of 1 µM rapamycin. After washing with TBS, the GST 
resin was boiled in 1x SDS sample buffer, and the supernatant was subjected to SDS-PAGE. 
Lane 7: protein size marker (band of 15 kDa) 
Lane 1: loading control: 1 µM GST-FRB and 1.5 µM FKBP52 FK1 
Lanes 2/ 8: control for unspecific binding to beads: 1.5 µM FK1 FKBP51 or FKBP52 in absence of GST-FRB 
52 51 
FKBP 
FRB 
FKBP FK1 FKBP FK1 
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The gel picture shows clearly that generally both the FK1 domain of FKBP51 and FKBP52 
are able to bind to FRB domain of mTOR (lanes 4-6 for FK1 FKBP52 and 10-12 for FK1 
FKBP51). At least for FKBP51, this binding seems to occur in a dose-dependent manner as 
the pulldown signal becomes more intensive with increasing FKBP concentrations. For 
FKBP52 such a result cannot be detected: binding appears to be similar at all three FKBP 
concentrations.  
In absence of rapamycin the binding is abolished almost completely indicating that the 
interaction of FKBP51/52 with FRB is specific and mediated by rapamycin. Furthermore the 
FKBPs do not display unspecific binding to the GST beads when FRB is not present (lanes 2 
and 8).  
As the isolated FK1 domains may behave differently compared to the full-length proteins, the 
pulldown experiment was also performed with recombinant full-length FKBP51 and 
FKBP52. Representative SDS gel images are shown in figure 4.2.2. 
 
                                        Pulldown          Load 
                                                                        FKBP 
                                       +       +       -                  Rapamycin 
                         FRB 
                                   FKBP12 
                                   FKBP51 
                                   FK1 FKBP51 
                                  FKBP52 
                                   FK1 FKBP52 
                                        1       2        3        4          lane 
     
Figure 4.2.2: Full-length FKBPs interact with FRB in a rapamycin-dependent manner 
SDS PAGE gel picture of GST pulldown assay; lanes 1-3: pulldown experiments; lane 4: loading control. 
Lane 1: 1 µM FKBP and 1 µM GST-FRB;     Lane 2: 2 µM FKBP and 1 µM GST-FRB;  
Lane 3: 2 µM FKBP and 1 µM GST-FRB;                 Lane 4: 1 µM FKBP or 1 µM GST-FRB 
FKBP12 load (lane 4) is taken from a second experiment performed under the same conditions. 
 
First of all, it can be stated that all tested FKBP*rapamycin complexes bind to GST-FRB in 
GST pulldown experiments: in the rapamycin-dependent pulldown lanes (lanes 1-2) protein 
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bands can be detected for all five FKBPs. When compared to the load in lane 4, the 
concentration of FKBP protein in the pulldown lanes is considerably lower; a big amount of 
protein is lost during the pulldown procedure. Nevertheless, binding to GST-FRB in presence 
of rapamycin seems similarly strong for all FKBPs. 
In the pulldown samples of lane 3, rapamycin has been omitted. Although there is a small 
amount of FKBP52 binding in the absence of rapamycin, it can be stated that signal intensity 
is much lower than in lanes 1 and 2 for all other FKBPs. Thus, binding of FKBP proteins to 
GST-FRB is indeed rapamycin-mediated.   
Altogether, the signal strength in this simple assay is not sufficient to measure specificity and 
intensity of binding. A further, more exact characterization of protein interactions including.     
EC50 values can only be achieved with more advanced binding assays.  
 
 
4.2.2 – In vitro FRET assay reveals high-affinity binding of FKBPs to FRB/mTOR: 
 
A commercially available FRET-based assay was utilized to further investigate binding of 
FKBPs to the FRB domain of mTOR. For usage in this assay, FKBPs were expressed as 
EGFP fusion proteins, and FRB was modified by addition of a GST domain. The resulting 
FRET pair consists of EGFP and a Terbium-labelled anti-GST antibody. Rapamycin was 
added to induce binding of the two protein partners. In the assay mixture final concentrations 
of 5 nM GST-FRB and 100 nM EGFP-FKBP were used. Thereby the concentration of the 
FRB-fusion protein was in the range of the antibody (2.5 nM) while the FKBPs were added in 
huge excess. Thus it was ensured that the FKBP protein did not become the limiting factor 
during titration. 
In order to obtain binding curves, a rapamycin titration was performed at constant protein 
concentrations. A half-logarithmic plot of the rapamycin concentration against the FRET 
ratios (Em520 / Em495) produced dose-response curves (see figure 4.2.3A). The experiment 
was performed with EGFP fusions of 6 different FKBPs, and for all of them a rapamycin-
dependent interaction with GST-FRB could be detected. The curves were analyzed in terms of 
EC50, hill slope and plateaus. All obtained values are represented in table 4.2.3B. 
Compared to the negative control EGFP (see appendix section 6.4), all EGFP-FKBP fusion 
proteins displayed highly affine binding to GST-FRB in the presence of rapamycin. EC50 
values ranged from 4 – 26 nM. FKBP12, 13 and 25 had very similar affinities of around         
5 nM which is in good agreement with a value of 12 nM for FKBP12 determined by 
4 – Results 
___________________________________________________________________________ 
82 
 
Banaszynski [276]. In contrast, the large FKBPs 51 and 52 showed a 5-fold lower binding 
strength. Interestingly, the isolated FK1 domain of FKBP51 displayed higher affinity to GST-
FRB than the full-length protein. This was not the case for FK1 FKBP52. 
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Protein 
 
EC50 
[nM] 
Hill slope Minimum  Maximum Difference 
Max-Min 
FKBP12 3.8 ± 0.6 - 1.3 0.2 1.1 0.9 
FKBP12.6 5.6 ± 0.9 - 1.44 0.4 1.0 0.6 
FKBP13 6.7 ± 1.6 - 0.9 0.4 1.1 0.7 
FKBP25 4.3 ± 0.9 - 1.35 0.4 1.1 0.7 
FKBP51 25 ± 6.7 - 1.3 0.4 0.7 0.3 
FKBP52 25.5 ± 5.8 - 1.2 0.4 0.7 0.3 
FK1 FKBP51 10.5 ± 1.8 -1.18 0.2 0.83 0.63 
FK1 FKBP52 26.2 ± 5.6 -1.38 0.2 0.46 0.26 
 
Figure 4.2.3: Six different FKBPs bind to FRB/mTOR with comparable affinity 
(A) Half-logarithmic plot of the rapamycin concentration against the observed FRET ratio (Em 520 nm/      
Em 495 nm). 5 nM GST-FRB, 100 nM EGFP-FKBPs and 2.5 nM of a Terbium-labelled anti-GST 
antibody were used. Rapamycin was titrated from 0 to 5 µM. Left panel: full-length FKBPs  
(●FKBP12; ○FKBP12.6; ▼FKBP13; ∆FKBP25; ■FKBP51; □FKBP52). Right panel: ● FKBP12 and 
FK1 domains of ○FKBP51 and ▼FKBP52.  
(B) Table summarizing the constants obtained by analysis of the binding curves (FKBP12 curve from right 
panel). 
 
This tendency can also be observed on the level of FRET efficiency: while FRET efficiency 
for FKBP12, 13 and 25 ranges over 0.7 units, the efficiency for FKBP51 and FKBP52 was 
only half as high. This might be explained by the size of the multi-domain proteins of around 
80 kDa which might not allow formation of the ternary complex in the same way as for the 
small FKBPs. Maybe the distance between the FRET partners is increased which leads to a 
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less effective energy transfer. Possibly, sterical effects influence the orientation or hinder the 
binding of anti-GST antibodies in the complex, causing changes in the FRET ratio. Reduced 
purity of the EGFP-FKBP protein preparations (see SDS gel analysis in figure 4.1.2) might 
also contribute to this effect. 
 
Next, different clinically used rapamycin analogues (“rapalogues”) were tested for their 
binding affinities to different FKBPs. Again, formation of the ternary complex was assayed 
by measuring the FRET ratio between GST-FRB and EGFP-FKBP51/52 at different 
rapalogue concentrations. The resulting FRET binding curves are represented in figure 4.2.4.  
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EC50 (nM) Rapamycin  Zotarolimus Everolimus Zotarolimus 
Isomer 
FKBP51 25  51  18  37  
FKBP52 25.5  25  31  51  
 
Figure 4.2.4: Rapalogues are able to induce interaction of FKBPs and FRB/mTOR 
(A) Half-logarithmic plot of rapalogue-dependent FRET ratio of 10 nM GST-FRB and 50 nM EGFP-FKBP. 
      Left panel: FKBP51; Right panel: FKBP52.    ●Everolimus; ○Zotarolimus; ▲Zotarolimus isomer. 
(B) Overview of EC50 values determined by FRET binding assays (values for rapamycin taken from 
       figure 4.2.3B) 
 
In summary, all three tested rapamycin derivatives induce formation of ternary complexes of 
FKBP51/52 and FRB successfully. Everolimus appears to even increase recruitment of FRB 
to FKBP51, while zotarolimus and its isomer reduce binding affinity. In the case of FKBP52, 
everolimus and zotarolimus are as good as rapamycin; only zotarolimus isomer displays 
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weaker complex induction capacity. Generally, we could not detect any significant preference 
of a rapalogue for FKBP51 over FKBP52.  
 
 
4.2.3 – FK506 can compete for binding of rapamycin to the FKBP active site: 
 
To demonstrate that the observed binding of FKBPs to FRB is really rapamycin-dependent, a 
competition with FK506 was performed. Hereby one can take advantage of the fact that 
rapamycin and FK506 compete for binding to FKBPs [277]. In doing so the affinity of both 
ligands is similarly high, ranking in the low nanomolar section [21].  
A pre-incubation of FKBPs with an excess of FK506 (2 and 4 µM) was performed in order to 
saturate all binding sites. When FRB and rapamycin were added, the formation of the ternary 
complex was largely inhibited: not until very high rapamycin concentrations were reached, 
the equilibrium between rapamycin binding and FK506 dissociation shifted to free rapamycin, 
and the complex formation started (see figure 4.2.4). Thus, the observed shift of the binding 
curve to higher rapamycin concentrations can be considered as a reliable control for 
specificity and rapamycin-dependency of complex formation.  
 
For FKBP12 the competition of ternary complex formation by FK506 was highly effective: 
the EC50 values shifted from 6 nM to >700 nM after pre-treatment with 2 µM FK506. EC50 
values of more than 1 µM could be reached by doubling the FK506 concentration to 4 µM. 
For FKBP51 an effect is clearly visible as well, although addition of FK506 did not cause a 
similarly big shift of the binding curve as in the case of FKBP12. Nevertheless, EC50 values 
of ~500 nM for 2 µM FK506 and ~800 nM in the presence of 4 µM FK506 suggest that a 
competition between the ligands for the same binding site takes place.  
A similar effect could be observed for full-length FKBP52: the competition works reliably. 
When the EGFP-fusion of the FK1 domain was used instead of the full-length form of 
FKBP52, EC50 of binding was shifted from 26 nM to more than 1 µM. This indicates a strong 
inhibition of rapamycin-dependent binding to the FK1 domain by FK506; other domains are 
obviously not involved in these binding events. 
 
Altogether, the competition experiments reveal that binding of FKBPs to the FRB domain of 
mTOR is indeed rapamycin-dependent, as affinity of the two protein partners can be lowered 
substantially by addition of an excess of FK506. 
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Figure 4.2.4: An excess of FK506 blocks formation of rapamycin-dependent ternary complexes 
Half-logarithmic plot of the rapamycin concentration against the observed FRET ratio. The following binding 
partners were used in the respective FRET assay:
(A) 5 nM GST-FRB and  25 nM EGFP-FKBP12  
(B) 5 nM GST-FRB and  25 nM EGFP-FKBP51  
(C) 5 nM GST-FRB and  25 nM EGFP-FKBP52 
(D) 5 nM GST-FRB and 50 nM FK1 FKBP52 
FKBPs were pre-incubated with 0, 2 and 4 µM FK506 before the assay was started.  
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4.3 – mTOR activity can be inhibited in vitro by a variety of FKBPs: 
 
4.3.1 – In a FRET activity assay, all FKBPs inhibit mTOR activity toward 4E-BP1:  
 
In the previous experiments, we were able to demonstrate that formation of ternary complexes 
with rapamycin and FRB/mTOR in vitro is not restricted to FKBP12, but is successful with 
several tested FKBPs. Therefore, we then concentrated on the question whether these 
“alternative ternary complexes” exert inhibitory effects on the kinase mTOR, or whether this 
function is exclusive to FKBP12. 
mTOR activity can be assessed easily by using a commercial in vitro FRET assay. The actual 
read-out is based on phosphorylation of the mTOR substrate 4E-BP1 which correlates directly 
to the activity of the heterologously expressed kinase (aa 1360-2549; N-terminally truncated 
product comprising FAT, FATC, FRB and PI3K-related kinase domain) [278]. As a positive 
control, the known mTOR inhibitors LY-294002 and PI-103 were titrated until kinase activity 
was totally abolished (see appendix section 6.5). Internally, we compared the inhibitory 
effects of different FKBPs with the one exerted by FKBP12 because its behavior is well 
known and characterized extensively.   
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Figure 4.3.1: Six different FKBPs reduce mTOR activity with nanomolar IC50 values 
Half-logarithmic plot of a rapamycin titration (0 – 1000 nM) against observed FRET ratio (Em 520 nm / Em 495 
nm) in presence of 100 nM FKBP protein (●FKBP12;  ○FKBP12.6;  ▲FKBP13;  ∆FKBP25;  ■FKBP51;  
□FKBP52). 
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Figure 4.3.1 gives an overview of the inhibition curves of six different FKBPs. Their 
concentration was constant (100 nM) while rapamycin was titrated from 0 to 1 µM. For all 
tested FKBP proteins, a significant and rapamycin-dependent inhibition of mTOR activity 
could be observed. 
The curves display maximum kinase activity at low rapamycin concentrations, resulting in a 
FRET ratio of around 1.0. When the concentration of the macrolide is increased, kinase 
activity is reduced; FRET ratio decreases accordingly and reaches a lower plateau of 0.3 – 0.5 
at around 10 nM rapamycin. For the case of total mTOR kinase inhibition, FRET ratio could 
theoretically be close to zero. Such a total inhibition cannot be accomplished by rapamycin 
and FKBPs proteins.  
 
Protein 
 
IC50 
(nM) 
Minimum Maximum Difference 
Max-Min 
FKBP12 0.69 ± 0.17 0.7 1.0 0.3 
FKBP12.6 4.79 ± 1.76 0.65 0.94 0.29 
FKBP13 2.48 ± 0.82 0.55 0.95 0.4 
FKBP25 2.61 ± 0.57 0.43 0.94 0.51 
FKBP51 1.95 ± 0.36 0.3 0.67 0.37 
FKBP52 1.68 ± 0.51 0.53 1.0 0.47 
 Table 4.3.1: Overview of all parameters determined doing mTOR activity assays 
 
The activity curves were characterized in terms of IC50 (see table 4.3.1). The data suggest that 
all examined FKBP proteins exert an inhibitory effect on mTOR kinase activity at nanomolar 
rapamycin concentrations. Furthermore, this inhibition seems to be highly effective; all IC50 
values range below 5 nM.   
FKBP12 inhibited mTOR activity in a rapamycin-dependent manner with an IC50 of 0.7 nM 
in our experiments. Reichling and colleagues determined a value of 4.3 nM under the same 
conditions [279]. Thus, it can be concluded that the assay works reliably, and that the minor 
deviation might be caused by different factors (e.g. serial rapamycin dilution). 
FKBP51 exhibits a special behavior: the plateaus of maximum kinase activity and maximum 
inhibition are shifted downwards. Compared to the FKBPs with the largest margins of 
inhibition, the maximum mTOR activity in absence of rapamycin reaches a level that 
corresponds to 50% of activity for FKBP13 or FKBP25. Apparently FKBP51 inhibits mTOR 
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kinase activity directly and in a way that is independent of rapamycin. The macrolide 
intensifies the effect even further and allows most effective inhibition among all FKBPs. 
However, unspecific quenching of the FRET signal by FKBP51 cannot be excluded. 
A direct comparison of the inhibition exerted by full-length FKBP51 and the FK1 domain 
reveals that the upper plateaus differ significantly, while IC50 values are similar (see figure 
4.3.2). From these observations it could be concluded that only full-length FKBP51 displays 
an intrinsic rapamycin-independent inhibitory effect on mTOR. This effect therefore seems to 
be mediated by the FKBD2 and/or the TPR domain of FKBP51. This could be further 
checked by repeating this experiment with a truncated FKBP51-FKBD2-TPR construct. To control 
for read-out artefacts, FKBP51 could be added after the mTOR kinase assay under otherwise 
identical conditions. 
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Figure 4.3.2: FK1 FKBP51 and full-length FKBP51 have different effects on mTOR kinase activity 
mTOR inhibition was induced by 50 nM FK1 FKBP51 and  50 nM FKBP51. Rapamycin was titrated from         
0  to  1 µM. A half-logarithmic plot of the rapamycin concentration against the respective FRET ratio              
(Em 520 nm / Em 495 nm) is shown. 
 
 
4.3.2 – FKBPs reduce phosphorylation of mTOR targets 4E-BP1 and S6Kinase in vitro:  
 
As the above described FRET-based mTOR in vitro activity assay uses isolated, truncated and 
recombinantly expressed mTOR protein and therefore does not allow a reliable 
characterization of mTOR complex components, we performed an in vitro kinase assay with 
intact mTORC1 [116, 179].  
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By expressing myc-tagged Raptor protein in HEK293 cells and by performing 
immunoprecipitation under conditions that preserve mTOR complex integrity, we isolated 
intact mTORC1 from living cells and used it directly in a kinase assay.  As different FKBPs, 
rapamycin and other inhibitors could be added in a well-defined manner, we were able to 
assess mTOR activity under different conditions more precisely. As a general readout, we 
determined the phosphorylation status of both substrates 4E-BP1 and S6Kinase. 
In order to assure general functionality and reliability of the assay, we examined 4E-BP1 and 
S6Kinase phosphorylation without FKBPs, in presence of rapamycin and in presence of both 
FKBP12 and rapamycin. In figure 4.3.3, the results of immunoblotting against phospho-
proteins are presented: for both substrates, phosphorylation can only be detected in presence 
of mTORC1 (lanes 1/2 vs. 3) while there is very few background of unspecific                        
4E-BP1/S6Kinase detection. The ATP-competitive mTOR inhibitor torin1 [116] blocks 
phosphorylation very effectively (lane 5) while rapamycin has no effect in absence of FKBPs 
(lane 4). When FKBP12 is added, there is only a minor inhibitory effect on mTOR; together 
with rapamycin, kinase activity is blocked almost completely, resulting in largely reduced 
substrate phosphorylation. Altogether, the in vitro kinase assay seems suitable for detection of 
rapamycin-dependent FKBP effects on mTOR. 
 
    -      -     +    +    +     +    +    + mTORC1 
    -      -     -     +    T     -     -     +   500 nM Rapamycin/ T: torin1 
                                       FKBP12      500 nM FKBP 
     -4E-BP1 phosphoT37/46 
   -4E-BP1 LOAD 
    -S6K phosphoT389 
  -HA LOAD        
 
   1     2     3     4     5     6    7    8       lane 
Figure 4.3.3: 4E-BP1 and S6Kinase phosphorylation can be inhibited by mTOR inhibitors and by 
FKBP12 in a rapamycin-dependent manner 
In vitro kinase assay: 100 ng recombinant EGFP-4E-BP1 or 5 µl IP of HA-S6Kinase were incubated with 
mTORC1 IP, FKBP12 and rapamycin (as indicated) in ATP-containing kinase buffer for 30 minutes at 37°C. 
Reaction was stopped, and samples were resolved by SDS-PAGE and subjected to Western blotting.  
 
 
4E-BP1 
S6Kinase 
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We were mainly interested in comparing effects of FKBP12 to those exerted by FKBP51 and 
FKBP52, both in absence and in presence of rapamycin. FKBP13 and FKBP25 were 
neglected because their cellular localization [82, 88] argues against a regulatory function in 
the cytoplasm. Thus, we modified the above assay and added FKBP12, FKBP51 and FKBP52 
at final concentrations of 500 nM in order to yield maximum inhibitory effects. 
Immunoblotting revealed phosphorylation patterns of 4E-BP1 and S6Kinase as presented in 
figure 4.3.4. As a control, total 4E-BP1/S6Kinase protein was assessed to assure uniform 
loading. Controls for unspecific effects exerted by rapamycin were included (see appendix 
section 6.5.2).   
In presence of mTORC1, S6K and 4E-BP1 phosphorylation was established (lane 2) and 
could be blocked by torin1 more or less completely (lane 3). All samples containing FKBPs, 
but no rapamycin, displayed stable substrate phosphorylation compared to the controls (lanes 
4, 5, 8, 9, 12, 13). Thus, no intrinsic inhibitory activity of FKBPs could be detected. When 
FKBPs were combined with the small molecule, phosphorylation of both 4E-BP1 and 
S6Kinase was greatly reduced (lanes 6, 7, 10, 11, 14, 15). The effects of all three FKBPs were 
comparable, and reduction of substrate phosphorylation was similar to the one achieved by 
torin1 (lane 3). 
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Figure 4.3.4: Inhibition of mTOR kinase activity is achieved by different FKBPs in in vitro kinase assays 
In vitro kinase assay was performed with immunoprecipitated mTORC1 in presence of EGFP-4E-BP1 or HA-
S6Kinase: IP eluate was combined with EGFP-4E-BP1/HA-S6Kinase, 500 nM of FKBP and 500 nM rapamycin 
in kinase buffer, incubated for 30 minutes at 37°C, boiled for 5 minutes and subjected to SDS-PAGE and 
immunoblotting analysis. 4E-BP1 phosphoT37/46 and S6Kinase phosphoT389 signal intensities were quantified 
and normalized to mTORC1-only treated sample (lane 2). As a control, 100 nM torin1 was used in the assay. 
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As full-length FKBP51 and FKBP52 seem to affect mTORC1 activity, we repeated the assay 
using FK1 domains instead.  In figure 4.3.5, the resulting pattern of T37/46 phosphorylation is 
represented: just like in the previous experiment, FKBP12/51/52 exert an inhibitory effect on 
mTOR kinase activity, resulting in reduced 4E-BP1 phosphorylation. Again, this effect is 
clearly rapamycin-dependent. Interestingly, the FK1 domains of FKBP51 and FKBP52 cause 
a larger decrease of phosphorylation signal compared to the full-length proteins. This finding 
might indicate that for successful mTORC1 inhibition only the rapamycin-binding FK1 
domain is necessary, while additional domains are rather counterproductive to this function 
(maybe by just increasing protein size).  
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Figure 4.3.5: FK1 domains of FKBP51/52 are sufficient for mTORC1 inhibition  
In vitro kinase assay was performed with immunoprecipitated mTORC1 in presence of 100 ng EGFP-4E-BP1. 
Anti-phosphoT37/46 signal intensity was quantified and normalized to load. 
 
In summary, our in vitro kinase experiments revealed that intact mTOR complex 1 can be inhibited 
not only by FKBP12, but also by FKBP51 and FKBP52 in a rapamycin-dependent manner. Thereby, 
the FK1 domain of the large FKBPs is sufficient. As this effect is equal for all three FKBPs, and as it 
is highly rapamycin-dependent, it could be assumed that the underlying mechanism is the same in all 
cases. 
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4.4 – In yeast, FK1 FKBP51 can substitute FKBP12 in terms of mTOR inhibition: 
 
4.4.1 – FK1 FKBP51 mimics effects of FKBP12 expression in FKBP-deficient yeast cells: 
 
In order to create a eukaryotic model system for FKBP action on mTOR, we used the yeast 
strain Y12941. This strain lacks the FKBP12 homologue Fpr1, the only cytoplasmatic yeast 
FKBP. Therefore, this strain is insensitive to the anti-proliferative effect of rapamycin. In our 
experiment, we overexpressed human FKBP proteins in the yeast cells and determined their 
ability to compensate for the missing endogenous FKBP. It is well known that human and 
fungal FKBP12 rescue the system and thus restore the growth-inhibitory action of rapamycin 
[280, 281]. This finding served as a positive control to judge the effect of other FKBPs, but 
especially possible effects of FKBP51 and FKBP52. Galactose-induced FKBP expression was 
controlled by Western blotting of lysed yeast cells (see appendix section 6.9). 
In figure 4.4.1, representative images of yeast cultures growing on SD agar plates are shown. 
The upper panel (A) displays yeast growth on SD medium without galactose which does not 
induce expression of human FKBPs. Since the deletion strain lacks endogenous FKBP, no 
binding partner was present that could mediate rapamycin action. Thus, no significant 
differences could be detected between the cultures growing on rapamycin-free plates or on 
rapamycin-containing plates.  
The lower panel of images (figure 4.4.1B) represents yeast cultures that have been 
supplemented with galactose (“SG medium”) and therefore expressed human FKBPs. In 
absence of rapamycin, no effect on yeast growth could be detected, just as expected. If the 
cells were grown on agar containing rapamycin, a clear reduction of growth could be 
observed for the cells expressing human FKBP12. This well-known effect could be 
reproduced successfully. 
Interestingly, a similar effect is also present for FK1 FKBP51: the yeast cells that expressed 
the FK1 domain of human FKBP51 showed much slower growth on rapamycin-containing 
plates than control cells. This growth reduction was as strong as the one observed for 
FKBP12, and it was clearly rapamycin-dependent. Thus, FK1 FKBP51 can exert the same 
function as FKBP12 in this yeast complementation system. Altogether, growth effects could 
be observed for FKBP12 and FK1 FKBP51. These findings are presented and directly 
compared in figure 4.4.2, indicating that they are similarly effective.  
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Figure 4.4.1: Human FKBPs have different effects on rapamycin-sensitivity of yeast cells 
Yeast cells (FKBP deletion strain Y12941, short Δ) were transformed with the indicated expression vector (or 
empty vector as a control) and grown for 3 days at 30°C on glucose-containing  SD medium or on galactose-
containing SD medium (SG) to induce expression of FKBPs. 5 µM rapamycin were present on the plates marked 
by a star *. Each 2 individual clones are shown. 
  
(A) Growth on SD medium (does not contain galactose; no induction of gene expression) 
(B) Growth on SG medium (contains galactose: induction of FKBP expression) 
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Figure 4.4.2: Yeast clones expressing human FK1 FKBP51 lose their rapamycin-resistance 
Yeast cells (FKBP deletion strain Δ) were grown for 3 days at 30°C on galactose-containing SD medium. This 
medium induces expression of the respective FKBP gene on the transformed expression vector. Left panel shows 
yeast growth in absence of rapamycin, right panel shows growth in presence of 5 µM rapamycin (marked by a 
star *). 
(A) Deletion mutants (2 individual clones) 
(B) Deletion mutant with inducible FKBP12 expression  
(C) Deletion mutant with inducible FK1 FKBP51 expression 
 
 
For more intensive analysis, growth of the clones was also recorded as a function of time in 
order to obtain growth curves (see figure 4.4.3). This representation demonstrates more 
clearly that rapamycin resistance of the deletion mutant (red curves) can be abolished by 
overexpression of human FKBP12. As soon as the clone grew on rapamycin- and galactose-
containing medium (SG) its growth was significantly reduced. In absence of rapamycin the 
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overexpression of the human protein caused only mild growth interference; this might be 
explained by mechanisms that directly influence the yeast cells’ metabolism.  
For FKBP12 and the FK1 domain of FKBP51 virtually identical growth curves were 
obtained. Thus, the FK1 domain of FKBP51 is able to function as a cellular receptor for 
rapamycin and induces cell cycle and growth arrest by inhibition of TOR complex in yeast. 
The expression of full-length FKBP51 in yeast deletion mutants leads to delayed growth; this 
effect is independent of rapamycin. Unfortunately it cannot be estimated whether the protein 
itself is toxic in yeast cells or whether it is a specific effect, mediated by mTOR. 
 
time (h)
0 10 20 30 40 50 60 70
O
D
60
0
0,0
0,1
0,2
0,3
0,4
0,5
SD
SD + rapamycin
SG
SG + rapamycin
time (h)
0 10 20 30 40 50
O
D
60
0
0,0
0,1
0,2
0,3
0,4
0,5
0,6
SD
SD + rapamycin
SG
SG + rapamycin
                                                                               
         Deletion mutant  Δ                                             Δ + FKBP12 
time (h)
0 10 20 30 40 50
O
D
60
0
0,0
0,1
0,2
0,3
0,4
0,5
SD
SD + rapamycin
SG
SG + rapamycin
time (h)
0 10 20 30 40 50 60
O
D
60
0
0,0
0,1
0,2
0,3
0,4
0,5
0,6
SD
SD + rapamycin
SG
SG + rapamycin
 
         Δ + FK1 FKBP51                                              Δ + FKBP51 
                                                                                                                                                           
 
Figure 4.4.3: Yeast growth curves corroborate effect of FKBP12 and FK1 FKBP51  
In glucose (SD) or galactose containing medium (SG), the indicated yeast clones were grown at 30°C in the 
presence or the absence of rapamycin (5 µM final concentration). OD600 was measured every 180 minutes and 
plotted against time. 
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In contrast to the FK1 domain of FKBP51, the highly homologous FK1 FKBP52 did not 
cause the same effects: when the protein was expressed in presence of rapamycin, no 
substantial change in growth rates compared to control conditions could be observed (see 
figure 4.4.4). 
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Figure 4.4.4: Not all FKBPs are able to complete the deletion system 
The indicated yeast cultures were incbuated in glucose- or galactose-containing selective medium (with or 
without rapamycin) at 30°C. Optical density (OD600) was measured every 180 minutes and was blotted as a 
function of time to generate growth curves. 
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The influence of human FKBP13 on deletion mutants is similar to the one of full-length 
FKBP51: cell growth slows down significantly when yeast express the protein. The presence 
of rapamycin does not have an additional effect. Thus, it could be assumed that FKBP13 acts 
as a cytotoxin that possibly masks any additional rapamycin-dependent effects. This result 
was obtained for full-length FKBP13 as well as for the truncated variant (lacking the N-
terminal signal peptide; data not shown). Similarly, the overexpression of human FKBP25 
had no effect on growth of the deletion mutants. Only a slight growth delay could be detected, 
but it cannot be considered as significant. 
Also, it should be noted that technical reasons could account for the absence of rapamycin-
induced effects in the experiments with FKBP52 or FKBP25. In particular, it is unclear 
whether these constructs were expressed functionally in sufficient amounts. For FKBP25, its 
nuclear location might explain the absence of any rapamycin-dependent effects.  
 
Altogether, the results of the yeast complementation experiments demonstrate clearly that 
FKBP51 can substitute FKBP12 as the protein mediating rapamycin action in vivo. It can also 
be stated that the FK1 domain of FKBP51 is as effective in inducing rapamycin-dependent 
growth arrest in yeast cells as FKBP12.  
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4.5 – Crystal structures of three ternary complexes are highly similar: 
 
4.5.1 – Ternary complexes can be purified and crystallized: 
 
As the in vitro binding and the in vivo complementation assays both indicate a potential 
involvement of FKBP51 and FKBP52 in rapamycin-mediated mTOR regulation, we decided 
to compare the structures of these “alternative” ternary complexes with the original one 
containing FKBP12. Thus, the ternary complexes FRB*rapamycin*FK1 FKBP51 and 
FKBP52 were reconstituted in vitro using recombinantly expressed proteins and purified by 
gel filtration. 
The UV elution profile of a column volume of 130 ml is shown in figure 4.5.1A: the main 
peak at 63 ml (1) can clearly be assigned to the ternary complex while the small shoulder at 
its side (2) consists of unbound FK1 and FRB domains. The degree of separation seems to be 
insufficient to divide these 12 kDa components from the 22 kDa complex. At around 130 ml, 
free rapamycin is eluted (3). This molecule has a weight of around 1 kDa and is retained by 
the column very efficiently.   
 
 
        
 
 
Figure 4.5.1: The ternary complexes were reconstituted and purified successfully  
(A) Elution diagram represents a plot of the volume against the respective mAU absorption, recorded by the 
Äkta HPLC system. Important peaks are: 
(1) Ternary complex FRB*rapamycin* FK1 FKBP51     (2)  Unbound FK1 FKBP51 and FRB                                 
(3) Unbound rapamycin 
(B) Coomassie stained SDS gel; 100 pmol protein per lane were separated by gel electrophoresis: 
       (1)  FRB                         (2)  FK1 FKBP51                       (3)  FK1 FKBP52   
       (4)  complex FRB*rapamycin* FK1 FKBP51                  (5) complex FRB*rapamycin* FK1 FKBP52  
       (6)  Protein size ladder  
1     2     3      4      5    St 
1 
2 3 
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Integrity of both the single protein components and the ternary complexes was checked by 
SDS gel electrophoresis. The gel picture (see figure 4.5.1B) clearly shows two explicit bands 
in lanes 4 and 5 which correspond to the single ones in the lanes 1 and 2/3. This proves that 
the ternary complexes indeed form spontaneously after addition of rapamycin and that they 
are stable even during the process of purification. 
Furthermore, the protein contaminations that can be seen in the lanes 2 and 3 disappear after 
gel filtration and cannot be detected in the final complexes. Thus, purity of the protein 
preparation, a major requirement for successful crystallization, is confirmed.  
 
The structure of the complex FRB*rapamycin*FKBP12 has been solved at high resolution 
(2.2 Å; [111]). Unfortunately, the buffer conditions and the used precipitant can vary 
extremely even between highly homologous proteins. Thus, the following standard screens 
were performed using robotics at the department of structural cell biology (E. Conti, MPI of 
Biochemistry, Martinsried) in order to determine appropriate conditions for crystallization: 
 
                      Protein Complex Suite 
                      Protein Complex Suite 2  
                      Index Screen 
 
During this procedure, two conditions appeared especially suitable to promote crystal growth. 
These conditions were selected for further optimization:  
 
FRB*rapamycin*FK1 FKBP51:  40% PPG-400; 0.1 M BisTris, pH 6.5; 
                            20% PEG-3350; 0.1 M NaCl; 0.1 M Hepes-NaOH, pH 7.5 
FRB*rapamycin*FK1 FKBP52:  1.9 M Ammonium sulfate; 0,1 M BisTris, pH 6.5; 
                           18% PEG-4000; 0.1 M BisTris, pH 6.5 
 
Ammonium sulfate and PEG/PPG concentrations were varied systematically until growth of 
large and well shaped crystals was successful. In figure 4.5.2A, images of the crystals are 
presented. They grew under the following final buffer conditions: 
 
   FRB*rapamycin*FK1 FKBP51:  25% PEG-3350; 0.1 M NaCl; 0.1 M Hepes-NaOH, pH 7.5 
   FRB*rapamycin*FK1 FKBP52: 1.95 M NH4SO4; 0.1 M BisTris, pH 6.5 
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Each one of the crystals was used for data collection at the synchrotron in Grenoble at 
beamline ID29, yielding well-resolved diffraction patterns which could be used to solve the 
crystal structures (see figure 4.5.2B). 
 
 
                          
                          A262 B4                                                                   A263 B4 
        FRB*rapamycin*FK1 FKBP51                              FRB*rapamycin*FK1 FKBP52 
 
 
 
 
   
 
 
Figure 4.5.2: Protein crystals and X-ray diffraction pattern  
 
(A) Microscopic image of the protein crystals used for x-ray crystallography 
(B) Representative diffraction pattern recorded after X-ray exposure 
A 
 
B 
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4.5.2 – Crystals can be used for X-ray structure determination: 
 
After computer-assisted analysis of the diffraction patterns, all key parameters of the final 
datasets were collected and are listed in table 4.5.1. 
 
Parameter 
 
FRB*rap*FK1 FKBP51 
Crystal A262 B4 
FRB*rap*FK1 FKBP52 
Crystal A263 B4 
Maximum resolution (Å) 1.45 1.8 
Wavelength 0,9788 0,9788 
Space group P212121 P212121 
Completeness 95.16% 98.6% 
Cell dimensions (Å) 59.50  59.55  67.79 58.52  62.99  70.14 
α, ß, gamma 90°, 90°, 90° 90°, 90°, 90° 
Wilson B factor (Å 2) 21.767 32.313 
Solvent content 44.6% 51.83% 
Refinement (REFMAC) 
Resolution range (Å) 19.05 – 1.45 19.76 – 1.8 
Reflections (test set) 39213 23105 
Number of atoms 1995 1841 
Rfree 0.24054 0.24834 
R 0.21173 0.22404 
r.m.s.d. bonds (Å) 0.022 0.022 
r.m.s.d. angles 2.001° 2.000° 
Ramachandran Plot (determined by Procheck) 
Additionally allowed 5% 2.9% 
Most favored region 94% 94.7% 
 
Table 4.5.1: Crystal structures of the ternary complexes could be solved with resolutions of 1.45 and 1.8 Å  
Characteristics of two crystals used for x-ray structure determination and results of computational analysis  
 
There are two structures of the ternary complex of FRB*rapamycin*FKBP12 that have been 
solved at resolutions of 2.7 Å by Choi [23] and of 2.2 Å by Liang [111], using the rapamycin-
derivative (C16)-ethoxy-rapamycin. Our datasets of the ternary complexes with FK1 51 and 
FK1 52 are substantially better and display resolutions of below 1.45 and 1.8 Å, respectively. 
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4.5.3 – Overall architecture of the ternary complexes is similar to the one of FKBP12: 
 
4.5.3.1 – Structure of FKBPs does not differ significantly: 
 
Generally, the overall structural arrangements in the ternary complexes FRB*rapamycin*FK1 
FKBP51/52 are very similar to the complex containing FKBP12 (see figure 4.5.3): the ligand 
rapamycin can be found in the center of the complexes where it interacts via two defined 
areas with the FK1 domain on the one side, and with FRB on the other side. The FK1 
domains of FKBP51 and FKBP52 are highly homologous to FKBP12 and display mainly ß-
sheets as secondary structure element. Between one ß-sheet and a short -helix, a 
hydrophobic pocket is located which represents the PPIase active site and the actual binding 
pocket of rapamycin. 
 
 
Figure 4.5.3: The three ternary complexes do not differ much and can be overlaid almost perfectly 
Ribbon representation of the ternary complexes of FRB*rapamycin*FKBP12, FRB*rapamycin*FK1 FKBP51 
and FRB*rapamycin*FK1 FKBP52. The FKBP parts of all three structures are overlaid, while one representative 
FRB (from 52 structure; α-helices 1-4 are indicated) and the central rapamycin (from the 51 complex) are shown. 
Color scheme:   Green: FRB; Red: FKBP12;  
Blue: FK1 FKBP51; Yellow: FK1 FKBP52;  
Dark Blue: Rapamycin 
α3 
α2 
α4 
α1 
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The FK1 domain of FKBP51 consists of 5 antiparallel ß-strands that are interconnected by 
loop regions (see figure 4.5.4). A large loop can be found between ß2 and ß3 (80S loop). ß5 is 
interrupted by a small loop (40S) and ends as the 50S loop region which is followed by a 
short -helical structure. The binding pocket for rapamycin is located between ß5 and the    
-helix; residues in the 40S, 50S and 80S loop contribute mainly to the interactions with 
rapamycin. It has been shown for both FKBP12 and FKBP51 that the loop regions are highly 
ordered only in complex with rapamycin, while they display much more flexibility in absence 
of the ligand [282].  
 
 
Figure 4.5.4: Overall structure of FK1 FKBP51 shows characteristic elements of all FKBPs 
Cartoon representation of FK1 FKBP51; ß-sheet structures and -helices are labeled (ß1 – ß5; 1); the ligand 
rapamycin is represented as a stick model (light blue). 
 
 
80S loop 
40S loop 
50S loop ß1 ß2 
ß4 
ß3 
ß5 
1 
rapamycin 
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When the three FKBP domains are overlaid, only minor structural deviations can be observed 
(see figure 4.5.3). These differences mainly concern the loop regions where larger 
discrepancies between the proteins can be detected. In contrast, the regions around the 
rapamycin-binding pocket show highly conserved structures which can be generally expected 
from these largely homologous proteins. Functional differentiation between the FKBPs is 
rather achieved by addition of independent domains. 
 
 
4.5.3.2 – The FRB domain is structurally unchanged in all complexes: 
 
The FK506-rapamycin-binding (FRB) domain of mTOR represents only around 3% of the 
total multi-domain protein (10 kDa vs. 290 kDa) and appears to be the mTOR domain that can 
be crystallized easily. Structurally, FRB consists of a compact bundle of four α-helices which 
are linked by short streaks of loops (α1-4, see figure 4.5.3, left part). At the regions that 
interact with rapamycin it forms a hydrophobic pocket, consisting of mainly aromatic 
residues. Here, the triene arm of rapamycin interacts with FRB (see figure 4.5.5A/C), and this 
happens exclusively via hydrophobic contacts. In detail, the residues S2035, F2039, Y2105, 
W2101 and F2108 can be found within a van-der-waals distance of 4 Å to rapamycin (see 
figure 4.5.5B). These amino acids form a total of 14 contacts to the triene arm C atoms   
(C17-24) of the ligand.  The methyl group at C23 of rapamycin is responsible for another 8 
contacts because it is located deep within the hollow space between the FRB residues 
Leu2031 and Phe2108 (see figure 4.5.5A/C). No direct H-bonds play a role in stabilizing the 
interaction between the natural compound and the FRB domain.  
The rapamycin binding pockets of FRB are very similar in the ternary complexes of FKBP12 
(in 2fap), FK1 FKBP51 and FKBP52. Only minor differences can be detected. For example, 
the location of the phenyl moiety of Y2105 seems to be variable: while it is closest to the 
rapamycin triene arm in the FKBP52 structure, it is significantly shifted out of the pocket in 
the FKBP51 ternary complex. For FRB*rapamycin*FKBP12, the residue is located in-
between (see appendix section 6.6.4). This structural deviation results in the loss of 
hydrophobic contacts to the ligand: while the FKBP52 structure displays a total amount of 11 
contacts between Y2105 and rapamycin, the number is reduced to 10 in 2fap, and goes down 
to 6 in the FKBP51 structure. Similarly, the residue R2036 interacts with C50 of rapamycin in 
the FKBP12 structure (2 contacts), while it is located beyond the 4 Å threshold in the 
FKBP52 ternary complex. For the FKBP51 structure, only one contact can be counted. 
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Figure 4.5.5: Interactions of rapamycin and the FRB domain are mainly hydrophobic 
(A) Surface representation of the mTOR FRB domain (grey; from complex FRB*rapamycin*FK1 FKBP52) 
with rapamycin binding pocket (green) and rapamycin (dark blue). 
(B) Binding pocket of FRB with aromatic amino acids as stick models. Rapamycin has been omitted. 
(C) Graphical representation of the FRB residues interacting with rapamycin (carbon atoms involved in 
hydrophobic interactions are marked with a green circle). 
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4.5.3.3 – Rapamycin is bound to the FKBP binding sites in a similar manner: 
 
Generally, the rapamycin binding site of all FKBPs is highly conserved: from the 13 residues 
involved in ligand binding, 10 are identical in the ternary complexes of FKBP12, FK1 
FKBP51 and FK1 FKBP52. Between the latter two, only one residue, Q85 in 52 and E85 in 
51, differs slightly. FKBP12 displays two additional mutations, namely Q53 (corresponding 
to G84 in 51/52) and I90 (K121 in 51/52) (see table 4.5.2). Thus, substantial differences in 
binding of rapamycin to the active site of the three FKBPs cannot be expected. 
Just like in FKBP12, rapamycin interacts with FKBP51 and FKBP52 in a hydrophobic pocket 
that lies between an α-helix and a ß-sheet element. This binding site consists mainly of 
residues which can be found within three loop regions, namely the 40S, 50S and 80S loop. 
Only 5 or 6 direct H-bonds can be detected between the small molecule and the protein 
partner (involving D37, Q53, E54, I56, Y82 in FKBP12; D68, G84, Q85, I87, R73, Y113 in 
FK1 FKBP51; D68, G84, Q85, I87, Y113, K121 in FK1 FKBP52). Just like at the FRB-
rapamycin interface, aromatic residues contribute mainly to the interactions between the 
pipecolyl ring of rapamycin and the FKBP protein. This heterocycle is the compound’s 
moiety that reaches deepest into the binding pocket whose back wall consists of 4 aromatic 
residues (see figure 4.5.6). Again, stabilization of the binding is largely mediated by 
hydrophobic interactions. Altogether, 29 contacts (defined by proximity of less than 4 Å) are 
present between the FKBP-interacting portion of rapamycin and the residues Y57, F77, W90 
and F130 in FK1 FKBP51, even 33 in FK1 FKBP52 (see appendix section 6.6.1 for a detailed 
register).  
 
 
 
Structure Number 
of 
residues 
Unique residues Contacts by 
unique 
residue 
H-
bonds 
Non-conserved 
Residues 
FKBP12 
(2fap) 
13 I90 1 5 Q53 (G84 in 51,52) 
I90 (K121 in 51, 52) 
FK1 FKBP51 13 R73 9 6 Q85 (E85 in 51, E54 
in 12) 
FK1 FKBP52 13 K121 7 6 - 
 
Table 4.5.2: Overview of differences in rapamycin binding pocket of three ternary complexes 
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Figure 4.5.6:  The rapamycin binding pockets of FKBP12, FKBP51 and FKBP52 are very similar     
Surface representation of the rapamycin binding pockets of FKBP12 (from 2fap) (A), FK1 FKBP51 (B) and FK1 
FKBP52 (C). Surface representation is laid over a stick model of the residues.  
Dark blue: Rapamycin.    Red: FKBP12.    Blue: FK1 FKBP51.    Yellow: FK1 FKBP52. 
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In FKBP51 and FKBP52, the residues G84, E/Q85, V86 and I87 form a hinge region which is 
involved in accommodation of the cyclohexyl moiety and the ester linkage of rapamycin. At 
the opposite site of the small molecule, Y57, F67, D68 and R73 contribute to binding of the 
pyranose moiety. 
While 12 of 13 amino acids involved in rapamycin binding are totally conserved in the 
structures of FKBP51 and FKBP52, one lysine residues (K121) displays a clear exception: the 
FKBP52 species is engaged in interactions with rapamycin, whereas the FKBP51 counterpart 
is oriented away from the binding pocket. Like this, K121 of FKBP51 is unable to form 
contacts to the ligand. Compared to FKBP52, a total of 7 contacts (including 1 H-bond) are 
lost. The corresponding residue I90 is unique in FKBP12; it contributes only 1 contact to 
C10-14 of rapamycin (see figure 4.5.7).   
  
                
  
Figure 4.5.7:  The rapamycin binding pockets of FKBP12, FKBP51 and FKBP52 differ in some details  
Surface representation of the rapamycin binding pocket of FKBP51; residues that differ between FKBP12, 
FKBP51 and FKBP52 are shown. K121 of FKBP51 does not interact with rapamycin. The complementary 
residue I90 in FKBP12 is involved in such an interaction.  
Dark blue: Rapamycin.   Red: FKBP12.    Blue: FK1 FKBP51.    Yellow: FKBP52 FK1. 
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Interestingly, one arginine residue plays different roles in FKBP12, 51 and 52: an additional 
H-bond is present between arginine R73 of FK1 FKBP51 (NH2) and rapamycin (O7 next to 
C13). Furthermore, this residue is located within the 40S loop region which is crucial for 
rapamycin binding. Whether this interaction exerts stabilizing effects or whether affinity is 
reduced without R73 might be determined by mutational analysis. The side chain of the 
corresponding arginine residue in FK1 FKBP52 is not well defined; thus, no specific 
interactions and especially no H-bond can be assigned. In FKBP12, the corresponding residue 
R42 does not interact with rapamycin; it rather forms an intramolecular H-bond via a water 
molecule to the backbone of K44 (see figure 4.5.7). 
 
 
     
 
Figure 4.5.7: An additional H-bond is present between R73 and rapamycin in FK1 FKBP51 
Ribbon representation of the 40S loop region of FK1 FKBP51 (A) and FKBP12 (B; taken from 2fap). The 
residues R73/R42/K44 are displayed as a stick model, with nitrogen atoms in blue and oxygen atoms in bright 
red. Dark blue, with oxygen atoms in red: Rapamycin; Green, with oxygen atoms in red: (C16)-ethoxy 
rapamycin. 
   
 
Altogether, rapamycin interacts with the binding pocket of FKBP51 via 99 contacts. For 
FKBP52, 101 contacts can be observed, for FKBP12 (analyzed in 2fap) there are only 85. 
Most of these interactions are hydrophobic, while only a total 5 or 6 consists of H-bonds. A 
table listing all contacts can be found in the appendix (see section 6.6.1). In conclusion, 
rapamycin binding to FKBPs is strongly conserved, but differs in some interesting details. 
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4.5.3.4 – Interactions between the protein domains involve different residues: 
  
Analysis of protein-protein contacts between the FKBP and the FRB domain within the 
ternary complex reveals that these contacts are quite rare: only the 40s and 80s loop regions of 
the FKBPs are involved in direct interactions with FRB. Thereby, the contacts mainly consist 
of hydrophobic interactions, while only few H-bonds are present. FK1 FKBP51 displays a 
sum of 48 contacts (4 H-bonds via R73, P76 and V78), while FK1 FKBP52 interacts with 
FRB only 21 times (1 H-bond via R52). FKBP12 ranges in-between with 27 total interactions 
(analyzed in 2fap; no H-bonds). A detailed list of all values can be found in the appendix   
(see section 6.6.2). 
The differences regarding the number of interactions are also reflected by their distribution 
between the 40s and 80s loop regions (see figure 4.5.8). For FKBP12, only 3 contacts are 
located within the 40s loop. For FKBP51, 42 of 48 total interactions can be found in the 40s 
loop, while in FK1 FKBP52 there are only 5. Thus, FKBP12 interacts preferentially with the 
80s loop, while FK1 FKBP51 makes much more contacts with its 40s loop. FK1 FKBP52 
must be placed in-between (see table 4.5.3).  
Strikingly, FK1 of FKBP51 displays the highest number of contacts to the FRB domain. 
Furthermore, there are two H-bonds which theoretically contribute up to 5-fold more binding 
enthalpy than typical van-der-waals interactions [283]. Thus, a hypothetical rapamycin-
independent binding to FRB might be more probable for FKBP51 than for FKBP12 or 
FKBP52. Nevertheless, these few contacts might rather play a role in supporting rapamycin-
mediated interaction; they are presumably much too weak to allow rapamycin-independent 
binding of FKBPs to FRB. 
 
Structure Total 
contacts 
40S loop 
contacts 
Percentage 40S loop 
contacts 
H-bonds  
FKBP12 (2fap) 27 3 11.1% 0 
FK1 FKBP51 48 42 87.5% 4 
FK1 FKBP52 21 13 61.9% 1 
 
Table 4.5.3: Direct protein-protein contacts differ in localization and number 
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Figure 4.5.8: Direct protein-protein interactions between FK1 domains and FRB differ substantially 
Representation of protein-protein interfaces of FRB (green; left side, ribbon) and FKBP (right side, ribbon). 
Ternary complexes of   (A) FKBP12 (2fap), red    (B) FK1 FKBP51, blue   (C) FK1 FKBP52, yellow. 
H-bonds are shown as black lines, van-der-Waals contacts are shown as grey dashed lines.
A 
 
 
B 
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Analysis of the residues involved in direct protein-protein contacts revealed striking 
differences between the three ternary complexes: importantly, the only residue which is 
totally conserved is F46 of FKBP12 (corresponding to F77 in FKBP51/52); it interacts with 
Y2105 (R2109 in FKBP52). 7 residues of FK1 FKBP51 are involved in contacts to 6 residues 
in FRB, while there are only 6 in FKBP52 (to 4 in FRB) and 10 in FKBP12 (to 7 in FRB). 
Notably, only 2 of these residues are identical between FKBP51 and 52 (P120 and A116), the 
others differ. Furthermore, the positions 76 and 78 are conserved in 51 and 52. In FKBP12, 
T85 corresponds to A116, G89 to P120, K44 to E75 and K47 to V/S78 in terms of sequence 
position. As an exclusive item of FKBP51, R73 interacts intensively with D2102, displaying 7 
contacts to the FRB residue. Importantly, interactions of the FKBP12 residues H87 and I90 
with FRB comprise 12 contacts which represent 44% of the total number of interactions. No 
comparable contacts can be found in the ternary complexes of FKBP51 and FKBP52         
(see table 4.5.4). 
Altogether, the protein-protein interface between FRB and the FKBPs can be considered as 
much more variant than the rapamycin-binding pockets because the interactions at the 
interface are maintained by different FKBP residues.  
 
Residue in FRB 
with contact to… 
…FKBP12 
residue (2fap) 
…FK1 FKBP51 
residue 
…FK1 FKBP52 
residue 
V2094 I90, G89, P88 P120 P120 
R2042 H87, P88, G86, T85 A116 A116 
R2109 K44 E75, P76, V78 K76, F77, S78 
Y2105 F46, K47 F77, V78 R52, S78 
H2109 - E75 - 
F2039 H87 - - 
Y2038 H87 - - 
T2098 I90 - - 
D2102 - R73 - 
 
Table 4.5.4: Overview of residues involved in protein-protein contacts between FRB and FKBPs in the 
respective ternary complexes 
Contacts are defined as hydrophobic contacts or H-bonds between atoms that can be found within a proximity of 
4 Å or less. 
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4.5.3.5 – Water molecules form an H-bond network across the protein-protein interface: 
 
In all three ternary complexes, the interface between the two protein partners comprises 
mainly the 40S- and 80S-loop regions of FKBPs and the helices α4/1of FRB. At the centre of 
the interface, the ligand rapamycin can be found. Furthermore, plenty of well-defined water 
molecules are present in this area, bridging FRB residues with FKBPs residues via networks 
of H-bonds. The total number of water molecules in the interface differs little between the 
ternary complex of FKBP12 (2fap; ~30 waters) and the one of FK1 FKBP52 (~34 waters), 
whereas there are clearly more water molecules visible in the structure of FK1 FKBP51     
(~47 waters).  
Water molecules which function as direct mediators between the two protein domains are 
relatively rare: there are 2 in the FKBP12 complex, 2 in FKBP51 and 3 in FKBP52 (see figure 
4.6.9, circles and appendix section 6.6.3). Interestingly, the FRB residues Y2105 and Y2038 
act as H-bond acceptors in the complexes of FKBP12 and FKBP52, while F2039 is a shared 
feature of both FKBP51 and FKBP52 complexes. On the FKBP side, Ser118 mediates         
H-bonds in both FKBP51 and FKBP52, while E54 of FKBP12 corresponds to E85 in 
FKBP52. Thus, a certain degree of conservation between the residues involved in water-
mediated H-bond formation can be observed.  
Due to the high number of water molecules, the H-bond network between FK1 FKBP51 and 
FRB displays a high density: via one or several water molecules, residues in FKBP51 interact 
indirectly with residues in FRB. Most of the waters are involved in H-bond formation, either 
to neighboring waters or to amino acids; only few water molecules are isolated within the 
interface area (see figure 4.6.9B). 
In contrast, the H-bond networks of the ternary complexes of FKBP12 and FKBP52 are much 
less defined. This could be explained by the smaller number of ordered water molecules in the 
interface. Furthermore, many of the water molecules stabilize intra-molecular contacts in FRB 
or the FKBP domains (see figure 4.6.9A/C). It also should be mentioned that the lower 
resolution of the structure 2fap might limit the number of detectable water molecules.  
Importantly, one conserved water molecule mediates H-bond formation between the ligand 
rapamycin and the residue E2032 in FRB (H2O 331 (in 2fap) [111], H2O 71 (in 51 complex), 
H2O 42 (in 52 complex; see figure 4.6.9D)). Since all the other contacts between the two 
binding partners are purely hydrophobic, it could be speculated that such an H-bond 
constitutes an important parameter for increasing affinity.   
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Figure 4.6.9: Water molecules bridge FRB and FKBP protein partners in the ternary complexes 
Surface representation of the ternary complex FRB*rapamycin*FKBP12 (A; from 2fap)), FRB*rapamycin*FK1 FKBP51 (B) 
and FRB*rapamycin*FK1 FKBP52 (C) with water molecules in the interface region of the protein partners. Waters which 
directly mediate interaction between FRB and FKBP are marked (O). 
(D) H-bonds between E2032 in FRB and O8 of rapamycin, mediated by the conserved H2O 71 (in FRB*rapamycin*FK1 
FKBP51). 
Green: FRB (in (D): oxygen atoms of E2032 in red); blue: FK1 FKBP51; red: FKBP12; red dots: water molecules; grey 
dashes: H-bonds; blue sticks: rapamycin (in (D): oxygen atoms in red). 
A 
C 
B 
D 
E2032 
H2O 71 
Rap, O8 
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As water-mediated H-bonds between the two protein parts of the ternary complexes are quite 
frequent and as such interactions are known to have an effect on binding energetics [284], it is 
probable that they contribute to stabilization of the central rapamycin-mediated binding of 
FRB and FKBP. Similarly to the direct protein-protein contacts, the residues involved in these 
water-mediated interactions are rather variable.  
 
Altogether, analysis of the crystal structures of the alternative ternary complexes of FK1 
FKBP51 and FKBP52 reveal that they bind to FRB in a strictly rapamycin-dependent manner, 
and that the complexes are very similar to the one of FKBP12. These findings appear 
reasonable considering the high degree of homology of the three FKBPs’ FK1 domains. 
Nevertheless, some details can be found in the binding patterns which are not conserved 
between the structures: an additional H-bond stabilizes rapamycin binding in FKBP51, and 
protein-protein contacts between FRB and FKBP are especially pronounced in FKBP51 
compared to FKBP12 and FKBP52. Altogether, it seems that these variations do not have a 
significant impact on the overall affinity of rapamycin to the FKBP partner; such a differential 
binding would have been detected in in vitro binding assays. But as binding affinities and 
EC50 values of complex formation were relatively similar in the previous experiments for all 
three FKBPs, speculations about mechanistic differences in rapamycin binding or complex 
formation would be highly risky. 
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4.6 – FKBP51 interacts with mTORC1 and affects mTOR kinase activity: 
 
4.6.1 – FKBP12 and FKBP51 interact with mTOR in a rapamycin-dependent way: 
 
As all tested FKBPs bind to the FRB domain of mTOR under in vitro conditions, we were 
interested in detecting rapamycin-induced interactions in living cells. For this purpose we 
transfected HEK293 cells with a FLAG-mTOR or FLAG-mTORS2035T expression plasmid, 
treated them with rapamycin before lysis and subjected the lysates to immunoprecipitation 
using protein A affinity resin and an -mTOR antibody. Endogenous proteins co-
immunoprecipitating with FLAG-mTOR were characterized by immunoblotting. This 
procedure has been described in detail by others [139, 140]. Since FK506 competes for 
binding to the active sites of FKBP proteins with rapamycin [20], and since FK506*FKBP12 
complex does not bind to mTOR-FRB [20, 285], co-immunoprecipitation experiments were 
performed either in presence of rapamycin, FK506 or DMSO. 
 
 
                                   IP: -mTOR 
pcDNA3-FLAG       mTOR        S2035T 
  
compound          Rap      FK     veh.    Rap 
-mTOR 
 
-Raptor 
 
-FKBP12 
 
-FKBP51 
 
-FKBP52 
 
 
  
                     Load           IP: -FLAG 
pcDNA3-FLAG                    mTOR 
compound                      Rap      FK    veh. 
-mTOR      
-FKBP12    
-FKBP51    
 
Figure 4.6.1: mTOR interacts with FKBP12 and FKBP51 in a rapamycin-dependent manner   
(A) HEK293 and (B) HeLa cells were transfected with a FLAG-mTOR expression plasmid. 30 minutes prior to 
lysis, rapamycin, FK506 (final concentration: each 25 nM) or vehicle DMSO were added. The cell lysates were 
subjected to immunoprecipitation. The resin was washed and eluted by boiling for 5 minutes in SDS sample 
buffer. The eluates were separated by SDS-PAGE and analyzed by immunoblotting. 
 
It turned out that FLAG-mTOR/mTORS2035T immunoprecipitation yields were similar in all 
samples (see figure 4.6.1A). The rapamycin-mediated interaction of FKBP12 with mTOR was 
used as positive control. As already known, FKBP12 only binds to the FRB domain of mTOR 
B A 
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if rapamycin is present. Without rapamycin or in the presence of FK506, no interaction could 
be expected. We replicated this control experiment in the co-IP assays. Furthermore, FKBP51 
was clearly co-precipitated in the presence of rapamycin, while FK506 could not induce such 
a binding. This finding points to a rapamycin-induced interaction between mTOR and 
FKBP51. DMSO-treated HEK293 cells served as control and displayed merely weak binding.  
Similar results were obtained for FKBP52: rapamycin mediated an interaction with mTOR 
while it was totally absent in presence of FK506. The intensity of the co-IP signals was 
generally lower than for FKBP51. In the DMSO-treated controls there were no signals at all. 
As a negative control, we immunoprecipitated the mTOR mutant S2035T which is defective 
in rapamycin binding [21]. No rapamycin-dependent binding of FKBPs could be detected 
here. 
Oshiro and Yoshino demonstrated that by rapamycin treatment the interaction between mTOR 
and Raptor is impaired: in co-IP experiments less Raptor could be detected in presence of 
rapamycin concentrations higher than 100 nM [131]. This result could be confirmed only 
partially; the used rapamycin doses in our experiments might be too low (25 nM). 
 
Secondly, FLAG-mTOR was immunoprecipitated in HeLa cells, and endogenous FKBPs 
were detected as binding partners (see figure 4.6.1B). Western blot analysis revealed that 
rapamycin induces binding of both FKBP12 and FKBP51 to mTOR. Without rapamycin or in 
the presence of FK506, almost no interaction could be observed for FKBP12. FKBP51 
displays a certain degree of binding even in absence of the compound. The nature of this 
interaction is largely unknown, because an interaction of the FK1 domain with FRB seems 
impossible without rapamycin. 
 
In order to further verify the mTOR-FKBP interaction, HA-FKBPs und FLAG-mTOR were 
co-expressed in human cell systems. Immunoprecipitation was performed with HA-beads, and 
immunoblotting for interaction partners was done (as described in [113]). The addition or 
omission of 50 nM rapamycin to the cells prior to lysis allowed determination of rapamycin-
dependency of binding.  
Figure 4.6.2 demonstrates that immunoprecipitation of FKBPs in HEK293 cells was 
successful and yielded comparable amounts of protein per lane. In this case, a co-precipitation 
of mTOR could only be detected for FKBP12 and FKBP51. The interaction of FKBP52 and 
mTOR displays an intensity only slightly above background level. As Hsp90 recruits FKBP51 
and FKBP52 by their TPR domains [36], the chaperone is enriched in IP samples of FKBP51 
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and (in parts) of FKBP52. While FKBP12 and mTOR seem to associate clearly in a 
rapamycin-dependent manner, this is not obvious for FKBP51: mTOR co-IP signals are 
comparable in the samples with and without rapamycin. Thus, rapamycin might not be 
necessary for this interaction, or the applied concentration was too low to allow proper 
binding. 
 
 
                                                      IP: -HA 
pcDNA3-                                   FLAG-mTOR 
pcDNA3-HA                  FKBP12      FKBP51      FKBP52    
Rapamycin [nM]            0     50      0      50     0     50          
-mTOR                 
-FKBPs                   
-Hsp90                   
 
-mTOR                           LOAD 
-Hsp90                            LOAD 
 
 
Figure 4.6.2: Immunoprecipitated FKBPs interact with mTOR 
HEK293 cells were co-transfected with FLAG-mTOR and HA-FKBP12/51/52 expression plasmids. 30 minutes 
prior to lysis, rapamycin was added (final concentration: 50 nM) where indicated. The cell lysates were 
incubated for 2 hours with anti-HA affinity resin. After intensive washing, the resin was boiled in  SDS sample 
buffer for 5 minutes.  The supernatants were separated by SDS-PAGE and analyzed by immunoblotting. 
 
 
 
Altogether, we were able to demonstrate in several independent co-immunoprecipitation 
experiments that both FKBP12 and FKBP51 interact with mTOR via its FRB domain. For 
FKBP12, this binding is largely rapamycin-dependent, while FKBP51 also displays an 
additional constitutive binding mode. Nevertheless, FK506 can be clearly excluded as a 
mediator of interactions between mTOR and FKBPs. As binding of FKBP52 turns out to be 
rather weak, we decided to focus on FKBP51 and compare its effects on mTOR with those of 
FKBP12. 
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4.6.2 – FKBP51 associates with Raptor in a rapamycin-dependent manner: 
 
As FKBP51 has been found to interact with mTOR in a rapamycin-dependent as well as in a 
direct manner, we were interested in further examining the nature of this binding. First, one 
can differentiate between the two distinct mTOR complexes mTORC1 and mTORC2 that 
differ in their protein composition: while mTORC1 includes Raptor as the crucial recruiter of 
mTOR substrates [129], mTORC2 carries the protein Rictor [140]. By assessing interactions 
of FKBP proteins with Raptor and Rictor, it thus can be determined in which complex the 
FKBP binding occurs. 
Co-immunoprecipitation experiments with FLAG-FKBPs and myc-Raptor were performed, 
and clear binding patterns could be detected (see figure 4.6.3): FKBP12 seems to interact with 
Raptor in a rapamycin-dependent manner. Compared to background signal caused by 
unspecific binding to the beads, this interaction appears rather weak. For FKBP51, a much 
stronger signal can be obtained. Again, binding seems to be increased by rapamycin. 
Altogether it could be concluded that FKBP12 and FKBP51 interact with Raptor, a 
component of the mTOR complex 1. This complex is known to be rapamycin-sensitive.  
 
 
                                      IP: -FLAG  
pRK5-                           myc-Raptor                      
pcDNA3-FLAG    FKBP12            FKBP51                           
Rap [nM]           0    20     0      20    0      20       
-myc            
-Hsp90         
-FLAG         
 
-myc                        LOAD 
-FLAG                     LOAD 
-FLAG                     LOAD 
 
 
Figure 4.6.3: FKBP12 and FKBP51 interact with the mTORC1 component Raptor 
HEK293 cells were transfected with myc-Raptor and FLAG-FKBPs, starved and stimulated with FCS in absence 
or presence of 20 nM rapamycin for 60 minutes. Cell lysates were subjected to FLAG-IP. Beads were washed 
four times with CHAPS-containing lysis buffer and eluted by boiling with SDS sample buffer for 5 minutes. 
Supernatants were analyzed by SDS-PAGE and immunoblotting. 
50 kDa 
10 kDa 
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4.6.3 – FKBP51 and FKBP52 interact with p70 S6Kinase: 
 
As FKBP51 seems to interact with components of mTORC1, we performed further IP 
experiments to characterize the binding partners more precisely. As one candidate protein,                 
p70 S6Kinase appears interesting because it is directly recruited into the complex by Raptor 
and phosphorylated by the kinase activity of mTOR [124]. 
When HA-S6Kinase and FLAG-FKBPs were co-expressed in HeLa cells, a robust interaction 
between FKBP51 and S6Kinase could be detected (see figure 4.6.4A). Similarly, FKBP52 
was bound to the kinase. These effects seem to be mostly rapamycin-independent for 
FKBP52, while rapamycin enhanced the interaction of S6Kinase and FKBP51. For FKBP12, 
no obvious interaction could be observed.   
In order to verify the results described above, we inverted the co-IP pattern by 
immunoprecipitating FLAG-FKBPs and detecting co-expressed S6Kinase. Thereby it turned 
out that HA-S6Kinase was detectable as an interaction partner for all tested FKBPs; 
nevertheless, clear differences in binding preference became obvious (see figure 4.6.4B): 
interaction of S6Kinase occurs mainly with FKBP51 while it is weakened for FKBP52 and 
even weaker for FKBP12. The Hsp90-binding defective TPR mutants of FKBP51 and 
FKBP52 did not display significantly different binding patterns. Thus, Hsp90 may not play a 
crucial role in modulating FKBP*S6Kinase interaction. 
Interestingly, binding of FKBP51 to S6Kinase could be increased by rapamycin treatment. 
This effect is present for both wild type and TPR mutant FKBP51, and it is considerably 
strong: densitometric quantification revealed that rapamycin treatment elevates signal 
intensity by 200%.  For FKBP52 proteins, the effect is less pronounced; for FKBP12, a signal 
indicating S6Kinase interaction is totally missing in absence of rapamycin. Treatment with 
the small molecule brings up a signal which is comparable to the one of untreated FKBP51.  
Altogether, it can be concluded from the above experiments that FKBP12, FKBP51 and 
FKBP52 interact with S6Kinase. While this interaction can be increased by short-term 
rapamycin treatment especially for FKBP51, it tends to be equally strong under all conditions 
for FKBP52. FKBP12 seems to display a weak obligatorily rapamycin-induced binding to 
S6Kinase. Hsp90 recruitment may not be crucial for formation of this complex. From 
experiments that maintain integrity of mTORC1, no conclusions can be drawn concerning the 
question whether S6Kinase interacts with FKBPs within the mTOR complex or in an 
independent way. 
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                                                   IP: -HA  
pRK7–                                           HA-S6Kinase 
pcDNA3-FLAG                    FKBP12     FKBP51    FKBP52   51/52          
Rapamycin [nM]              0       25      0      25       0      25      0            
Ponceau: S6Kinase               
-S6Kinase                           
-Hsp90                                
-FLAG                                 
 
-FLAG                                        LOAD 
-FLAG                                        LOAD 
 
 
                                                          IP: -FLAG 
 
pRK7-                                               HA-S6Kinase 
pcDNA3-FLAG                FKBP12   FKBP51   51TPR    FKBP52   52TPR            ctrl 
Rapamycin [nM]       0   100     0   100    0   100    0   100    0   100     0      0 
-S6K                     
-Hsp90                  
-FLAG                  
-FLAG                  
 
-S6K                                  LOAD 
-Hsp90                               LOAD 
-FLAG                               LOAD 
-FLAG                                LOAD 
 
 
Figure 4.6.4: Co-IP assays demonstrate interaction between p70 S6Kinase and FKBP51/52 
HeLa cells were co-transfected for expression of FLAG-FKBPs and HA-S6Kinase, treated with rapamycin for 
60 minutes (where indicated) and lysed. Lysates were subjected to FLAG/HA-IP. Binging partners were 
analyzed by Western blotting. Unspecific signals are marked (*). 
(A) HA-IP of  HA-S6Kinase   
(B) FLAG-IP of FLAG-FKBPs 
Control lane (ctrl): expression of FLAG-FKBP12/51/52 
 
A 
B 
* 
50 kDa 
10 kDa 
50 kDa 
10 kDa 
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4.6.4 – FKBPs influence interaction between S6Kinase and Raptor: 
 
In order to assess a possible role of FKBP51 and FKBP52 in mediating and modulating the 
interaction of S6Kinase and Raptor in a rapamycin-dependent manner, we performed 
modified co-immunoprecipitation experiments: while FLAG-FKBP proteins were 
overexpressed, HA-S6 Kinase was precipitated from HeLa cells, and binding of co-expressed 
myc-Raptor was analyzed by Western blotting. Thus, a system of three simultaneously 
expressed and orthogonally tagged proteins could be studied in terms of rapamycin-dependent 
interaction. 
Expression levels of all three putative interaction partners were verified, and unspecific 
binding to the HA-beads was checked (see figure 4.6.5). Overexpressed myc-Raptor binds to 
immunoprecipitated HA-S6Kinase. This binding was slightly increased in presence of 
overexpressed FKBP12 and FKBP52; only FKBP51 seemed to repress this interaction under 
basal conditions. For all three FKBPs, a rapamycin-induced binding of S6Kinase to Raptor 
could be observed, and co-IP signals of Raptor were increased compared to basal conditions 
(see quantification in figure 4.6.5B). Thus, S6Kinase seems to aggregate more efficiently with 
Raptor if FKBPs are overexpressed, and a rapamycin-dependency of this interaction is 
obvious. 
This binding pattern seems contradictory to the classical model of rapamycin action which 
suggests a competition between Raptor and FKBP*rapamycin for mTOR binding. The 
interactions seen in our co-IP experiments rather suggest that after rapamycin application an 
mTOR*Raptor*rapamycin*FKBP complex exists that allows simultaneous binding of the two 
competing proteins. It could further be speculated whether FKBP*rapamycin prevents Raptor 
from being excluded from the complex, possibly blocking substrate turnover. Such a model is 
discussed in section 5.1.3.  
 
Altogether, the above experiment indicates that FKBP51 and FKBP52 exert their influence on 
mTORC1 activity in a rapamycin-dependent manner similarly to FKBP12, namely by 
modulating interactions between mTOR/Raptor and its substrate S6Kinase. Assuming that 
overexpression of an individual FKBP renders it the dominant cellular FKBP species, our co-
IP data suggest that the effects of FKBP51 and FKBP52 might be more pronounced. 
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                                                   IP: -HA 
pRK7-                                      myc-Raptor 
pcDNA3-                               HA-S6Kinase 
pcDNA3-FLAG                   FKBP12 FKBP51 FKBP52          51/52 
Rapamycin [nM]    0    100   0   100   0   100   0   100    -      - 
-Raptor                
-FKBP52            
-FKBP51            
-S6K                   
-Raptor                    LOAD 
-FLAG                    LOAD 
-S6Kinase              LOAD 
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Figure 4.6.5: Rapamycin increases Raptor-S6Kinase interaction in presence of FKBPs 
HeLa cells were transfected for expression of myc-Raptor, HA-S6 Kinase and FLAG-FKBPs as indicated. Cells 
were starved, stimulated with serum/insulin and treated with rapamycin for 60 minutes. Lysates were subjected 
to HA-immunoprecipitation, and binding partners were analyzed by Western blotting. 
 
(A) Upper part: IP signals; lower part: Loads 
      Unspecific signals are marked (*) 
(B) Densitometric quantification of -Raptor IP signals (absolute signal intensities) 
 
A 
B 
* 
50 kDa 
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4.6.5 - FKBP51 overexpression affects S6Kinase phosphorylation: 
 
In order to shed a light on the effects of different FKBPs on S6Kinase phosphorylation, we 
overexpressed human FKBPs in HeLa cells. S6Kinase phosphorylation was induced by 
starvation and subsequent stimulation with serum and insulin in the absence or presence of  
0.25 nM rapamycin (as described in [119]). This rapamycin concentration is slightly below 
the concentration necessary for complete S6Kinase de-phosphorylation in mock-transfected 
cells. Phosphorylation status of differently treated samples was assessed by immunoblotting. 
 
 
 pcDNA3-FLAG                            mock        FKBP12       FKBP51 
                                   
Rapamycin [nM]                       0     0.25       0     0.25      0     0.25    
-S6Kinase phosphoT389             
-S6Kinase                               
-FLAG                                                                    
 
Figure 4.6.6: Overexpression of FKBP12 or FKBP51 has different effects on S6Kinase  
HeLa cells were transfected with FKBP12/51 overexpression vectors, starved for 16 hours and stimulated with 
serum and insulin for 60 minutes in presence of rapamycin (concentrations as indicated). Then, cells were lysed 
and subjected to SDS-PAGE and Western blotting. The membrane was probed against the indicated proteins or 
antigens with appropriate antibodies. 
  
Here, it turned out that FKBP expression indeed exerted effects on S6Kinase phosphorylation: 
when compared to mock-transfected cells, samples overexpressing FKBP12 displayed a slight 
rapamycin-dependent reduction in phospho-signal intensity (see figure 4.6.6). In cells 
transfected for FKBP51 overexpression, phosphorylation of the critical S6Kinase residue 
Thr389 was even lower at rapamycin concentrations of 0.25 nM, suggesting a more efficient 
mTOR kinase inhibition than observed for mock control or FKBP12 overexpression. As 
S6Kinase expression levels remain unaltered, it can be assumed that the protein‟s 
phosphorylation state is the actual effect. 
 
The above results suggest that FKBP12 and FKBP51 influence S6Kinase phosphorylation and 
thus might have an effect on mTORC1 activity in HeLa cells: when overexpressed, the FKBP 
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proteins seem to cause a more effective rapamycin-induced mTOR inhibition, maybe by 
modulating interactions between S6Kinase and Raptor or by directly acting on mTOR kinase 
activity. Altogether the effect of FKBP51 appears stronger than the one of FKBP12. This may 
support a hypothesis in which parts of rapamycin action are carried out by FKBP51. 
 
 
4.6.6 – FKBP12 knockdown does not abolish effects of rapamycin: 
 
As it is difficult to assess the effects of other FKBPs on mTOR in presence of FKBP12, we 
performed siRNA knockdown experiments to reduce cellular FKBP12 content. In such a 
system, one would generally expect that rapamycin sensitivity is reduced. 
Western blot analysis revealed that FKBP12 was knocked down efficiently: 90% less signal 
was detected for samples transfected with anti-FKBP12 siRNA. Mock-transfected cells with 
non-targeting siRNA did not show any altered FKBP12 expression levels. 
S6Kinase phosphorylation was assessed, and only minor differences could be detected: in 
both cases, rapamycin caused a clear dose-dependent reduction in phosphoThr389 signal. For 
the control samples, no phosphorylation was detectable at 2 nM rapamycin, while the signals 
had disappeared for the FKBP12-siRNA samples at 2.5 nM. Thus, in spite of reduced 
FKBP12 concentration, rapamycin is still able to inhibit mTOR kinase activity, possibly by 
recruiting other FKBPs.  
 
 
siRNA                                  control                        FKBP12 
 
Rapamycin [nM]           0    0.5   1    1.5   3            0   0.5     1    1.5    3 
-S6K phosphoT389    
-S6Kinase                
-FKBP12                   
-FKBP25                 
 
 
Figure 4.6.7: In FKBP12 knockdown HeLa cells, rapamycin still affects S6K phosphorylation 
HeLa cells were transfected with siRNA (non-targeting control or anti-FKBP12), starved and stimulated with 
FCS and insulin for 60 minutes in presence of 0-3 nM rapamycin. Cells were lysed and analyzed by 
immunoblotting. FKBP25 was detected as additional loading control.  
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4.7 – FKBP51 associates with mTORC2 and influences phosphorylation status of Akt: 
4.7.1 – FKBP51 interacts with Rictor in a stimulation-dependent way:  
As previous experiments demonstrated that FKBP12 and FKBP51 interact with mTORC1 in a 
rapamycin-dependent manner, we were also interested in assessing binding to mTORC2 
although this complex is generally considered to be rapamycin-independent upon acute 
treatment.  
In order to perform co-IP experiments with HeLa cells, we transfected them for simultaneous 
expression of HA-FKBP51 and myc-Rictor. When we analyzed the binding partners of 
immunoprecipitated HA-FKBP51, we found myc-Rictor to robustly interact with FKBP51 
(see figure 4.7.1). Compared to background binding of myc-Rictor to HA-beads, most IP-
signals of Rictor were clearly stronger. We did not find an obvious rapamycin-dependency of 
these interactions. Rather it can be stated that FKBP51 preferentially binds to Rictor in 
unstimulated cells; after serum-stimulation, the signal intensity decreased. Hsp90 recruitment 
could be detected, too; it runs in parallel with the Rictor signal. 
 
 
                                                        IP: -HA 
                                                                             
pRK5-                            myc-Rictor                 Ric   
pcDNA3-                       HA-FKBP51    -    51 
Stimulation                    -     -    +     +    -     -     -      - 
Rap [nM]                      0    100   0   100     0     0      0       0 
-Rictor         
-Hsp90             
-FKBP51           
 
-Rictor                  LOAD  
-Hsp90                LOAD  
 
Figure 4.7.1: FKBP51 interacts with myc-Rictor in unstimulated HeLa cells  
HeLa cells were transfected for expression of HA-FKBP51 and myc-Rictor. Cells were either starved or 
starved/stimulated with FCS for 24 h. Rapamycin was added as indicated for 60 minutes.  Lysates were 
subjected to HA-IP. Beads were washed four times with CHAPS-containing lysis buffer and extracted by 
boiling. Eluates were analyzed by SDS-PAGE and immunoblotting. 
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We also performed this experiment with FKBP12. Here, binding to myc-Rictor was present 
mainly under conditions of serum-stimulation (see appendix, section 6.7). 
In summary, these results suggest that FKBP51 interacts with the mTORC2 component 
Rictor. The interaction seems to be modulated by stimulation conditions, and a certain degree 
of Hsp90 recruitment might be involved in this process. 
  
4.7.2 – FKBP51 mediates binding of the mTORC2 substrate Akt to Rictor:  
 
As FKBP51 seems to associate with Rictor in mTORC2 complexes, we asked ourselves 
whether FKBP51 is involved in substrate recruitment. As the kinase Akt is the most 
prominent substrate of this TOR complex [141], we performed co-IP experiments in order to 
determine binding of Akt to Rictor in presence of FKBPs and rapamycin.  
First, it turned out that Akt interacts with FKBP51. This finding was already described by Pei 
and colleagues [57], and we were able to verify it. Furthermore, we determined a clear 
rapamycin-dependency of this interaction which has not been demonstrated before (see figure 
4.7.2A). Interestingly, endogenous FKBP51 was detectable as readily as overexpressed 
FLAG-FKBP51. As Hsp90 interacts strongly with FKBP51, the chaperone protein could be 
found in the complex, too. Under conditions of long-term rapamycin exposure, interaction 
with both FKBP51 and Hsp90 seemed to increase compared to short-term conditions. 
More importantly, we checked for presence of the mTORC2 component Rictor in the Akt-
FKBP complexes. Compared to background levels (lane 1, 2), Rictor protein was clearly 
enriched under conditions of FKBP51 overexpression. Strikingly, maximum Rictor signal 
intensity could only be detected in presence of rapamycin. This rapamycin-dependent binding 
pattern could be verified in 3 of 4 independent duplicates (marked as boxes in figure 4.7.2A; 
lanes 3,4 and 7,8 and 9,10) while it was inverted once (lanes 5,6). Nevertheless, rapamycin 
probably mediates an interaction of Akt, Rictor and FKBP51. 
When we performed the same experiment with FLAG-FKBP12, 51TPRmut and 52, we 
realized that no comparable interaction with Akt and Rictor could be observed. Only for the 
FKBP51 TPR mutant, we detected some binding in absence of rapamycin; signal intensity 
was clearly below the one observed for FKBP51/rapamycin (see figure 4.7.2B).  
In conclusion, these results demonstrate that interaction of Akt kinase with FKBP51 is 
rapamycin-dependent, and that the mTORC2 component Rictor can be found in the complex 
of Akt and FKBP51. To our knowledge, such an interaction of Akt and Rictor has not been 
described before. 
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                                                       IP: -HA 
 
pRK5/7-                               myc-Rictor/HA-Akt               Ric 
pcDNA3-                                 FLAG-FKBP51                        51 
Rap [nM]              0    100   0   100    0   100    0    100   0    100    0     0 
Time (h)                 1      1    24   24    24    24    1      1     1      1      -       - 
-Rictor               Gel I 
-Rictor               Gel II 
-FKBP51            
-Hsp90           
-Akt                 
 
-Rictor              LOAD 
-Hsp90                LOAD  
-FKBP51/52       LOAD 
lane                       1     2    3    4    5     6     7    8    9   10  11   12 
 
 
                                                     IP: -HA 
 
pRK5/7-                           myc-Rictor/HA-Akt                   Ric 
pcDNA3-FLAG                FKBP12      FKBP51     FKBP52       51TPR             12/51      
Rap [nM]            0    100   0   100   0   100     0   100      0   100     0      0 
-Rictor      
-Hsp90           
-FKBP51/52   
 
-Rictor           LOAD 
-Hsp90            LOAD 
-FLAG             LOAD 
-HA               LOAD 
 
 
Figure 4.7.2: Rictor can be found associated with Akt in presence of FKBP51  
(A) HeLa cells were transfected with myc-Rictor, HA-Akt and FLAG-FKBP12/51/51. After 24 h, medium 
was changed and cells were treated with rapamycin and insulin (each 100 nM) or vehicle for either 1 or 
24 h, lysed and subjected to HA-IP. Beads were washed four times with TBS/0.3% CHAPS, extracted 
and analyzed by SDS-PAGE and immunoblotting. Lanes representing “load” are marked.  
(B) Similar experiment as in (A), but only 1 h exposition to rapamycin (final concentration: 100 nM). 
A 
B 
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4.7.3 – In HeLa cells, FKBP51 overexpression increases Akt phosphorylation: 
 
In order to assess whether FKBP51 is involved in Akt recruitment to mTORC2 via Rictor, we 
performed overexpression experiments in HeLa cells and determined phosphorylation of the 
mTORC2-dependent Akt residue S473. As rapamycin may be an essential mediator of 
Rictor/substrate assembly, we checked for Akt phosphorylation at different rapamycin 
concentrations. 
The experiments revealed that FKBP51 overexpression generally raises rapamycin-dependent 
Akt phosphorylation: compared to mock conditions, FKBP51 overexpression increased 
mTORC2 activity toward Akt S473 up to 30% (see figure 4.7.3). This effect is clearly 
rapamycin-dependent, as basal phosphorylation levels are not significantly altered under 
conditions of FKBP51 overexpression. Importantly, these effects are short-term rapamycin 
effects: the small molecule was added for 1 h before cell lysis and analysis. 
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Figure 4.7.3: FKBP51 overexpression increases Akt phosphorylation in HeLa cells 
HeLa cells were transfected for expression of FLAG-FKBP12/51/52. After 24 h, cells were starved (DMEM 
without serum). After another 24 h, cells were stimulated with serum and insulin for 60 minutes in presence of  
0-25 nM rapamycin. Cells were lysed and subjected to immunoblotting analysis. (A) Western blot analysis and 
(B) densitometric analysis of phosphoS473 Akt signals (relative to load).  
A 
B 
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By increasing exposure time of rapamycin to 24 hours, the effect on Akt phosphorylation 
could be enhanced even more. As demonstrated in figure 4.7.4, FKBP51 overexpression 
resulted in a 90% increase in phosphoS473 signal compared to mock controls. For this effect, 
3 nM rapamycin was sufficient. Control samples, supplemented with 5 nM torin1, displayed 
the expected reduction of Akt phosphorylation. 
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Figure 4.7.4: Effects of long-term rapamycin treatment on Akt phosphorylation are more pronounced 
HeLa cells were transfected with human FLAG-FKBP51 and incubated for 24 h. Medium was changed 
(DMEM/FCS), and rapamycin/torin1 (T) was added (0-5 nM or 5 nM, as indicated). Cells were incubated for 
another 24 h, then lysed and subjected to immunoblotting analysis.  
(A) Western blots; unspecific signals are marked (*). 
(B) Quantification of phosphoS473 Akt signal intensities, relative to load (FKBP25) 
 
Altogether, our results suggest that FKBP51 overexpression has increasing effects on 
rapamycin-dependent Akt phosphorylation in HeLa cells. While basal phosphoS473 signal is 
unaltered, intensity increases significantly after short- or long-term exposure to rapamycin. 
For this effect, rapamycin concentrations of 10 nM (short-term) and 3 nM (long-term) are 
sufficient. 
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5 – Discussion:  
 
5.1 – Different FKBPs can be involved in rapamycin-dependent mTOR regulation:  
 
5.1.1 – All ternary complexes of FRB*rapamycin*FKBP have similar structures: 
 
Initially, we performed in vitro binding assays in order to determine binding of different 
FKBP proteins to the FRB domain of mTOR (see section 4.2). These experiments revealed 
that FKBP12 is just one of many FKBPs that form ternary complexes with FRB in presence 
of rapamycin: the large FKBPs FKBP51 and FKBP52 displayed comparably affine binding as 
the smaller FKBPs FKBP12.6, FKBP13 and FKBP25. Importantly, EC50 values for complex 
formation cluster below 30 nM, suggesting a possible competition for binding to FRB/mTOR 
in vivo.  
Indeed, our structure determination of the alternative ternary complexes 
FRB*rapamycin*FK1 FKBP51/52 revealed that these FKBPs are able to form rapamycin-
mediated complexes with the FRB domain of mTOR. Binding mode and structure 
architecture are very similar to FKBP12 (see section 4.5). Thus, it may be possible that these 
alternative complexes are present in vivo and might contribute to the effects generated by 
rapamycin in living cells. 
 
Structural comparison of the three ternary complexes FRB*rapamycin*FKBP:  
 
The FK1 domains of all immunophilins are highly conserved and very similar to the 
archetypical FKBP12 (see figure 5.1). Hereby, the overall residue similarity between FKBP12 
and FK1 FKBP51 is 64%, while 50% of the residues are identical. For FK1 of FKBP52, 53% 
of the residues are identical to FKBP12, while similarity reaches 64%. When the FK1 
domains of FKBP51 and FKBP52 are directly compared, an even higher identity of 62% is 
yielded with an overall similarity of 75%.  
Our crystal structures demonstrate that the binding of rapamycin as observed in the FK1 
domains of FKBP51 and FKBP52 is highly similar to FKBP12, involving mainly conserved 
residues. 12 of the 13 residues interacting with rapamycin are identical in FK1 FKBP51 and 
FKBP52 (K121 is unique in FK1 52, R73 in 51), and FKBP12 shares 9 interacting residues 
with 51/52 (apart from Q53, E54 and I91). The total number of hydrophobic contacts is very 
similar in all three cases, and the contribution of one additional H-bond in FKBP51 via R73 is 
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hard to estimate. In general, it is assumed that one H-bond can contribute up to 10-20 kJ/mol 
to the binding energy, while one hydrophobic interaction provides only around 2-5 kJ/mol 
[286]. Furthermore, hydrophobic contacts occur as clusters while H-bonds are well defined 
and directional. Thus, missing interactions of one kind could easily be compensated by other 
kinds of interactions.  
 
 
Figure 5.1: The protein sequences of the FK1 domains of human FKBPs are conserved 
PRALINE representation of a multiple sequence alignment [287], indicating the degree of consistency for human 
FKBP12, FK1 FKBP51 (FK1_51) and FK1 FKBP52 (FK1_52). 
 
As the complex formation with FRB is almost exclusively mediated by the small molecule 
rapamycin, no differences between the three complex structures were expected concerning 
this part of the complex: FRB interacts with the triene arm of rapamycin, and this interaction 
is apparently not influenced by the FKBP binding partner, resulting in a high degree of 
similarity of the binding mode for all three FKBPs. Some residues, for example Y2105, are 
slightly shifted and therefore display variations in the number of hydrophobic contacts (see 
appendix section 6.6.4). For R2036, contacts to rapamycin within 4 Å can be detected in the 
ternary complexes of FKBP12 and FKBP51, but they are located only slightly below the cut-
off of the contact search engine. A minor shift of the arginine’s position in FKBP52 locates it 
at 4.1 Å; thus, these contacts are not detected by the algorithm. Nevertheless, it is probable 
that these contacts are comparably important as the ones below 4 Å even if binding energy 
crucially depends on the distance. Since the contribution of these subtle variations can hardly 
be assessed, it must be assumed that missing contacts at one position are balanced by some 
additional ones at another position. This is also reflected in the fact that the total number of 
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FRB-rapamycin interactions is very similar (ternary complex FKBP12:42; FKBP51:42; 
FKBP52: 45). 
Direct protein-protein interactions are underrepresented in the ternary complexes, and it must 
be hypothesized that crucial interactions are mediated by the shared ligand rapamycin. 
Nevertheless, direct contacts between FKBP and FRB might contribute to stabilization of the 
complexes. Importantly, the total number of direct protein-protein interactions is different 
between the three complexes, and in FKBP51 the 40S region seems to engage in an especially 
high number of contacts to FRB. As the pattern of direct contacts between FRB and FKBP12 
and FKBP52 is well comparable, it appears that in both cases high-affine, direct binding of 
the protein partners is less probable. This hypothesis is also supported by the networks of 
water-mediated H-bonds which are much more expanded between the binding partners 
FKBP51 and FRB.  
Strikingly, the residues involved in direct interactions of FRB and FKBPs differ significantly: 
only 2 of these residues are conserved in FKBP12, 51 and 52, although general similarity of 
FKBPs suggests a higher degree of conservation. The sequence position of the residues is 
more consistent, reflecting their position in the 40S and 80S loops. Nevertheless, structural 
heterogeneity seems to be big enough to favor one residue in one structure over the adjacent 
one in another ternary complex (see figure 5.2). Altogether, the substantial deviations in direct 
protein-protein contacts between FRB and FKBPs may indicate that these interactions act 
mainly as a supporting feature in order to strengthen the rapamycin-induced assembly of the 
ternary complex. Thus, these peripheral contacts might be much more tolerant towards 
variations in number, position and strength without affecting the central rapamycin binding in 
a negative manner.  
 
40S 
80S 
Figure 5.2: Residues involved in direct protein-
protein contacts are less conserved 
Amino acids of FKBP12 (red), FK1 FKBP51 
(blue) and FK1 FKBP52 (yellow) that interact 
with FRB are shown as stick representation. A 
complete list can be found in the appendix, 
section 6.6.2. 
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We observed in our FP binding assays that the rapamycin-derivative CK97 binds to the 
isolated FRB domain of mTOR in absence of any FKBP binding partner (see appendix 
section 6.8). Normally, it is assumed that the pre-formed complex of FKBP and rapamycin 
binds to FRB with low nanomolar affinity, while rapamycin alone displays a much weaker 
binding (26 µM; 490 nM for Fluorescein-Rapamycin, as reported in [276]). We determined an 
EC50 value of 290 nM for CK97 and 1.04 µM for rapamycin (IC50 value, determined in 
competition experiments) which is relatively low compared to other reports; nevertheless, the 
values differs by two orders of magnitude from FKBP*rapamycin complex binding.   
When the number of contacts between the protein domains and rapamycin is determined, 
there are strikingly less contacts between FRB and rapamycin (44 in structure “2fap”) than 
between FKBPs and rapamycin (100 in “2fap”). Additionally, all these contacts are purely 
hydrophobic and therefore relatively week; H-bonds that contribute much stronger to 
increasing binding affinity are not present at all.  Thus, these differences might be an 
explanation for the weaker binding of rapamycin to FRB. 
Since the binding affinities of isolated rapamycin and the FKBP12*rapamycin complex differ 
a lot, it can be speculated whether the direct protein-protein contacts between FRB and FKBP 
are crucially involved in stabilizing the complex. Our analysis of the residues forming this 
interface in the three ternary complex rather suggest that due to the big variability these 
contacts have a more random character and are less conserved. Nevertheless, mutational 
analysis of the residues might be interesting in order to shed a light on their importance in 
interface formation. 
Initially, FKBP12 was considered as the only cellular target mediating the inhibitory effects 
of rapamycin on mTOR. Apart from that, FKBP12.6, a highly related homologue to FKBP12 
with partially overlapping functions, was also found to allow the ternary complex formation 
with rapamycin and FRB-mTOR [74]. Later, researchers tried to deduce the structure of 
alternative ternary complexes by superimposing structures of rapamycin-complexed FKBP13 
and FKBP25 with the FKBP12*rapamycin crystal structure: they argued that within the 80S 
loop there are unfavorable sterical clashed that would not allow stable complex formation 
with FRB [111]. Although our results proof highly affine binding and thus indicate that 
complex formation with FRB is possible, FKBP13 and FKBP25 are probably not involved in 
complex formation in vivo: they are located mainly in the ER and in the nucleus, respectively. 
Only very recently, FKBP38 has been proposed as a player in rapamycin-independent mTOR 
inhibition by competition with Rheb GTPase for mTOR binding [113]. Here, a rapamycin-
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independent binding to mTOR was implicated. Such binding presumably does not involve 
FRB but rather happens elsewhere in the mTOR complex. 
 
Different FKBPs regulate calcineurin activity in presence of FK506: 
 
The structure of the ternary complex FKBP12*FK506*calcineurin [288, 289] substantially 
differs from the complexes of FKBPs with rapamycin and FRB, although the small molecules 
are bound to the FKBP moiety in very similar manners. Due to the larger ring size of 
rapamycin, the distance between the two interacting proteins is bigger than in the complex 
with FK506 and calcineurin. Therefore, direct protein-protein contacts are limited in the first 
case, whereas FKBP12 and calcineurin engage in more intensive interactions (see figure 5.3). 
While FKBP12 binds to FRB mainly via its 40S and 80S regions, its interactions with 
calcineurin are more diverse, including some residues adjacent to the 80S loop. The ligand 
FK506 is almost completely buried between residues of FKBP12 and FRB that interact with 
each other; in contrast, big parts of rapamycin are solvent-accessible. Altogether, 18 residues 
in calcineurin engage with FKBP12 via direct protein-protein contacts, while there are only 9 
in FRB (see section 4.5.3.2). 
 
        
 
 
Figure 5.3: FKBP12*FK506 interacts more intensively with calcineurin than FKBP12*rapamycin does 
with FRB 
(A) Surface representation of the ternary complex FRB*rapamycin*FKBP12 (2fap) 
(B) Surface representation of the ternary complex calcineurin*FK506*FKBP12 (1tco) 
Colour scheme: red: FKBP12; green: FRB; pale green: calcineurin; blue: rapamycin/FK506. 
 
FRB calcineurin 
A B 
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Weiwad and Edlich characterized calcineurin inhibition by different FKBPs in an in vitro 
assay [290]. Although binding to FK506 happens with high affinity, only FKBP12, 12.6 and 
51 were able to form a complex with calcineurin and inhibit kinase activity effectively. These 
differences can be explained by substitution of two critical residues of FKBP12 that interfere 
with binding to calcineurin in some FKBPs. In contrast to these results, we observed 
comparable IC50 values for mTOR inhibition by all tested FKBP proteins (see section 4.3.1). 
This might be explained by a high degree of conservation between FKBP residues involved in 
rapamycin binding, in contrast to a putatively reduced importance and high variability of 
residues involved in direct contacts to FRB.    
Similarly to our results for FRET mTOR activity assays, it has been found that FKBP51 can 
replace FKBP12 in inhibiting calcineurin activity in vitro in a weaker, but clearly FK506-
dependent manner [34]. Later, it has been demonstrated in pulldown assays that FKBP51 can 
be bound to calcineurin even in absence of FK506, and that this alternative binding mode 
demands the C-terminal domain of FKBP51 [291]. Nevertheless, overexpression of FKBP51 
did not affect calcineurin activity in vivo. In contrast, we were able to demonstrate rapamycin-
dependent effects of FKBP51 on mTOR activity, assessed by quantification of S6Kinase 
phosphorylation (see section 4.6.5). 
 
 
5.1.2 – FKBP51 is more abundant than FKBP12 in some tissues: 
 
In all our in vitro experiments we demonstrate that FKBP51 can be involved in rapamycin-
dependent inhibition of mTOR activity. Furthermore, the effects of the larger FKBP appear to 
be more pronounced than those of FKBP12 in terms of degree of in vivo inhibition (see 
section 4.6.5). Thus, it could be argued that actually FKBP51 might be a main mediator of 
rapamycin action in some tissues in vivo.  
Most of FKBP family members bind to rapamycin with comparably high affinity. 
Consequently, a mixture of FKBP proteins will compete for binding to rapamycin when the 
compound is administered. While rapamycin-bound FKBP12 will certainly participate in FRB 
binding and mTOR inhibition, other FKBP proteins might form non-productive complexes 
with rapamycin due to their localization in the ER or the nucleus which results in sequestering 
the compound from its actual destination. Nevertheless, a small fraction of 
FKBP12*rapamycin seems to be sufficient for mTOR inhibition, as rapamycin exerts its 
action in a concentration range below 5 nM. Thus, the actual concentration of active complex 
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might be in the low nM range, sufficient for successful inhibition of the mTOR protein 
(80.000 - 200.000 copies per HeLa cell [292]). As very small amounts of FKBP*rapamycin 
complexes seem to be effective, it appears rather probable that FRB binding and mTOR 
inhibition is executed by the FKBP complex species that is most abundant in the cell. In the 
case of roughly similar concentration levels, these FKBPs might contribute equally to mTOR 
inhibition. 
Whether this hypothesis is true depends largely on the abundance of FKBPs in living cells, 
comprising protein concentration and availability in the cytosol. Consequently, in the case of 
a high molar excess of one FKBP compared to another, the effect of the second should be 
more or less negligible. 
Baughman and Wiederrecht characterized the tissue distribution and cellular concentration of 
FKBP51 and directly compared it to FKBP12 [19]. They found that FKBP51 is more 
abundant in 11 of 17 tissues, with rates of molar excess of 2-fold up to 12-fold. In kidneys, 
they quantified the ratio of FKBP51:FKBP12 with 3.5, while the value reaches 7.3 in the 
heart and even 11.6 in the liver. As FKBP51 and FKBP12 are both present in the cytosol, 
FKBP51 possibly competes with FKBP12 for binding to rapamycin, and FKBP51 might be 
the major component of the inhibitory rapamycin complex. Thus, it may be responsible for 
the majority of rapamycin-mediated effects in certain cell types that hitherto have been 
assigned to FKBP12.  
Furthermore, mRNA quantification revealed that FKBP51 is highly overexpressed especially 
in adipocytes and in skeletal muscle cells, compared to median expression [293]. Therefore, 
these tissues might be especially rapamycin-sensitive. Furthermore, these cell types are linked 
to insulin action, and altered mTOR pathway activity plays a crucial role in development of 
insulin resistance and diabetes [294].  
When we performed RNAi experiments for knockdown of FKBP12, we did not see a 
substantial decrease in mTOR inhibition by rapamycin: S6Kinase T389 phosphorylation was 
largely unaltered compared to control conditions (see section 4.6.6). This result further 
consolidates our hypothesis that FKBP51 is indeed able to replace FKBP12 function, and that 
FKBP51 mediates the inhibitory effect of rapamycin on mTOR kinase activity.  
Nevertheless, it must be kept in mind that knockdown by means of siRNA is never 
quantitative. In our case, up to 10% of the total FKBP12 still might be present in knockdown 
cells, and this concentration might be sufficient for effective rapamycin-dependent mTOR 
inhibition, as discussed before. More reliable experiments could be performed with 
FKBP12KO MEF cells because they lack any background levels of FKBP12. 
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Generally, tissue-selective mTOR inhibition appears attractive, because classical, systemic 
rapamycin treatment causes potent immunosuppression in patients by acting on T cell 
proliferation [295]. Other side effect like nausea, fatigue and diarrhoea are quite common 
among patients [296]. Furthermore, the small molecule exerts toxic effects on the lungs, 
triggering severe pulmonary inflammation in some cases [297, 298]. In order to avoid global 
mTOR inhibition mainly mediated by FKBP12, a rapamycin analogue would be useful that 
binds selectively to FKBP51. Like this, cells that display high expression levels of FKBP51 
could be selectively targeted for inhibition. In contrast, mTOR activity would remain 
unaffected in cells with FKBP51 levels that are insufficient for mediating the inhibitory effect 
of the rapamycin-derivative. Unfortunately, the rapalogues we tested in FRET binding assays 
did not show any selectivity for different FKBPs (see section 4.2.2). Also, considering the 
highly conserved rapamycin binding pocket of FKBP12 and FKBP51, it appears challenging 
to achieve total selectivity. Nevertheless, research with model compounds suggests that it 
might be possible to generate at least preferential binding to one FKBP (Steffen Gaali, MPI of 
Psychiatry, personal communication, May 2011). Our crystal structures of the alternative 
ternary complex can also be considered as excellent starting points for rational design of 
FKBP51-specific compounds. 
 
 
5.1.3 – Possible mechanism of mTOR inhibition by large FKBPs: 
 
Based on the cryo-EM mTOR complex structure: 
 
Very recently, Yip and colleagues analyzed cryo-electron microscopic structures of mTOR 
complex 1 and proposed a model of rapamycin action on complex integrity [112]. They 
observed that FKBP12*rapamycin binds to the FRB domain of mTOR, just opposite to the 
substrate recruiter Raptor. Notably, one complex FKBP12*rapamycin is bound to one 
mTORC1 dimer (see figure 5.4). This initial binding results in a weakening of the mTOR-
raptor interaction which forms the main interface of the dimer. Increasing structural 
fluctuation might trigger the binding of a second FKBP12*rapamycin complex, resulting in 
proceeding disassembly of mTORC1 dimers over time. Interestingly, S6Kinase can even be 
phosphorylated by monomeric mTOR, while the substrate 4E-BP1 is strictly obliged to the 
intact dimeric form.  
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Figure 5.4: Model representation of dimeric mTOR and the FKBP12*rapamycin binding site  
(A) Original cryo-EM image of mTORC1 dimers (white) in complex with FKBP12*rapamycin (pink)  
(B) Model of mTOR dimers: dimer interface and individual components are indicated. Location of the FRB 
domain is shown.  Taken from [112] , image 4A. 
 
The EM image of mTORC1 in complex with FKBP12 and rapamycin shows clearly that 
FKBP12 is bound to the readily accessible FRB domain, and that this binding does not appear 
sterically challenging: both mLST8 and PRAS40 are also bound to mTOR in such a way that 
they do not interfere with FKBP12 binding. Thus, it might be concluded that this binding 
mode also allows accommodation of the larger multi-domain FKBP51 at the FRB site of 
mTOR.   
The authors claim that binding of one FKBP12*rapamycin also may block the entry of big 
substrates like S6Kinase into the active site. Regarding this assumption, it could be speculated 
that a larger FKBP molecule might represent a more effective steric hindrance compared to 
small FKBP12. Unfortunately it is not known how the single domains of multi-domain 
FKBP51 are oriented within a complex with mTORC1. 
As the degree of mTORC1 dimer dissociation cannot be estimated by SDS PAGE analysis, it 
is not clear whether binding of FKBP51/52 to the complex triggers disassembly differently 
than binding of FKBP12 does. It might be possible that the larger FKBPs affect the integrity 
of the complex more efficiently, resulting in a faster release of mTORC1 monomers. The 
degree of interaction with the monomers may also differ between the small and the large 
FKBPs.     
 
 
Based on the conventional mechanism of FKBP*rapamycin action: 
 
In all our co-immunoprecipitation experiments, we used detergents and salt concentrations 
that allow purification of intact mTORC1 complexes. As S6Kinase is recruited to mTOR 
A B 
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kinase by the scaffolding protein Raptor [129], and as S6Kinase therefore might be an 
intermittent part of the complex, it is unclear how interactions of S6Kinase and FKBPs occur. 
Several scenarios are possible: first, S6Kinase might be bound to mTORC1, and FKBPs 
interact with the FRB domain of mTOR. Thus, S6Kinase and FKBPs would not bind to each 
other; the interaction would be perfectly indirect. This option appears to be the most realistic 
one. Secondly, mTORC1-bound S6Kinase may recruit free FKBPs. Such a scenario demands 
a plausible explanation for the rapamycin-dependent binding mode which cannot be provided 
readily. Finally, free S6Kinase might directly interact with unbound FKBPs. Again, no 
mechanism is known that includes rapamycin in such a case.    
As a fundamental mechanism of rapamycin action, a competition of binding to the mTOR 
complex 1 between Raptor and FKBP12*rapamycin has been proposed [131]: after FKBP12 
has bound to the FRB domain of mTOR,  Raptor is released from its binding site, resulting in 
abolishment of substrate phosphorylation by the mTOR kinase active site. Thus, at rapamycin 
concentrations of 100 nM and above, less Raptor is detected in immunoprecipitations of 
mTORC1. 500 nM rapamycin are necessary to reduce Raptor signal completely [299]. 
Presumably, the same result should be obtained for S6Kinase because this protein is recruited 
to mTORC1 by Raptor. 
In contrast, the results of our co-IP experiments showed a different binding pattern: we 
observed that in presence of rapamycin Raptor interaction with S6Kinase was increased, and 
FKBPs were part of these complexes (see section 4.6.4). This might be explained by a 
mechanism that differs slightly from the one described above: instead of perfectly blocking 
the access to the active site in presence of rapamycin and therefore inducing the release and 
dissociation of the S6Kinase*Raptor complex, the FKBPs might bind to mTORC1 in a 
rapamycin-mediated manner. This binding is compatible with Raptor*S6Kinase remaining 
part of the complex, hypothetically accompanied by reduced S6Kinase release from Raptor 
(as the substrate remains unphosphorylated). Thus, in co-IP experiments, FKBPs interact only 
in presence of rapamycin (see scheme in figure 5.5), and the binding of Raptor and S6Kinase 
increases in a rapamycin-dependent manner.  
Unfortunately, we were not able to determine whether Raptor remains part of the complex or 
whether it is rather expelled from mTORC1 as a consequence of FKBP binding. But as 
rapamycin-dependent FKBP binding is restricted to the FRB domain of mTOR, it must be 
assumed that Raptor stays an integral part of mTORC1. 
Altogether, it can be concluded that our results from co-IP experiments rather support a 
mechanism of FKBP*rapamycin action that involves sequential binding of the FKBP to the 
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complex which does not result in an immediate dissociation of the complex (especially of the 
mTORC1 component Raptor).  
 
 
Figure 5.5: Schematic representation of rapamycin-mediated S6Kinase release from mTORC1 
(A) Conventional mechanism of competitive binding of Raptor and FKBP*rapamycin to mTORC1 
(B) Proposed mechanism for FKBP blocking S6Kinase phosphorylation at the active site  
   
 
5.1.4 – mTOR inhibition in yeast: a valid model system? 
 
In a FKBP-deficient yeast cell system which is resistant to growth inhibition by rapamycin, 
we expressed the FK1 domain of FKBP51 and observed restored rapamycin sensitivity (see 
section 4.4). This demonstrates that FKBP51 can mediate rapamycin-dependent mTOR 
inhibition in this model organism which may implicate that FKBP12 function in presence of 
rapamycin can generally be executed by FKBP51. Importantly, this finding is only conclusive 
under conditions of conserved mTOR structure and functionality between the species.  
TOR was originally discovered in yeast cells represented by the two gene products TOR1 and 
TOR2, and two distinct complexes were characterized [126]. KOG1, the yeast homologue of 
Raptor, interacts with TOR1/2 to form TORC1, which controls different growth-associated 
downstream targets and is rapamycin-sensitive. The structure of this complex has been 
determined by EM [300], revealing a 1:1 stoichiometry: one TOR molecule engages 
intensively with one KOG1, and interactions comprise most of the domains in both proteins. 
The N-terminal domain of KOG1 is oriented toward the kinase domain of TOR and allows 
recruitment of substrates to the active site. Unlike in the mammalian complex, binding of 
FKBP12*rapamycin to yeast TORC1 does not weaken the binding of KOG1 to TOR [126]. 
A 
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The authors speculate whether in the yeast system binding of FKBP12*rapamycin to the FRB 
domain might either interfere with substrate presentation or might directly inhibit TOR kinase 
activity by interacting with the adjacent active site.   
Altogether, it must be stated that the structure of yeast and mammalian TORC1 differs 
considerably, and that the proposed mechanism of inhibition of the mammalian form cannot 
be transferred to yeast conditions: while disruption of the dimeric state plays an important role 
in mammals, TOR complexes seems to be generally monomeric in yeast. Maybe the more 
advanced weakening of Raptor interactions with mTOR might be accompanied by the more 
archetypical direct interactions with the active site.  
In yeast cells, no homologues of the larger human FKBPs are present [301], implicating that 
the FK1 domains of large FKBPs are sufficient for the inhibitory effect on TOR. Indeed, we 
observed this effect for human FKBP51, whose FK1 domain mediated growth arrest; the full-
length variant turned out to be cytotoxic in yeast. Thus, rapamycin-dependent effects could 
not be fully separated from unspecific ones. 
 
 
5.1.5 - mTOR in vitro kinase assay and its limitations: 
 
By overexpressing different FKBPs and examining the phosphorylation state of S6Kinase in 
HeLa cells, we were able to demonstrate influences of FKBPs on mTOR activity in vivo (see 
section 4.6.5). On the one hand, it is very convenient to perform such an assay in a cellular 
system where all components of mTOR complexes and substrates are present. On the other 
hand, the unpredictability of cellular processes and the still limited knowledge of mTOR 
complex regulation in vivo make the assay difficult to control, and the results should be 
interpreted with caution.  
In order to overcome these obstacles we performed an in vitro mTORC1 kinase assay with 
immunoprecipitated HA-S6Kinase and mTORC1. As the precipitate of HA-S6K was washed 
extensively with “triton X-100”-containing buffer, it was stripped and did not contain any 
additional proteins. mTORC1 preparation was purified with a CHAPS-containing buffer, 
maintaining complex integrity under these mild detergent conditions [129]. Thus, mTORC1 
contains mTOR, Raptor and mLST8 [126, 157]. This well-defined composition allows the 
performance of in vitro kinase assays with addition or omission of recombinant FKBPs, 
therefore making reaction conditions much more controllable.  
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Nevertheless, it must be considered that immunoprecipitated and even carefully washed 
mTOR complex 1 might contain additional, maybe unknown proteins that are not present 
under all washing conditions. During our in vitro kinase assays we observed that addition of 
rapamycin inhibited mTOR activity toward 4E-BP1 even in absence of any FKBP (see figure 
5.6).  
 
                 -        -      +      +      +       +          mTORC1 
                 -        +      -      +       -       +          Rapamycin 
                 -        -       -       -      +       +          FKBP12 
                   -4E-BP1; 3 washing steps  
                   -4E-BP1; 6 washing steps  
 
Figure 5.6: Influence of washing steps on mTOR in vitro kinase assay 
In vitro kinase assay, performed with 4E-BP1 as substrate and mTORC1 preparations as described in section 
4.3.2. mTORC1 immunoprecipitate has been washed 3 times or 6 times. 
 
For troubleshooting, we doubled the number of washing steps and realized that excessive 
washing eliminated the artefact. Thus, we concluded that some endogenous FKBPs bind to 
mTORC1 even in absence of rapamycin, and that this interaction is strong enough to survive 
normal washing procedures. 
 
 
5.2 – FKBP51 can exert rapamycin-independent effects on mTOR: 
 
5.2.1 – Functions of FKBP51 within or outside of the mTOR complexes: 
 
In our co-IP experiments, we were able to detect rapamycin-dependent interaction of FKBP12 
and FKBP51 with mTOR (see section 4.6.1). Considering the crystal structure with its 
intensive rapamycin-mediated contacts and its few direct protein-protein interactions, 
rapamycin apparently represents the crucial mediator of binding.  
Surprisingly, we also observed rapamycin-independent binding, especially in the case of 
FKBP51. As the mTOR complexes present themselves as multi-protein complexes, it seems 
probable that these kinds of interactions occur elsewhere in the big complex, but not 
necessarily within the FRB domain. Maybe rapamycin-independent binding does not involve 
 -         -       +      +       +       +       
 -     +      -      +    -       +       
 -         -        -      -        +       +          
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mTOR itself, but rather adaptor proteins (substrate recruiters like Raptor or Rictor) or even 
the mTOR substrates like S6Kinase and Akt kinase.  
Also, it could be speculated that FKBPs might play a role in modifying the activity or affinity 
of certain parts of the complex. Co-chaperones like FKBP51 are considerably good candidates 
for assisting target proteins in maintaining or modifying their structure. This can be observed 
in the glucocorticoid receptor complex where alternative binding of FKBP51 and FKBP52 
promotes maturation of the receptor [302]. Thus, multiple tasks can possibly be executed by 
FKBPs within a multi-protein complex.  
Connected to the idea of chaperoning function, it has been reported recently that mTORC2 is 
involved in stabilization of Akt protein: the complex associates with polysomes, binds to 
newly synthesized Akt polypeptide and phosphorylates Akt at its turn motif residue T450. 
This co-translational modification assures proper folding of the kinase and prevents it from 
being ubiquitinylated [303]. A role of co-chaperones within such a complex appears 
reasonable. 
Very recently, FKBP51 has been established as a negative regulator of the Akt signaling 
pathway: it functions as a scaffolding protein to recruit the phosphatase PHLPP to Akt, 
resulting in decreased survival signaling. Thus, certain cell lines are more susceptible to 
chemotherapeuticals. Interestingly, FKBP51 is downregulated in a number of cancer cell lines 
[57] and might be considered as a tumour suppressor protein. 
 
The above findings indicate that the classical view of FKBP action being limited to rapamycin 
and the FRB domain of mTOR might be out-dated. As this function seems to be mainly 
connected to the ability of FKBPs to bind rapamycin, recent reports clearly suggest additional 
regulatory influences that focus on the original co-chaperone and scaffolding function of these 
proteins. Maybe both rapamycin-dependent and rapamycin-independent effects cooperate for 
mediating regulation of mTOR complexes and the substrates, respectively. Further research, 
especially including methods of FKBP truncation and PPIase inactivation, will be necessary 
in order to assess the underlying mechanisms of these processes. 
 
 
5.2.2 – FKBP51 and Hsp90: 
 
In T cells, Hsp90 has been reported to interact with Raptor. When the Hsp90 inhibitor 
geldanamycin is administered, Raptor expression is reduced, resulting in decreased mTORC1 
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signaling [299]. In co-IP experiments performed in HeLa cells, we observed a slight increase 
in Hsp90 recruitments when FKBP51 interaction with either Raptor or mTOR was assesses 
(see sections 4.6.1 and 4.6.2). This finding may point to a rapamycin-independent function of 
FKBP51: it might be involved in recruiting Hsp90 to the complex, where the heat shock 
protein interacts especially with Raptor.  
Takai and colleagues proposed another important role for Hsp90 in mTOR complex 
maturation [292, 304]: together with Tel2, the chaperone is necessary for stabilization of 
immature mTOR until it has established the interactions with its partner proteins. Again, a 
rapamycin-independent role of FKBP51 as a co-chaperone could be possible, namely by 
mediating Hsp90 recruitment to the early mTOR*Raptor complex. As these processes occur 
during the maturation procedure, the involved chaperone proteins could not be detected in the 
complete mTOR complexes; thus, their detection is not possible with classical co-IP, but it 
demands more advanced pulse-chase techniques.  
In osteosarcoma cells, the Hsp90 inhibitor 17-AAG (17-N-Allylamino-17-demethoxy-
geldanamycin) was a potent inducer of apoptosis, in parts by inhibiting mTOR signaling and 
subsequent phosphorylation of all proteins involved [305]. Rapamycin was rather effective in 
affecting cell cycle progression, but it also reduced phosphorylation of Akt, mTOR and 
S6Kinase. The effects of 17-AAG clearly indicate that Hsp90 plays an important role in 
mTOR signaling. Again, a role of co-chaperones like FKBP51 or FKBP52 appears probable. 
 
 
5.3 – Possible side-effects of FKBP51 on other signaling pathways: 
 
When overexpressed in HeLa cells, we observed that FKBP51 decreases S6Kinase 
phosphorylation in a rapamycin-dependent manner (see section 4.6.5). This result indicates 
that FKBP51 exerts an inhibitory effect on mTOR in presence of the small molecule. 
Nevertheless, it must be considered that plasmid-based protein overexpression may influence 
different cellular processes and that such side-effects might influence the outcome of 
experiments.     
In 2002, Giraudier and colleagues discovered that FKBP51 is overexpressed in patients with 
malignant bone marrow, and that overexpression of FKBP51 in these megakaryocytes renders 
them resistant to apoptosis [306]. They postulated that this effect may be caused by inhibition 
of the phosphatase calcineurin which is normally considered to be regulated by 
FKBP12*FK506. As calcineurin activates pro-apoptotic genes via NF-AT dephosphorylation, 
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FKBP51 suppresses programmed cell death and favors cell survival under cytokine 
deprivation. Other groups also discuss an involvement of the JAK/STAT pathway [307]. 
Unlike regulation of calcineurin or mTOR, the effects of FKBP51 on glucocorticoid receptor 
are well characterized [39, 41, 308]: presumably by binding to the receptor, FKBP51 reduces 
binding affinity of cortisol and thus inhibits transcriptional activation of GR-regulated genes. 
Glucocorticoids are used in clinical treatment of patients suffering from lymphoma and 
leukemia as these hormones slow down growth of malignant cells. Similarly, glucocorticoids 
display anti-proliferative action against different types of adenocarcinoma [309, 310], while 
they stimulate the growth of others [311].     
Furthermore, a Japanese group reported that FKBP51 expression in colon cancer cells 
suppresses cell growth: when they knocked down the protein expression by means of siRNA, 
proliferation could be increased. This activating effect of FKBP51 was partially antagonized 
by the GR inhibitor mifepristone [312]. Thus, it could be concluded that tissue-specific 
expression levels of FKBP51 might influence glucocorticoid sensitivity which is reflected by 
expression level of downstream target genes. 
Very recently, Shimizu and colleagues discovered that GR and mTOR pathways are 
interconnected in skeletal muscle cells: while glucocorticoids trigger katabolic processes in 
the cell, growth factors and insulin stimulate anabolism via PI3K/mTOR signaling. By a 
direct mutual crosstalk between the two antagonistic pathways, a fine-tuning of cellular 
metabolism can be achieved [313], mainly by modulating transactivation capacities of 
downstream transcription factors. Thus, a treatment of the muscle cells with dexamethasone 
(DEX) causes a reduction of S6Kinase and 4E-BP1 phosphorylation, while mTOR activation 
by amino acid supplementation results in repression of dexamethasone-mediated gene 
expression. Notably, rapamycin treatment caused an increased expression of the DEX-
induced FKBP5 gene.  
Furthermore, FKBP51 has already been proposed as a modulator of cell growth and 
rapamycin-sensitivity in glioma cells [314]: overexpression of FKBP51 caused a reduced 
response to rapamycin treatment while FKBP51 knockdown rendered the cells sensitive. 
Importantly, the protein is highly expressed in these cancer cells by default. When NF-κB 
activity was assessed, it was found that FKBP51 generally activates signaling via this 
transcription factor. The authors discuss that mTOR inhibition by rapamycin plays a minor 
role during this process. 
Dan and Cooper demonstrated in prostate cancer cells that Akt is involved in NF-κB 
activation via IKK in an mTOR-dependent manner [315]. As Raptor is necessary for this 
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signaling pathway and as rapamycin suppresses IKK activity, it was assumed that 
Akt/mTORC1 signaling is crucially involved in regulating gene expression by modulating 
NF-κB activity. 
 
Altogether, it must be considered that FKBP51 can be involved in the regulation of numerous 
cellular processes, including hormone receptor activation, cytokine signaling and co-
chaperoning. In overexpression studies, one process cannot be favored against the others; 
thus, one might observe a combination of very different effects of FKBP51. Some of them 
may amplify each other, some of them may extinguish each other. As a consequence of this 
fact, it appears reasonable to modify only one parameter in a well-controlled way. Since 
mTOR activity might be negatively influenced by GR, GR inhibitors seem to be an important 
control to rule out those artefacts. As overexpression of wild type FKBP51 might modulate 
GR activity, the Hsp-binding defective TPR mutant could be used as a control to exclude a 
GR-dependent influence on mTOR. Probably, these issues do not play an important role in 
standard HEK293 or HeLa cells; but especially the GR effects of FKBP51 must be kept in 
mind in order to avoid false conclusions.    
 
 
5.4 – FKBP51 mediates effects of rapamycin on mTORC2: 
 
5.4.1 – FKBP51 increases Akt binding to Rictor in a rapamycin-dependent manner: 
 
Originally, the mTOR complex 2 was considered to be insensitive to short-term rapamycin 
treatment [140]. In co-IP experiments performed in HeLa cells, we clearly demonstrated that 
Akt forms a complex with the mTORC2 component Rictor in a rapamycin-dependent manner 
(see section 4.7.2). FKBP51 seems to be part of that complex, too. These results might 
question the classical paradigm of rapamycin not being directly involved in regulation of 
mTORC2. Recently, more and more evidence was found which strengthens the role of this 
small molecule: 
Sarbassov and colleagues claimed that in some cell types (especially in PC3 or in Jurkat cells) 
long-term treatment with rapamycin inhibits mTORC2 assembly, resulting in reduced Akt 
phosphorylation [139]. They observed that the amount of Rictor was dramatically reduced in 
mTORC immunoprecipitations, indicating a lack of intact and active complexes. This effect 
on the mTORC2 complex was thought to be mainly caused by binding of 
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FKBP12*rapamycin to free mTOR protein and thus sequestering it from complex assembly. 
As the pre-assembled active complexes have a certain life time, rapamycin action does not 
take place immediately. This explains the requirement for long-term treatment. 
Our results suggest that FKBP51 increases interaction of Akt with Rictor in a rapamycin-
dependent manner. As Rictor is a component of the mTOR complex 2, it can be assumed that 
Rictor is at least temporarily associated with the complex. Experiments performed by Pei and 
Li [57] indicate that FKBP51 might directly interact with Akt in a constitutive way. In 
contrast, we rather found a rapamycin-induced binding of FKBP51 to Akt. Thus, it could be 
speculated that FKBP51 binding to the mTORC2 complex is triggered by rapamycin, and that 
the resulting complex increases recruitment of Akt by Rictor (see scheme in figure 5.7). 
 
 
Figure 5.7: Rapamycin modulates interaction of Akt with the mTORC2 component Rictor 
Schematic representation of a proposed mechanism of Akt recruitment to mTORC2 via Rictor.   
 
Similar to S6Kinase, a direct binding of FKBP51 to Akt appears questionable, especially if it 
happens in a rapamycin-dependent manner. Nevertheless, in vitro pull-down experiments 
performed in our lab indicate that there may be a certain degree of constitutive, direct binding 
of Akt and FKBP51 in an environment that lacks mTOR (Anne Fabian, personal 
communication, April 2011).  
 
In contrast to the well-established interaction of S6Kinase and Raptor, binding of Akt to 
Rictor has not yet been studied intensively. Only one report can be found, describing an 
immunoprecipitation of Rictor which failed to demonstrate binding of Akt in HEK293 cells 
[316]. As we invested a lot of effort in optimizing our immunoprecipitation experiments in 
terms of stimulation (serum/insulin), incubation time, detergents and expression levels, it can 
be speculated that the simple co-IPs done by others were not elaborate enough. They also 
used a different cell system and pulled down endogenous Rictor without overexpressing the 
protein. Furthermore, they stimulated the cells with serum; our results indicate that insulin is 
necessary to increases interaction of Rictor and Akt significantly. Most importantly, this 
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interaction might be detectable only if it is amplified by rapamycin treatment; hence we did 
not observe increased complex formation under basal conditions. Altogether, our data indicate 
a rapamycin-dependent interaction, but they are insufficient to claim a general role of 
FKBP51 in recruitment of Akt to the mTOR complex 2.  
This conclusion is also supported by several observations in FKBP51 knockout mice: these 
animals show no differences in phenotype or behavior compared to wild type controls. 
Consequently, essential functions of the missing FKBP51 might be taken over by other 
proteins or might be compensated by other processes.  
 
 
5.4.2 – FKBP51 is involved in regulation of Akt phosphorylation: 
 
In 2009, FKBP51 was found to act as a scaffold protein that mediates an interaction of the 
phosphatase PHLPP with Akt kinase, resulting in reduced Akt phosphorylation when the 
FKBP is overexpressed [57]. Thus, a role of FKBP51 in Akt phosphorylation is established. 
When we overexpressed FKBP51 in HeLa cells, we observed that short-term treatment with 
rapamycin increases Akt phosphorylation. This effect was clearly rapamycin-dependent and 
more pronounced compared to mock-transfected cells (see section 4.7.3). While FKBP51 
recruits PHLPP to Akt under basal conditions, we did not observe any changes in Akt 
phosphorylation in absence of rapamycin. Maybe, the phosphatase does not play a big role in 
HeLa cells.  
Generally, Akt activation via the PI3K/Akt/mTOR signaling pathway is essential for 
regulation of cell growth and survival, and it is regulated in a very strict manner by feedback 
loops [317]. Rapamycin-induced Akt hyperphosphorylation can be explained by blockage of 
these negative feedbacks [139]: one signals via S6Kinase and the insulin receptor substrate 
IRS [318], while the second less characterized one is based on mTOR-dependent expression 
of the protein phosphatase PHLPP [319]. 
Concerning the latter, the expression of PHLPP is based on mTOR-mediated protein 
translation in colon carcinoma cells. Normally, PHLPP is available in sufficient amounts, 
associates with Akt kinase and inactivates it by dephosphorylation.  If mTOR signaling is 
blocked by rapamycin treatment or mTOR depletion, PHLPP protein concentration decreases, 
resulting in Akt hyperactivation. This is one mechanism that renders cancer cells rapamycin-
resistant [319]. Nevertheless, the effects of such a long-term regulation are unlikely to be 
triggered by a rapamycin exposure of 60 minutes (as done in our experiments). 
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In human lung cancer cell lines, rapamycin does not exert any inhibitory effect on cell growth, 
although mTORC1 signaling is clearly suppressed (resulting in reduced S6K and 4E-BP1 
phosphorylation) [320]. Surprisingly, survival signaling pathways involving Akt and eIF4E 
were hyperactive in presence of rapamycin or analogues, providing a possible explanation for 
missing growth arrest. The role of PI3Kinase in Akt activation was proven by administration 
of the inhibitor LY294002 which reduced cell growth when co-administered with rapamycin. 
In contrast, Gupta and co-authors reported that PI3K inhibitors were not successful in 
suppressing the rapamycin-induced increase in Akt phosphorylation in a lymphoma cell 
culture [321]. Furthermore, Raptor knockdown did not affect Akt phosphorylation, arguing 
against an involvement of the mTORC1-dependent feedback in mTORC2 regulation. In 
contrast, a knockdown of Rictor abolished Akt phosphorylation.      
Wan and colleagues also reported that rapamycin treatment increases Akt phosphorylation in 
some cancer cell lines (especially in human rhabdomyosarcoma cell lines) [322]. In contrast 
to our findings, rapamycin must be administered for at least 3 hours at a relatively high dose  
(10-100 nM). The authors assume that Akt activity is increased by signaling via the insulin-
like growth factor 1 (IGF-1) receptor, but they also admit a scenario in which mTORC2 is 
directly activated by rapamycin. Importantly, it can be stated that for a possible negative 
feedback via mTORC1 and IRS-1 both time and necessary rapamycin concentration are 
suspiciously high; this might indicate that the mTORC1-dependent feedback is not 
necessarily involved in this regulatory circuit.  
 
Generally, it must be conceded that the above mentioned feedback mechanisms can influence 
Akt phosphorylation significantly. Concerning our experiments analyzing short-term effects 
of rapamycin on Akt phosphorylation (see section 4.7.3), it appears possible that increased 
Akt phosphorylation is simply caused by mTORC1 inhibition and subsequent abolishment of 
S6Kinase/IRS-1 negative feedback. In case of FKBP51 overexpression, rapamycin might be 
more effective in mediating its inhibitory effect on mTORC1, resulting in total shut-down of 
S6Kinase activity. Thus, FKBP51 might be superior to FKBP12 in generating rapamycin-
induced Akt hyperphosphorylation. 
As the involvement of mTORC1-mediated negative feedback via PI3Kinase seems to be 
inconsistent between different cancer cell lines, no conclusion can be drawn about its role in 
HeLa cells. To overcome this obstacle, it will be necessary to perform experiments which 
allow control of mTORC1 signaling, e.g. by combining rapamycin treatment with 
administration of the PI3Kinase inhibitor Wortmannin.   
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5.4.3 – Possible mechanism of FKBP51 affecting Akt phosphorylation: 
 
Altogether, rapamycin-mediated Akt activation can be based on several, different 
mechanisms. It also cannot be estimated whether these mechanisms act independently, or 
whether they influence each other. Nevertheless, based on the above research findings, a 
hypothesis can be created that integrates two mechanisms of FKBP51 influencing mTORC2 
activity and Akt phosphorylation, maybe resulting in a rapamycin-resistant phenotype in 
cancer cell lines. 
In such a scenario, FKBP51 initially binds to mTORC1 in a rapamycin-dependent manner and 
prevents phosphorylation of the mTOR substrate S6Kinase. This causes downregulation of 
cap-dependent protein biosynthesis via S6Kinase and 4E-BP1, combined with a reduction of 
the negative feedback loop provided by IRS-1. As a result, signaling via PI3Kinase becomes 
highly active, and Akt is phosphorylated in an mTORC2-dependent manner. Importantly, 
FKBP51 is also directly involved in this process by increasing recruitment of Akt kinase to 
mTORC2 via Rictor in a rapamycin-dependent way. Thus, Akt is hyperphosphorylated at 
S473, causing increased pro-survival signaling via downstream substrates. Altogether, 
FKBP51 and rapamycin co-operate in rendering Akt hyperactive by affecting the two mTOR 
complexes differently (see scheme in figure 5.8). As a consequence, the cancer cells might 
display rapamycin-resistance, and their growth in rapamycin-containing medium should be 
unchanged or even increased compared to control conditions. 
 
Maybe, FKBP51 expression levels could be assessed in order to predict rapamycin-sensitivity 
of cancer cell lines. It could be expected that cells that contain high concentrations of 
FKBP51 are able to mediate rapamycin-induced effects more efficiently than cells that 
express less FKBP51. Supporting this idea, Staibano and colleagues collected reports on 
FKBP51 expression in cancer cells and concluded that there is generally an overexpression of 
the protein, especially in prostate, skin and colon cancer [323]. These finding are in contrast 
to the role of FKBP51 as a PHLPP-dependent tumour suppressor protein which has been 
proposed by Pei for breast and pancreatic cancer cell lines [57, 324, 325]; here, FKBP51 
expression levels are especially low.  
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Figure 5.8: Model of rapamycin-mediated FKBP51 effects on mTOR signaling  
FKBP51 potentially exerts distinct rapamycin-dependent effects on both mTOR complexes. While it inhibits 
mTORC1 and thus shuts down S6Kinase negative feedback, it might enhance substrate recruitment of mTORC2 
and may increase Akt-dependent survival signaling. 
 
 
 
 
 
 
 
FKBP51 
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5.5 – Summary: 
 
The kinase “mammalian Target of Rapamycin” (mTOR) plays a crucial role in the regulation 
of cell cycle progression and cell growth by integrating signals of growth factors, energy 
levels and amino acid availability. mTOR activity can be inhibited potently by a complex of 
rapamycin and FKBP12 leading to growth arrest in immune and cancer cell lines. FKBP51, 
another member of the family of FK506-binding proteins, is best known for its function in 
glucocorticoid receptor maturation and for its influence on antidepressive treatment. 
Rapamycin tightly binds to most members of the FKBP protein family. To examine the effect 
of the larger FKBP homologues on mTOR regulation, we tested different FKBP proteins for 
mTOR binding and kinase inhibition in vitro. In the presence of rapamycin all FKBPs 
exhibited high affinity to the FRB domain of mTOR (EC50 < 30 nM) and inhibited mTOR 
activity (IC50 < 10 nM) in a rapamycin-dependent manner. 
In order to elucidate the structural basis of these interactions, we solved the high-resolution 
crystal structures of two alternative ternary complexes (FRB*rapamycin*FK1 FKBP51/52). 
The overall architecture of the complexes was very similar to the one known for FKBP12. 
However, FKBP51 showed novel intensive contacts to FRB via its 40S loop region while for 
FKBP52 these protein-protein interactions were more prominent within the 80S loop. A large 
number of water-mediated H-bonds were identified that bridge residues of FRB with those in 
FKBP51 and contribute to stabilization of the complex. Furthermore, an additional H-bond to 
rapamycin and between the protein domains could be observed in the complex with FKBP51.  
To assess FKBP action in vivo, we transformed FKBP12-deficient yeast cells with human 
FKBPs. In this complementation assay, FKBP51 restored rapamycin sensitivity similar to 
FKBP12. In mammalian cells treated with rapamycin, FKBP51 could be found in mTORC1 
complexes, implying a functional role of the larger FKBP. By overexpressing FKBP51 in 
HeLa cells, we observed decreased p70S6K phosphorylation, resulting from reduced mTOR 
activity in presence of rapamycin compared to FKBP12-overexpressing cells. When FKBP12 
was knocked down, rapamycin still inhibited mTOR kinase activity, indicating that FKBP12 
might be dispensable. 
Co-IP experiments in HeLa cells revealed that the mTORC2 component Rictor binds to Akt 
kinase in a rapamycin- and FKBP51-dependent manner. When FKBP51 is overexpressed, Akt 
phosphorylation by mTORC2 is elevated compared to mock conditions. Thus, FKBP51 might 
be involved in substrate recruitment. 
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Altogether, our results demonstrate that mTOR is able to form stable and inhibitory ternary 
complexes with different FKBPs in vitro and in eukaryotic cells. FKBP51 might contribute to 
classical rapamycin-dependent inhibition of mTORC1, and tissues with high FKBP51 
expression levels may be attractive targets for pharmacological effects of rapamycin. 
Furthermore, FKBP51 may also play a more exclusive role in modulating Akt 
phosphorylation by mTORC2. Potentially, the effects on mTORC1 and mTORC2 might 
cooperate in rendering cancer cells resistant to chemotherapeuticals like rapamycin.  
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6 – Appendix:  
 
6.1 – Extinction coefficients for expressed proteins: 
 
In order to determine concentration of protein preparations, we calculated the extinction 
coefficients based on the protein sequence, using a web-based application (protein calculator, 
see  http://www.mrc-lmb.cam.ac.uk/ms/methods/proteincalculator.html ). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 
            
  
           Table 6.1: Overview of extinction coefficients used for calculation of protein concentrations 
 
Protein Molecular weight 
[kDa] 
Extinction coefficient 
[mol cm –1] 
FKBP12 15.2 15930 
FKBP12.6 15.1 9065 
FKBP13 15.8 14565 
FKBP25 28.5 33900 
FK1 FKBP51 18.6 17545 
FKBP51 55.5 48290 
FK1 FKBP52 18.6 21555 
FKBP52 56.1  53540 
EGFP-FKBP12 42.6 34420 
EGFP-FKBP12.6 46.8 27450 
EGFP-FKBP13 47.8 33140 
EGFP-FKBP25 55.4 52770 
EGFP-FKBP51 82.5 63700 
EGFP-FKBP52 83.1 69400 
EGFP-4E-BP1 43.3 27450 
FRB 14.7 29910 
GST-FRB 37.2 65800 
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6.2 – Active site titration: 
 
Active site titration has been performed for FKBP13 and FKBP25, too. Experimental 
procedures were the same as described for FKBP12, 12.6, 51 and 52. The resulting graph is 
shown in figure 6.1. 
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Figure 6.1: Active site titration reveals high affinity of tracers to recombinant FKBP13 and FKBP25 
Plot of calculated EC50 values against corresponding tracer concentration; linear equation is shown, intersection 
with y-axis is printed in bold. 
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6.3 – Formula for curve fitting and Kd determination: 
 
A formula for determination of Kd values in protein-ligand titration experiments has been 
described before [326]: 
 
[LR] = [([R]t + [L]t + Kd)/2] –{[(R]t + [L]t + Kd)/2]2 – [L]t[R]t}0.5} 
 
As fluorescence anisotropy (A) increases with increasing concentrations of the receptor-
ligand complex [LR], it can be expressed as follows: 
 
A = (∆A / [L]t) [LR] + Amin  
 
Finally, the terms can be combined, resulting in the formula used for Kd fitting: 
 
A = [(Amax - Amin) / [L]t] x {[([R]t + [L]t + Kd)/2] –{[(R]t + [L]t + Kd)/2]2 – [L]t[R]t}0.5} + Amin 
 
A formula for determination of Kd values in two-ligand competition experiments was 
published by Wang [327]. In this formula, anisotropy values were introduced by combining it 
with A = (∆A / [L]t) [LR] + Amin.  The final term was used for Kd fitting of competition assays 
[274] and reads as follows: 
 
A = (Amax - Amin) / [L]t x (([L]t x ((2x((Klig + Kcomp + [L]t + [I]t - [R]t)^2 - 3x( Kcomp x ([L]t - [R]t) + Klig x ([I]t - 
[R]t) + Klig x Kcomp))^0.5x COS(ARCCOS((-2x( Klig + Kcomp + [L]t + [I]t - [R]t)^3 + 9x( Klig + Kcomp + [L]t + 
[I]t - [R]t) x ( Kcomp x ([L]t - [R]t)+ Klig x ([I]t - [R]t) + Klig x Kcomp) - 27x(-1x Klig x Kcomp x [R]t)) / (2x (((( Klig + 
Kcomp + [L]t + [I]t - [R]t)^2 - 3x ( Kcomp x ([L]t - [R]t) + Klig x ([I]t - [R]t) + Klig x Kcomp))^3)^0.5))) / 3)) - (Klig + 
Kcomp + [L]t + [I]t - [R]t))) / ((3x Klig) + ((2x(( Klig + Kcomp + [L]t + [I]t - [R]t)^2 - 3x(Kcomp x ([L]t - [R]t) + Klig x 
([I]t - [R]t) + Klig x Kcomp))^0.5xCOS(ARCCOS((-2x(Klig + Kcomp + [L]t + [I]t - [R]t)^3 + 9x(Klig + Kcomp + [L]t 
+ [I]t - [R]t) x (Kcomp x ([L]t - [R]t) + Klig x ([I]t - [R]t) + Klig x Kcomp) - 27x(-1x Klig x Kcomp x [R]t)) / (2x(((( Klig 
+ Kcomp + [L]t + [I]t - [R]t)^2 - 3x(Kcomp x ([L]t - [R]t) + Klig x ([I]t - [R]t) + Klig x Kcomp))^3)^0.5)))/3)) - (Klig + 
Kcomp + [L]t + [I]t - [R]t)))) + Amin  
 
being:   Klig: Kd values of the used tracer 
  Kcomp: Kd values of the competitor 
  [I]t: total concentration of the inhibitor  
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6.4 – FRET binding: controls 
 
In order to test for unspecific FRET events, we performed the FRET binding assay with GST-
FRB and EGFP-FKBP12 in absence of rapamycin. As figure 6.2 shows, no increase in FRET 
ratio could be observed. If simple EGFP was used instead of the EGFP-FKBP12 fusion 
protein, rapamycin was unable to induce any binding; thus, a flat line was observed when 
FRET ratio was plotted against the rapamycin concentration. 
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Figure 6.2: Rapamycin and FKBP12 are essential components of FRET binding assay 
Half-logarithmic plot of the rapamycin concentration vs. the observed FRET ratio. 5 nM GST-FRB, 25 nM 
EGFP-FKBPs and 2.5 nM anti-GST antibody were used.  Rapamycin was titrated from 0 to 100 nM. 
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6.5 – mTOR activity assay 
 
6.5.1 – FRET mTOR activity assay: LY294002 and PI-103 controls  
 
In order to verify the reliability of the mTOR FRET activity assay, different known 
mTOR/PI3K inhibitors were used as a control. For the assay, the compounds were pre-diluted 
in DMSO, and a fixed amount of DMSO dilution was added to the FRET samples.             
LY294002 inhibited 4E-BP1 phosphorylation with an IC50 value of 170 nM which is 
considerably lower than a reported value of 2 µM [328]. PI-103 was even more potent; an 
IC50 of 12 nM was determined (literature value: 20 nM [329]).   
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Figure 6.3: LY294002 and PI-103 potently inhibit 4E-BP1 phosphorylation  
Half-logarithmic plot of the inhibitor concentration against the FRET ratio. Assay was performed as described 
before. (A)  LY-294002   (B)  PI-103 
 
6.5.2 – In vitro kinase assay: rapamycin control 
 
In order to exclude effects that are exerted by rapamycin alone, we included a sample that 
contains mTORC1 and 500 nM rapamycin. Unlike torin1, rapamycin did not induce a 
dramatic reduction of S6Kinase phosphorylation (see figure 6.4). 
     mTORC1 
    500 nM rapamycin/torin1 
 α-phosphoT389 S6Kinase 
 
Figure 6.4: Rapamycin alone has only minor effects on S6Kinase phosphorylation
A B 
-  +     +    +    +  
                R    T    T   
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6.6 – Crystal structures: interaction data: 
 
Analysis of molecular contacts was performed using the program CONTACT which is part of 
the CCP4 suite. H-bonds were detected using the program FindHBond of the Chimera 
package.   
 
 
6.6.1 – Interactions between rapamycin and protein domains: 
 
 
All interactions between rapamycin and the FRB domain (in the structure FRB*rapamycin* 
FK1 FKBP52) with a range of up to 4 Å are listed in the following table.  
 
 
 
Residue in FRB 
 (FKBP52 ternary complex) 
Atom in rapamycin Distance 
(Å) 
Number of 
contacts 
Leu2031 C, O, CB Rap C45, C45, C45 3.64 – 3.76 3 
Glu2032 O, N Rap C51, C45 3.47 – 3.92 2 
Ser2035 OG, OG, OG, OG, 
OG, OG, CB 
Rap C27, O9, C51, C24, C23, 
C22, C22 
3.35 – 3.99 7 
Phe2039 CG, CD2, CZ, 
CE1, CD1, CB, CE2 
Rap C47, C47, C18, C13, 
C49, C36, C18 
3.76 – 3.96 7 
Thr2098 O, CG2 Rap C50, C50 3.36; 3.66 2 
Trp2101 CB, CZ3 Rap C50, C22 3.72; 3.98 2 
Asp2102 OD1, N, OD1, CG Rap O7, C50, C50, C50 3.34 – 3.95 4 
Tyr2105 CZ, CE2, CE1, 
CD1, CB, CG, CD1, CE1, 
CB, CG, CD2 
Rap C48, C48, C46, C23, 
C21, C21, C21, C21, C19, 
C19, C19 
3.36 – 3.99 11 
Phe2108 CD2, CB, CG, 
CD1, CE1, CD2 
Rap C23, C45, C45, C45, 
C45, C45 
3.42 – 3.90 6 
 Total contacts 44 
 
 
Table 6.2: Interactions between rapamycin and FRB 
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Interactions between rapamycin and FKBP12, the FK1 domains of FKBP51 and FKBP52 are 
listed in the following tables: 
 
 
Residue in FKBP12 Atoms in (C16)-ethoxy 
rapamycin (RAD) 
Distance 
(Å) 
Number of 
contacts 
Tyr26 CE1, CE2, CZ RAD 04, C5, C5 3.66-3.81 3 
Phe36 CD1, CD1, CE1, 
CE1, CE1 
RAD O4, C42, C8, O4, C42 3.23-3.86 5 
Asp37 CB, CB, CG, CG, 
OD2 (6x) 
RAD O4, O6, O4, O6, O5, 
C13, C8, C9, O4, O6 
2.74-3.95 10 
Phe46 CE2, CZ (3x) RAD C4, C4, C5, O11 3.69-3.99 4 
Gln53 C, O (4x), CB RAD O13, C38, C39, C40, 
O13, O13 
2.65-3.91 6 
Glu54 CA, C, O (7x), CB RAD O10, O10, C27, C28, 
O10, C29, C31, O11, C36, 
O10 
2.82-3.96 10 
Val55 CA, CA, C, C, O, CB, 
CG1 (3x) 
RAD O2, C40, O2, C40, C40, 
O2, C4, O2, O11 
3.28-3.96 9 
Ile56 N (3x), CA, CG1, 
CG2, CG2 
RAD O2, C41, C40, C40, O2, 
O2, C41 
3.00-3.99 7 
Trp59 CG, CD1, CD2, NE1, 
CE2, CE2, CE3, CZ2, CZ2, 
CZ3, CH2 
RAD C3, C3, C4, C3, C3, C4, 
C3, C4, C4, C3, C4, C4 
3.35-3.92 12 
Tyr82 CE1, CE2, CZ, OH 
(10x) 
RAD C34, O3, O3, C1, O1, 
O2, C33, C34, C48, C2, N7, 
O3, C7 
2.75-3.95 13 
Ile90 CG2 RADC42 3.82 1 
Ile91 CG1, CD1 RAD  C42, C42 3.89-3.90 2 
Phe99 CE1, CZ, CZ RAD O4, O3, C7 3.68-3.89 3 
Total contacts 85 
 
Table 6.3: Interactions between (C16)-ethoxy rapamycin and FKBP12 (analyzed in 2fap) 
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Residue in FK1 FKBP51 Atom in rapamycin Distance 
(Å) 
Number of 
contacts 
Tyr57 CE1, CZ, OH, OH, 
CZ, OH, CE2 
Rap O4, O4, O4, C6, C5, C5, 
C5 
3.49 – 3.92 7 
Phe67 CD1, CE1, CE1 Rap O4, O4, C9 3.43 - 3.94 3 
Asp68 OD2, OD2, CB, CG, 
OD2, OD2, CB, CG, OD2 
Rap O5, C10, O6, O6, O6, 
C9, O4, O4, O4 
2.73 – 3.85 9 
Arg73 NE, CZ, NH2, NH3, 
NE, CZ, NH2, NH2, NH2, 
(NH2) 
Rap C44, C44, C44, C16, O7, 
O7, O7, C15, C14,  
3.02 – 3.97 9 
Phe77 CZ, CZ, CZ, CE2, 
CZ, CE2 
Rap O11, C48, C5, C5, C4, 
C4 
3.32 – 3.88 6 
Gly84 O, O, C, O, O Rap C41, C40, O13, O13, 
C39 
2.66 – 3.80 5 
Gln85 O, O, O, O, O, CG, 
CA, CB, C, O, CG, O, O, O 
Rap C32, O11, C30, C29, 
C28, O10, O10, O10, O10, 
O10, O8, C37, C41, C41 
2.69 – 3.92 14 
Val86 CG1, CG1, CA, CB, 
CG1, C, O, CA, C 
Rap O11, C4, O2, O2, O2, 
O2, C41, C41, C41 
3.21 – 3.99 9 
Ile87 N, CG1, CG2, CA, N Rap O2, O2, O2, O2, C41 2.87 – 4.00 5 
Trp90 CH2, CZ2, CE3, 
CD2, CZ3, CH2, CE2, CZ2, 
CG, CD1, CD1, NE1, CE2, 
CZ2 
Rap C5, C5, C4, C4, C4, C4, 
C4, C4, C3, C3, C3, C3, C3, 
C3 
3.49 – 3.93 14 
Tyr113 OH, CE1, OH, CE1, 
OH, OH, OH, OH, CZ, OH, 
CE2, OH, OH, OH, OH 
Rap C34, C35, C35, C49, 
C49, O1, C11, C8, O3, O3, 
O3, N7, C2, C1, O2 
2.65 – 3.99 15 
Ile122 CD1 Rap C43 3.46 1 
Phe130 CE1, CZ Rap O4, O3 3.69 - 3.93 2 
 Total contacts 99   
 
Table 6.4: Interactions between rapamycin and FK1 FKBP51 
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Residue in FK1 FKBP52 Atom in rapamycin Distance 
(Å) 
Number of 
contacts 
Tyr57 OH, CZ, OH, CZ, 
OH, CZ, OH, CE2, CE1 
Rap O5, O4, O4, C6, C6, C5, 
C5, C5, O4 
3.54 – 3.93 9 
Phe67 CE1, CE1 Rap C9, O4 3.47; 4.00 2 
Asp68 OD2, OD2, CG, 
OD2, CB, OD2, CG, OD2, 
CB 
Rap O5, C10, O6, O6, O6, 
C9, O4, O4, O4 
2.68 – 3.90 9 
Phe77 CZ, CE1, CZ, CZ, 
CE2, CZ, CE2 
Rap O11, C48, C48, C5, C5, 
C4, C4 
3.32 – 3.89 7 
Gly84 O, O, C, O, O Rap C41, C40, O13, O13, 
C39 
2.68 – 3.79 5 
Glu85 O, O, O, O, O, CA, 
CB, C, O, O, O 
Rap C32, O11, C30, C29, 
C28, O10, O10, O10, O10, 
C37, C41 
2.74 – 3.99 11 
Val86 CG1, CA, C, O, C, 
CG2, CB, CG1, CA, C  
Rap O11, C41, C41, C41, 
C42, C4, O2, O2, O2, O2 
2.85 – 3.99 10 
Ile87 N, N, N, CA, CG2, 
CG1, CB 
Rap C41, C42, O2, O2, O2, 
O2, O2 
2.85 – 4.00 7 
Trp90 CH2, CZ2, CZ3, CE2, 
CD2, CE3, CH2, CZ2, CG, 
CD1 NE1, CE2, CD2, CZ2 
Rap C5, C5, C4, C4, C4, C4, 
C4, C4, C3, C3, C3, C3, C3, 
C3 
3.47 – 3.99 14 
Tyr113 OH, OH, CZ, OH, 
CE2, OH, OH, OH, OH, 
OH, CE1, OH, CE1, OH, 
OH 
Rap C11, C8, O3, O3, O3, 
N7, C2, C1, O1, C34, C35, 
C35, C49, C49, O2 
2.64 – 3.94 15 
Lys121 NZ, NZ, CE, NZ, 
NZ, CE 
Rap C14, C12, C12, C43, 
C10, O6, O6  
2.76 – 4.00 7 
Ile122 CG1, CD1 Rap C43, C43 3.78 – 3.99 2 
Phe130 CE1, CZ, CZ Rap O4, C8, O3 3.72 – 3.95 3 
 Total contacts 101 
 
Table 6.5: Interactions between rapamycin and FK1 FKBP52 
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6.6.2 – Interactions between protein domains: 
 
All direct contacts between the FKBP and the corresponding FRB domain are listed below. 
Atoms involved in H-bond formation are underlined. H-bonds have been defined as contacts 
between the classical H-donor and H-acceptor atoms N and O. Distance between donor and 
acceptor must be less than 4 Å. 
 
 
 
Residue in FKBP12 (2fap) Residue in FRB Distance 
(Å) 
Number of 
contacts 
Lys44 CE Arg2109 NH2 3.68 1 
Phe46 CE1 Tyr2105 OH 3.87 1 
Lys47 O Tyr2105 OH 3.57 1 
Thr85 OG1 Arg2042 CZ, NH2 3.92 – 3.98 2 
Gly86 O Arg2042 CZ, NH1 3.08 – 3.91 2 
His87 NE2 Tyr2038 OH 3.94 1 
His87 CE1, NE2, CE1, NE2, 
CE1, NE2, NE2 
Phe2039 CA, CA, O, O, CD1, 
CD1, CD1 
3.25 – 3.96 7 
His87 ND1, CE1 Arg2042 NH1, NH1 3.47 – 3.93 3 
Pro88 CD, CG, CD Arg2042 CG, CG, CD 3.75 – 4.0 3 
Pro88 O Val2094 CG2 3.45 1 
Gly89  CA, C, O Val2094 CG1 3.58 – 3.98 3 
Ile90 CG1 Val2094 CG1 3.95 1 
Ile90 CD1 Thr2098 CG2 3.74 1 
 Total contacts 27 
 
 
Table 6.6: Interactions between FKBP12 and FRB (determined from structure 2fap) 
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Residue in FK1 FKBP51 Residue in FRB Distance 
(Å) 
Number of 
contacts 
Arg73 CD, NE, CG, CD, 
NE, CZ, NH2 
Asp2102 CG, CG, OD1, 
OD1, OD1, OD1, OD1 
2.72 - 3.97 7 
Glu75 OE2, OE2 His2106 NE2, CD2 3.26 – 3.91 2 
Glu75 OE2, OE2, CD, OE2, 
CG, CD, OE2, CB, CG 
Arg2109 CD, NE, CZ, CZ, 
CZ, NH1, NH1, NH1 
3.57 – 3.90 8 
Pro76 O, C, O, C, O Arg2109 CZ, NH1, NH1, 
NH2, NH2 
2.78 – 3.92 5 
Phe77 CD1, CE1, CA, C, 
CD1, CG, CE1, CD1 
Tyr2105 CZ, CZ, OH, OH, 
OH, OH, OH, CE2 
3.38 - 3.92 8 
Val78 O, O, CA, CG1, C, O, 
N 
Tyr2105 CE1, CZ, OH, OH, 
OH, OH, OH 
2.60 – 3.87 7 
Val78 CG1, CG1, CG1, CB, 
CG1 
Arg2109 NE, CZ, NH1, NH2, 
NH2 
3.42 – 3.86 5 
Ala116 CB, CB Arg2042 NE, NH2 3.59 – 3.97 2 
Pro120 CG, CD, CD, CD Val2094 CB, CB, CG1, CG2 3.67 – 3.98 4 
 Total contacts 48   
Table 6.7: Interactions between FK1 FKBP51 and FRB  
 
 
Residue in FK1 FKBP52 Residue in FRB Distance 
(Å) 
Number of 
contacts 
Arg52 NH2 Tyr2105 OH 3.14 1 
Arg52 NH2 Arg2109 CG 3.81 1 
Lys76 C, O Arg2109 NH2, NH2 2.83 – 3.92 2 
Phe77 CA Arg2109 NH2 3.94 1 
Ser78 C, O, O, O Tyr2105 OH, OH, CE2, CZ 2.36 – 3.72 4 
Ser78 OG, OG, N, OG Arg2109 NE, CZ, NH2, NH2 3.20 – 3.66 4 
Ala116 CB, CB, CB Arg2042 NE, CZ, NH2 3.68 – 3.90 3 
Pro120 CG, CD, CG, CD, 
CD 
Val2094 CB, CB, CG, CG1, 
CG2 
3.53 – 3.83 5 
 Total contacts 21 
 
Table 6.8: Interactions between FK1 FKBP52 and FRB  
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6.6.3 – Waters involved in interactions between the protein domains: 
 
A list of water molecules that are involved in mediating protein-protein interactions via H-
bonds can be found below: 
 
Water number Residue in  
FKBP12 
Residue in FRB Distances 
(A) 
317 Lys47, Glu54 Tyr2105 2.7; 2.9 
422 Pro88 Tyr2038 2.7; 2.9 
 
Table 6.9: Water molecules that mediate protein-protein interactions between FRB and FKBP12 (from 
2fap) 
 
Water number Residue in FK1 
FKBP51 
Residue in FRB Distances 
(A) 
94 Glu75 His2106 3.5; 3.1  
107 Ser118 Phe2039 2.7; 3.6  
 
Table 6.10: Water molecules that mediate protein-protein interactions between FRB and FK1 FKBP51 
 
 
Water number Residue in FK1 
FKBP52 
Residue in FRB Distances 
(A) 
22 Glu85 Tyr2105 2.7; 3.2  
27 Pro119 Tyr2038 3.1; 2.8  
47 Ser118 Phe2039 2.9; 2.7  
 
Table 6.11: Water molecules that mediate protein-protein interactions between FRB and FK1 FKBP52 
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6.6.4 – Small differences are present in the rapamycin binding pockets of FRBs: 
 
An overlay of the residues involved in binding of rapamycin reveals a high degree of 
structural conservation between the FRB domains of the three ternary complexes. 
Nevertheless, some minor differences can be seen, especially involving the residues Y2105 
and R2036. Also, only G2040 in the FKBP12 structure seems to be involved in rapamycin 
binding, while the residue does not play such a role in the FK1 FKBP51 and the FK1 FKBP52 
ternary complex. 
 
                  
                                         
 
Figure 6.5: Overlay of the residues in FRB involved in rapamycin binding 
Color scheme:  FRB of FKBP12 (2fap): red 
  FRB of FK1 FKBP51 complex: light blue 
  FRB of FK1 FKBP52 complex: green 
In box: magnification of Y2105 which is shifted. Distances are indicated. 
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6.7 – Rictor interacts with FKBP12 in a constitutive manner: 
 
Co-IP experiments were also performed with FLAG-FKBP12 and myc-Rictor. Here, 
interaction mainly appeared under conditions of serum stimulation. Again, no obvious 
rapamycin-dependence could be observed. 
 
 
                          
-Rictor            
-Hsp90              
-FKBP12            
 
-Rictor                LOAD 
-Hsp90                LOAD  
 
 
 
Figure 6.6: FKBP12 interacts with myc-Rictor in stimulated HeLa cells 
HeLa cells were transfected for expression of HA-FKBP12 and myc-Rictor. Cells were either starved or starved 
and stimulated with FCS for 24 h. Lysates were subjected to HA-IP. Beads were washed four times with 
CHAPS-containing lysis buffer and extracted by boiling. Eluates were analyzed by SDS-PAGE and 
immunoblotting. 
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6.8 – Rapamycin binds to His-FRB: 
 
In FP assays using the fluorescein-labeled rapamycin derivative CK97, we observed binding 
of the tracer to His-tagged FRB with an EC50 value of 290 nM ±17.4 (see figure 6.7). No 
FKBP component was present in the assay. 
By performing competition binding experiments with fixed concentrations of CK97 and His-
FRB and increasing concentrations of rapamycin, we determined an IC50 value for rapamycin 
of 1.04 µM ± 0.11. 
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Figure 6.7: CK97 binds to the FRB domain of mTOR in absence of FKBPs 
(A) 5 nM CK97 was titrated to increasing concentrations of His-FRB. An EC50 value of 290 nM was 
determined by fitting the curve with “Four Parameter Logistic” in SigmaPlot. 
(B) Competitive FP assays were performed with 5 nM CK97 and 750 nM His-FRB. Rapamycin was titrated 
from 0 – 20 µM. Curve fitting was performed using “Four Parameter Logistic” in SigmaPlot. 
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6.9 - Immunoblotting proves galactose-dependent FKBP expression in yeast cells: 
 
 
As the expression activity of transfected plasmids can vary dramatically in yeast, the FKBP 
protein levels were checked by immunoblotting. During this procedure, a definite amount of 
yeast cells (determined by OD600) was harvested and analyzed. Thus, FKBP protein levels can 
be quantified by blotting against the protein tag. 
It turned out that all checked clones exhibited heterologous expression of the transformed 
plasmid. No expressed protein could be detected for clones grown in glucose-containing 
medium, while expression is strong in presence of the inducer galactose (see figure 6.8). 
Thus, the expression system seems to be tight. 
 
                        
-FKBP51                               
-HA        
 
 
Figure 6.8: Western blot quantification of yeast clone expression 
For quantification of protein expression, yeast cell lysates were boiled in SDS sample buffer and subjected to 
SDS PAGE. HA-tagged proteins were detected by immunoblotting. For FKBP12, FK1 FKBP51 and FK1 
FKBP52 each two SG clones are represented. 
SD: growth in medium containing glucose 
SG: growth in medium containing galactose 
 
When protein expression levels of different clones are compared, it is obvious that the amount 
of HA-tagged protein differs a lot. Even two clones containing the same plasmid display big 
variations in protein expression. This is especially pronounced for the two samples of clones 
expressing the FK1 domain of FKBP52. For FKBP12 and FK1 FKBP51, these differences are 
less distinct. Probably, copy numbers of these 2-µm plasmids differ considerably in the 
selected clones and thus create varying expression levels.   
For the FK1 domains, an additional band appears in all the samples, representing either a 
truncated product or another variant of the protein. It could not be determined whether protein 
degradation occurred in vivo or during preparation of the samples. Only one species could be 
observed for the full-length FKBP51 expressing clone. 
FKBP 
SD/SG 
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6.10 – Abbreviations: 
 
 
Å      Angstrom (1 Å = 10-10 m)  
AP           Alkaline Phosphatase  
aa     amino acid  
ATP           adenosine-5’-triphosphate   
bp            base pair(s) 
BSA          bovine serum albumin  
CIP          calf intestine phosphatase 
CV        column volume  
d         day 
Da           Dalton  
bidest. H2O       double distilled water  
DMSO         dimethylsulfoxide  
DNA       deoxyribonucleic acid  
dNTP       2’-deoxynucleoside 5’-triphosphate  
dsDNA         double strand DNA  
E. coli          Escherichia coli  
EDTA          ethylendiamine-tetraacetic acid  
EtOH          ethanol  
FCS           fetal calf serum  
g        gram(s)  
h           hour(s)  
HEPES        4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
FPLC        Fast Performance Liquid Chromatography  
IPTG           Isopropyl-β-D-1-thiogalactopyranoside  
kb            kilo base pair(s)  
kDa          kilo Dalton  
l           litre  
LB Medium       lysogeny broth 
M           molar (mol/l)  
m        metre(s) 
mA     milliAmpere(s) 
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min          minute(s)  
ml        millilitre(s)  
mM        millimolar  
MW          molecular weight  
nM     nanomolar 
OD          optical density 
ORF          open reading frame 
PCR        polymerase chain reaction  
pM     picomolar 
RNase  A       Ribonuclease A 
rpm      round(s) per minute 
Rap     Rapamycin 
RT           room temperature 
SDS        sodium dodecyl sulfate  
s           second(s)  
ssDNA      single strand DNA 
Tris           tris(hydroxymethyl)aminomethane 
Triton X-100       polyethylene glycol p-(tetramethylbutyl)-phenyl ether 
U      enzymatic unit(s) 
UV        ultraviolet  
V        Volt  
v/v      volume per volume 
w/v         weight per volume  
wt      wild type 
μl        microlitre(s) 
μM        micromolar  
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